Morphine

Identification

Summary

Morphine is an opioid agonist used for the relief of moderate to severe acute and chronic pain.

Brand Names

Arymo, Avinza, Duramorph, Embeda, Infumorph, Kadian, M-ediat, M-eslon, MSIR, Mitigo, Ms Contin, Statex

Generic Name

Morphine

DrugBank Accession Number

DB00295

Background

Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.¹ It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.² Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone.

Morphine was granted FDA approval in 1941.¹³

Type

Small Molecule

Groups

Approved, Investigational

Structure

Similar Structures

Weight: Average: 285.3377
Monoisotopic: 285.136493479
Chemical Formula: C₁₇H₁₉NO₃

Synonyms

(−)-morphine
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
Anhydrous morphine
Morfina
Morphia
Morphin
Morphine
Morphinum
Morphium

External IDs

IDS-NM-009
N02AA01

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Morphine is used for the management of chronic, moderate to severe pain.²

Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.¹¹

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Patient Characteristics	Dose Form
Treatment of	Chronic intractable pain		••••••••••••		•••••••••• ••••••••
Used in combination to manage	Chronic pain	Combination Product in combination with: Naltrexone (DB00704)	••••••••••••	•••••••••• ••••••••••• ••••••••• •••••••
Management of	Chronic pain		••••••••••••
Used in combination to manage	Severe pain	Combination Product in combination with: Naltrexone (DB00704)	••••••••••••	•••••••••• ••••••••••• ••••••••• •••••••
Treatment of	Severe pain		••••••••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Morphine binding to opioid receptors blocks transmission of nociceptive signals, signals pain-modulating neurons in the spinal cord, and inhibits primary afferent nociceptors to the dorsal horn sensory projection cells.¹

Morphine has a time to onset of 6-30 minutes.¹ Excess consumption of morphine and other opioids can lead to changes in synaptic neuroplasticity, including changes in neuron density, changes at postsynaptic sites, and changes at dendritic terminals.³

Intravenous morphine's analgesic effect is sex dependent. The EC₅₀ in men is 76ng/mL and in women is 22ng/mL.⁵

Morphine-6-glucuronide is 22 times less potent than morphine in eliciting pupil constriction.⁵

Mechanism of action

Morphine-6-glucuronide is responsible for approximately 85% of the response observed by morphine administration.⁴ Morphine and its metabolites act as agonists of the mu and kappa opioid receptors.¹ The mu-opioid receptor is integral to morphine's effects on the ventral tegmental area of the brain. Morphine's activation of the reward pathway is mediated by agonism of the delta-opioid receptor in the nucleus accumbens,² while modification of the respiratory system and addiction disorder are mediated by agonism of the mu-opioid receptor.³

Target	Actions	Organism
AMu-type opioid receptor	agonist regulator	Humans
AKappa-type opioid receptor	agonist	Humans
ADelta-type opioid receptor	agonist	Humans
ULymphocyte antigen 96	activator	Humans

Absorption

Morphine is absorbed in the alkaline environments of the upper intestine and rectal mucosa.⁶ The bioavailability of morphine is 80-100%.⁸ There is significant first-pass metabolism, therefore oral doses are 6 times larger than parenteral doses to achieve the same effect. Morphine reaches steady-state concentrations after 24-48 hours.¹ Parenteral morphine has a T_max of 15 minutes and oral morphine has a T_max of 90 minutes, with a C_max of 283nmol/L.^7,8 The AUC of morphine is 225-290nmol*h/L.⁸

Volume of distribution

The volume of distribution of morphine is 5.31L/kg.⁶ Morphine-6-glucuronide has a volume of distribution of 3.61L/kg.⁶

Protein binding

Morphine is 35% protein bound, the metabolite morphine-3-glucuronide is 10% protein bound, and morphine-6-glucuronide is 15% protein bound.⁴

Metabolism

Morphine is 90% metabolized by glucuronidation by UGT2B7 and sulfation at positions 3 and 6.⁴ Morphine can also be metabolized to codeine, normorphine, and morphine ethereal sulfate.⁶

Hover over products below to view reaction partners

Morphine

Route of elimination

70-80% of an administered dose is excreted within 48 hours.⁶ Morphine is predominantly eliminated in the urine with 2-10% of a dose recovered as the unchanged parent drug.⁴ 7-10% of a dose of morphine is eliminated in the feces.¹³

Half-life

Morphine has a half life of 2-3 hours.⁵

Clearance

The apparent clearance of intravenous or subcutaneous morphine is 1600 mL/min.⁸

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

The LD₅₀ is 0.78µg/mL in males and 0.98µg/mL in females.⁹

Patients experiencing an overdose present with respiratory depression, somnolence, skeletal muscle flaccidity, cold and clammy skin, miosis, and mydriasis. Symptoms of overdose can progress to pulmonary edema, bradycardia, hypotension, cardiac arrest, and death.¹² Treat overdose with symptomatic and supportive treatment which may include the use of oxygen, vasopressors, and naloxone.¹²

Pathways

Pathway	Category
Morphine Action Pathway	Drug action
Codeine Action Pathway	Drug action
Heroin Metabolism Pathway	Drug metabolism
Heroin Action Pathway	Drug action
Codeine Metabolism Pathway	Drug metabolism
Morphine Metabolism Pathway	Drug metabolism

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Multidrug resistance protein 1	---	(T;T) / (C;T)	T Allele	Effect Directly Studied	Patients with this genotype may have an increased analgesic response to morphine.	Details
Mu-type opioid receptor	---	(A;A)	A Allele	Effect Directly Studied	Patients with this genotype may have an increased analgesic response to morphine.	Details

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of adverse effects can be increased when Morphine is combined with 1,2-Benzodiazepine.
Abaloparatide	The risk or severity of adverse effects can be increased when Morphine is combined with Abaloparatide.
Abametapir	The serum concentration of Morphine can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Morphine can be increased when combined with Abatacept.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Morphine.
Abiraterone	The metabolism of Morphine can be decreased when combined with Abiraterone.
Abrocitinib	The serum concentration of Morphine can be increased when it is combined with Abrocitinib.
Acebutolol	The risk or severity of adverse effects can be increased when Morphine is combined with Acebutolol.
Acetazolamide	The risk or severity of CNS depression can be increased when Morphine is combined with Acetazolamide.
Acetophenazine	The risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Morphine.
Aclidinium	The risk or severity of adverse effects can be increased when Aclidinium is combined with Morphine.
Adagrasib	The serum concentration of Morphine can be increased when it is combined with Adagrasib.
Adalimumab	The metabolism of Morphine can be increased when combined with Adalimumab.
Adenine	The metabolism of Morphine can be decreased when combined with Adenine.
Afatinib	The serum concentration of Morphine can be increased when it is combined with Afatinib.
Agomelatine	The risk or severity of CNS depression can be increased when Morphine is combined with Agomelatine.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Morphine.
Alfentanil	The risk or severity of adverse effects can be increased when Morphine is combined with Alfentanil.
Alimemazine	The risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Morphine.
Aliskiren	The risk or severity of adverse effects can be increased when Morphine is combined with Aliskiren.
Alloin	The therapeutic efficacy of Alloin can be decreased when used in combination with Morphine.
Almotriptan	The risk or severity of CNS depression can be increased when Morphine is combined with Almotriptan.
Alosetron	The risk or severity of CNS depression can be increased when Morphine is combined with Alosetron.
Alpelisib	The metabolism of Morphine can be decreased when combined with Alpelisib.
Alprazolam	The risk or severity of adverse effects can be increased when Morphine is combined with Alprazolam.
Alverine	The risk or severity of CNS depression can be increased when Morphine is combined with Alverine.
Alvimopan	The risk or severity of adverse effects can be increased when Morphine is combined with Alvimopan.
Amantadine	The risk or severity of adverse effects can be increased when Amantadine is combined with Morphine.
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Morphine.
Amifostine	The risk or severity of adverse effects can be increased when Morphine is combined with Amifostine.
Amiloride	The therapeutic efficacy of Amiloride can be decreased when used in combination with Morphine.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Morphine.
Amiodarone	The metabolism of Morphine can be decreased when combined with Amiodarone.
Amisulpride	The risk or severity of CNS depression can be increased when Morphine is combined with Amisulpride.
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Morphine.
Amitriptylinoxide	The risk or severity of CNS depression can be increased when Morphine is combined with Amitriptylinoxide.
Amlodipine	The risk or severity of adverse effects can be increased when Morphine is combined with Amlodipine.
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Morphine.
Amodiaquine	The metabolism of Amodiaquine can be decreased when combined with Morphine.
Amoxapine	The risk or severity of adverse effects can be increased when Amoxapine is combined with Morphine.
Amphetamine	Amphetamine may increase the analgesic activities of Morphine.
Amphotericin B	The risk or severity of adverse effects can be increased when Morphine is combined with Amphotericin B.
Amprenavir	The metabolism of Morphine can be decreased when combined with Amprenavir.
Amyl Nitrite	The risk or severity of adverse effects can be increased when Morphine is combined with Amyl Nitrite.
Anakinra	The metabolism of Morphine can be increased when combined with Anakinra.
Anastrozole	The metabolism of Anastrozole can be decreased when combined with Morphine.
Anisotropine methylbromide	The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Morphine.
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Morphine.
Apalutamide	The serum concentration of Morphine can be decreased when it is combined with Apalutamide.
Apixaban	The metabolism of Apixaban can be decreased when combined with Morphine.
Apomorphine	The risk or severity of CNS depression can be increased when Morphine is combined with Apomorphine.
Apremilast	The metabolism of Morphine can be increased when combined with Apremilast.
Aprepitant	The metabolism of Morphine can be decreased when combined with Aprepitant.
Aprocitentan	Morphine may increase the hypotensive activities of Aprocitentan.
Apronalide	The risk or severity of CNS depression can be increased when Morphine is combined with Apronalide.
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Morphine.
Aripiprazole lauroxil	The risk or severity of CNS depression can be increased when Morphine is combined with Aripiprazole lauroxil.
Arsenic trioxide	The serum concentration of Morphine can be increased when it is combined with Arsenic trioxide.
Articaine	The risk or severity of CNS depression can be increased when Morphine is combined with Articaine.
Asciminib	The serum concentration of Morphine can be increased when it is combined with Asciminib.
Asenapine	The risk or severity of CNS depression can be increased when Morphine is combined with Asenapine.
Asunaprevir	The serum concentration of Morphine can be increased when it is combined with Asunaprevir.
Atazanavir	The metabolism of Morphine can be decreased when combined with Atazanavir.
Atenolol	The risk or severity of adverse effects can be increased when Morphine is combined with Atenolol.
Atorvastatin	The metabolism of Atorvastatin can be decreased when combined with Morphine.
Atracurium	The risk or severity of adverse effects can be increased when Atracurium is combined with Morphine.
Atracurium besylate	The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Morphine.
Atropine	The risk or severity of adverse effects can be increased when Atropine is combined with Morphine.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Morphine.
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Morphine.
Azatadine	The risk or severity of adverse effects can be increased when Azatadine is combined with Morphine.
Azelastine	Morphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Morphine is combined with Azilsartan medoxomil.
Baclofen	Baclofen may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Belantamab mafodotin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Morphine.
Belinostat	The serum concentration of Belinostat can be increased when it is combined with Morphine.
Belladonna	The risk or severity of adverse effects can be increased when Belladonna is combined with Morphine.
Belumosudil	The serum concentration of Morphine can be increased when it is combined with Belumosudil.
Benazepril	The risk or severity of adverse effects can be increased when Morphine is combined with Benazepril.
Bendamustine	The serum concentration of Bendamustine can be increased when it is combined with Morphine.
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Morphine.
Benperidol	The risk or severity of CNS depression can be increased when Morphine is combined with Benperidol.
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Morphine.
Benzhydrocodone	The risk or severity of adverse effects can be increased when Morphine is combined with Benzhydrocodone.
Benzocaine	The risk or severity of CNS depression can be increased when Morphine is combined with Benzocaine.
Benzphetamine	Benzphetamine may increase the analgesic activities of Morphine.
Benzthiazide	The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Morphine.
Benzyl alcohol	The risk or severity of CNS depression can be increased when Morphine is combined with Benzyl alcohol.
Bepridil	The risk or severity of adverse effects can be increased when Morphine is combined with Bepridil.
Berotralstat	The metabolism of Morphine can be decreased when combined with Berotralstat.
Betamethasone	The metabolism of Morphine can be increased when combined with Betamethasone.
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Morphine.
Bethanidine	Morphine may increase the hypotensive activities of Bethanidine.
Betrixaban	The serum concentration of Betrixaban can be increased when it is combined with Morphine.
Bexarotene	The metabolism of Morphine can be decreased when combined with Bexarotene.
Bezafibrate	The metabolism of Morphine can be decreased when combined with Bezafibrate.
Bimekizumab	The metabolism of Morphine can be increased when combined with Bimekizumab.
Binimetinib	The serum concentration of Binimetinib can be increased when it is combined with Morphine.
Biperiden	The risk or severity of adverse effects can be increased when Biperiden is combined with Morphine.
Bisacodyl	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Morphine.
Bisoprolol	The serum concentration of Bisoprolol can be increased when it is combined with Morphine.
Bisoxatin	The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Morphine.
Boceprevir	The metabolism of Morphine can be decreased when combined with Boceprevir.
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Morphine.
Bosentan	Morphine may increase the hypotensive activities of Bosentan.
Bosutinib	The metabolism of Morphine can be decreased when combined with Bosutinib.
Botulinum toxin type A	The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Morphine.
Botulinum toxin type B	The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Morphine.
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.
Bretylium	The risk or severity of adverse effects can be increased when Morphine is combined with Bretylium.
Brexanolone	The risk or severity of CNS depression can be increased when Morphine is combined with Brexanolone.
Brexpiprazole	The risk or severity of CNS depression can be increased when Morphine is combined with Brexpiprazole.
Brigatinib	The metabolism of Brigatinib can be decreased when combined with Morphine.
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Brivaracetam	The risk or severity of CNS depression can be increased when Morphine is combined with Brivaracetam.
Bromazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam.
Bromocriptine	The risk or severity of CNS depression can be increased when Morphine is combined with Bromocriptine.
Bromotheophylline	The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Morphine.
Bromperidol	The risk or severity of CNS depression can be increased when Morphine is combined with Bromperidol.
Brompheniramine	The risk or severity of adverse effects can be increased when Brompheniramine is combined with Morphine.
Buclizine	The risk or severity of adverse effects can be increased when Buclizine is combined with Morphine.
Bumetanide	The therapeutic efficacy of Bumetanide can be decreased when used in combination with Morphine.
Bupivacaine	The risk or severity of CNS depression can be increased when Morphine is combined with Bupivacaine.
Buprenorphine	Morphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion	The risk or severity of CNS depression can be increased when Morphine is combined with Bupropion.
Buspirone	The risk or severity of CNS depression can be increased when Morphine is combined with Buspirone.
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine.
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Morphine.
Butaperazine	The risk or severity of hypotension and CNS depression can be increased when Butaperazine is combined with Morphine.
Butobarbital	The risk or severity of adverse effects can be increased when Butobarbital is combined with Morphine.
Butorphanol	The therapeutic efficacy of Morphine can be decreased when used in combination with Butorphanol.
Butriptyline	The risk or severity of CNS depression can be increased when Morphine is combined with Butriptyline.
Butylscopolamine	The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Morphine.
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Morphine.
Cabergoline	The risk or severity of CNS depression can be increased when Cabergoline is combined with Morphine.
Cabozantinib	The metabolism of Morphine can be decreased when combined with Cabozantinib.
Calcium polycarbophil	The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Morphine.
Canagliflozin	The serum concentration of Morphine can be increased when it is combined with Canagliflozin.
Canakinumab	The metabolism of Morphine can be increased when combined with Canakinumab.
Candesartan cilexetil	The metabolism of Morphine can be decreased when combined with Candesartan cilexetil.
Cannabidiol	The risk or severity of adverse effects can be increased when Cannabidiol is combined with Morphine.
Canrenoic acid	The therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Morphine.
Capmatinib	The serum concentration of Morphine can be increased when it is combined with Capmatinib.
Captopril	The risk or severity of adverse effects can be increased when Morphine is combined with Captopril.
Carbamazepine	The metabolism of Morphine can be increased when combined with Carbamazepine.
Carbetocin	The risk or severity of adverse effects can be increased when Morphine is combined with Carbetocin.
Carbinoxamine	The risk or severity of CNS depression can be increased when Morphine is combined with Carbinoxamine.
Carboxymethylcellulose	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Morphine.
Carfilzomib	The serum concentration of Morphine can be increased when it is combined with Carfilzomib.
Cariprazine	The risk or severity of CNS depression can be increased when Morphine is combined with Cariprazine.
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Morphine.
Carvedilol	The serum concentration of Morphine can be increased when it is combined with Carvedilol.
Castor oil	The therapeutic efficacy of Castor oil can be decreased when used in combination with Morphine.
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Morphine.
Celiprolol	Morphine may increase the hypotensive activities of Celiprolol.
Cenobamate	The serum concentration of Morphine can be decreased when it is combined with Cenobamate.
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Morphine.
Cerivastatin	The metabolism of Morphine can be decreased when combined with Cerivastatin.
Certolizumab pegol	The metabolism of Morphine can be increased when combined with Certolizumab pegol.
Cetirizine	The risk or severity of CNS depression can be increased when Morphine is combined with Cetirizine.
Chenodeoxycholic acid	The metabolism of Morphine can be decreased when combined with Chenodeoxycholic acid.
Chloral hydrate	The risk or severity of CNS depression can be increased when Morphine is combined with Chloral hydrate.
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Morphine is combined with Chlordiazepoxide.
Chlormezanone	The risk or severity of CNS depression can be increased when Morphine is combined with Chlormezanone.
Chloroprocaine	The risk or severity of CNS depression can be increased when Morphine is combined with Chloroprocaine.
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Morphine.
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Morphine.
Chlorpheniramine	The risk or severity of CNS depression can be increased when Morphine is combined with Chlorpheniramine.
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Morphine.
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Morphine.
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Morphine.
Chlorzoxazone	The risk or severity of CNS depression can be increased when Morphine is combined with Chlorzoxazone.
Cilazapril	The risk or severity of adverse effects can be increased when Morphine is combined with Cilazapril.
Cimetidine	The risk or severity of adverse effects can be increased when Cimetidine is combined with Morphine.
Cinchocaine	The risk or severity of CNS depression can be increased when Morphine is combined with Cinchocaine.
Ciprofloxacin	The metabolism of Morphine can be decreased when combined with Ciprofloxacin.
Cisapride	The risk or severity of CNS depression can be increased when Morphine is combined with Cisapride.
Cisatracurium	The risk or severity of adverse effects can be increased when Cisatracurium is combined with Morphine.
Citalopram	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Citalopram.
Clarithromycin	The metabolism of Morphine can be decreased when combined with Clarithromycin.
Clemastine	The risk or severity of CNS depression can be increased when Clemastine is combined with Morphine.
Clevidipine	The risk or severity of adverse effects can be increased when Morphine is combined with Clevidipine.
Clidinium	The risk or severity of adverse effects can be increased when Clidinium is combined with Morphine.
Clobazam	The risk or severity of respiratory depression can be increased when Clobazam is combined with Morphine.
Clofarabine	The risk or severity of adverse effects can be increased when Morphine is combined with Clofarabine.
Clofazimine	The serum concentration of Morphine can be increased when it is combined with Clofazimine.
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Morphine.
Clomipramine	The risk or severity of CNS depression can be increased when Morphine is combined with Clomipramine.
Clonazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Clonazepam.
Clonidine	The risk or severity of sedation can be increased when Clonidine is combined with Morphine.
Clopidogrel	The serum concentration of the active metabolites of Clopidogrel can be decreased when Clopidogrel is used in combination with Morphine.
Clorazepic acid	The risk or severity of adverse effects can be increased when Morphine is combined with Clorazepic acid.
Clothiapine	The risk or severity of CNS depression can be increased when Morphine is combined with Clothiapine.
Clotiazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Clotiazepam.
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Morphine.
Cobicistat	The metabolism of Morphine can be decreased when combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Morphine.
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Morphine.
Codeine	The risk or severity of adverse effects can be increased when Morphine is combined with Codeine.
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Morphine.
Conivaptan	The metabolism of Morphine can be decreased when combined with Conivaptan.
Crizotinib	The metabolism of Morphine can be decreased when combined with Crizotinib.
Cryptenamine	Morphine may increase the hypotensive activities of Cryptenamine.
Curcumin	The metabolism of Morphine can be decreased when combined with Curcumin.
Cyclizine	The risk or severity of CNS depression can be increased when Morphine is combined with Cyclizine.
Cyclobenzaprine	The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Morphine.
Cyclopenthiazide	The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Morphine.
Cyclophosphamide	The metabolism of Morphine can be increased when combined with Cyclophosphamide.
Cyclosporine	The metabolism of Morphine can be decreased when combined with Cyclosporine.
Cyclothiazide	The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Morphine.
Cycrimine	The risk or severity of adverse effects can be increased when Cycrimine is combined with Morphine.
Cyproheptadine	The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Morphine.
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be increased when it is combined with Morphine.
Dabrafenib	The serum concentration of Morphine can be decreased when it is combined with Dabrafenib.
Daclatasvir	The serum concentration of Morphine can be increased when it is combined with Daclatasvir.
Dacomitinib	The serum concentration of Morphine can be increased when it is combined with Dacomitinib.
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Morphine.
Danazol	The metabolism of Morphine can be decreased when combined with Danazol.
Danicopan	The serum concentration of Morphine can be increased when it is combined with Danicopan.
Dantrolene	The risk or severity of CNS depression can be increased when Morphine is combined with Dantrolene.
Dantron	The therapeutic efficacy of Dantron can be decreased when used in combination with Morphine.
Dapagliflozin	The risk or severity of adverse effects can be increased when Morphine is combined with Dapagliflozin.
Daprodustat	The metabolism of Daprodustat can be decreased when combined with Morphine.
Dapsone	The metabolism of Morphine can be decreased when combined with Dapsone.
Daptomycin	The serum concentration of Morphine can be increased when it is combined with Daptomycin.
Daridorexant	The risk or severity of CNS depression can be increased when Morphine is combined with Daridorexant.
Darifenacin	The risk or severity of adverse effects can be increased when Darifenacin is combined with Morphine.
Darolutamide	The serum concentration of Darolutamide can be increased when it is combined with Morphine.
Darunavir	The metabolism of Morphine can be decreased when combined with Darunavir.
Dasabuvir	The metabolism of Morphine can be decreased when combined with Dasabuvir.
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Morphine.
Dasiglucagon	Morphine may increase the hypotensive activities of Dasiglucagon.
Debrisoquine	Morphine may increase the hypotensive activities of Debrisoquine.
Decamethonium	The risk or severity of CNS depression can be increased when Morphine is combined with Decamethonium.
Deferasirox	The metabolism of Morphine can be decreased when combined with Deferasirox.
Dehydrocholic acid	The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Morphine.
Delavirdine	The metabolism of Morphine can be decreased when combined with Delavirdine.
Deserpidine	Morphine may increase the hypotensive activities of Deserpidine.
Desflurane	The risk or severity of CNS depression can be increased when Morphine is combined with Desflurane.
Desipramine	The risk or severity of adverse effects can be increased when Desipramine is combined with Morphine.
Desloratadine	The risk or severity of adverse effects can be increased when Desloratadine is combined with Morphine.
Desmopressin	The risk or severity of hyponatremia can be increased when Morphine is combined with Desmopressin.
Desogestrel	The metabolism of Morphine can be increased when combined with Desogestrel.
Desvenlafaxine	The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Morphine.
Dexamethasone	The metabolism of Morphine can be increased when combined with Dexamethasone.
Dexbrompheniramine	The risk or severity of CNS depression can be increased when Morphine is combined with Dexbrompheniramine.
Dexfenfluramine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Dexfenfluramine.
Dexibuprofen	The metabolism of Dexibuprofen can be decreased when combined with Morphine.
Dexmedetomidine	The risk or severity of CNS depression can be increased when Morphine is combined with Dexmedetomidine.
Dexmethylphenidate	The risk or severity of CNS depression can be increased when Morphine is combined with Dexmethylphenidate.
Dextroamphetamine	Dextroamphetamine may increase the analgesic activities of Morphine.
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Morphine.
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene.
Dezocine	The risk or severity of adverse effects can be increased when Morphine is combined with Dezocine.
Diamorphine	The risk or severity of adverse effects can be increased when Morphine is combined with Diamorphine.
Diazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Diazepam.
Diazoxide	The risk or severity of adverse effects can be increased when Morphine is combined with Diazoxide.
Dibenzepin	The risk or severity of CNS depression can be increased when Morphine is combined with Dibenzepin.
Dichloralphenazone	The risk or severity of CNS depression can be increased when Morphine is combined with Dichloralphenazone.
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Morphine.
Diclofenamide	The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Morphine.
Dicyclomine	The risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.
Diethylpropion	Diethylpropion may increase the analgesic activities of Morphine.
Diethylstilbestrol	The metabolism of Morphine can be decreased when combined with Diethylstilbestrol.
Difenoxin	The risk or severity of CNS depression can be increased when Morphine is combined with Difenoxin.
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Morphine.
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Morphine.
Dihydralazine	Morphine may increase the hypotensive activities of Dihydralazine.
Dihydrocodeine	The risk or severity of adverse effects can be increased when Morphine is combined with Dihydrocodeine.
Dihydroergotamine	The risk or severity of CNS depression can be increased when Morphine is combined with Dihydroergotamine.
Diltiazem	The metabolism of Morphine can be decreased when combined with Diltiazem.
Dimenhydrinate	The risk or severity of CNS depression can be increased when Morphine is combined with Dimenhydrinate.
Dimetindene	The risk or severity of adverse effects can be increased when Dimetindene is combined with Morphine.
Dinutuximab	The risk or severity of adverse effects can be increased when Morphine is combined with Dinutuximab.
Diosmin	The serum concentration of Morphine can be increased when it is combined with Diosmin.
Diphemanil	The risk or severity of adverse effects can be increased when Diphemanil is combined with Morphine.
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Morphine.
Diphenidol	The risk or severity of adverse effects can be increased when Diphenidol is combined with Morphine.
Diphenoxylate	The risk or severity of adverse effects can be increased when Morphine is combined with Diphenoxylate.
Dipotassium phosphate	The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Morphine.
Dipyridamole	The risk or severity of adverse effects can be increased when Morphine is combined with Dipyridamole.
Disopyramide	The risk or severity of adverse effects can be increased when Disopyramide is combined with Morphine.
Docusate	The therapeutic efficacy of Docusate can be decreased when used in combination with Morphine.
Dolasetron	The risk or severity of CNS depression can be increased when Morphine is combined with Dolasetron.
Dolutegravir	The serum concentration of Dolutegravir can be increased when it is combined with Morphine.
Domperidone	The metabolism of Domperidone can be decreased when combined with Morphine.
Donepezil	The risk or severity of CNS depression can be increased when Morphine is combined with Donepezil.
Dosulepin	The risk or severity of adverse effects can be increased when Dosulepin is combined with Morphine.
Doxacurium	The risk or severity of adverse effects can be increased when Doxacurium is combined with Morphine.
Doxazosin	The risk or severity of adverse effects can be increased when Morphine is combined with Doxazosin.
Doxepin	The risk or severity of adverse effects can be increased when Doxepin is combined with Morphine.
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Dronedarone	The metabolism of Morphine can be decreased when combined with Dronedarone.
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Drospirenone	The therapeutic efficacy of Drospirenone can be decreased when used in combination with Morphine.
Duloxetine	The risk or severity of orthostatic hypotension and syncope can be increased when Morphine is combined with Duloxetine.
Duvelisib	The serum concentration of Duvelisib can be increased when it is combined with Morphine.
Dyclonine	The risk or severity of CNS depression can be increased when Morphine is combined with Dyclonine.
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Morphine.
Efavirenz	The metabolism of Morphine can be decreased when combined with Efavirenz.
Elacestrant	The serum concentration of Morphine can be increased when it is combined with Elacestrant.
Elagolix	The serum concentration of Morphine can be increased when it is combined with Elagolix.
Elbasvir	The serum concentration of Elbasvir can be increased when it is combined with Morphine.
Eletriptan	The risk or severity of CNS depression can be increased when Eletriptan is combined with Morphine.
Eliglustat	The serum concentration of Morphine can be increased when it is combined with Eliglustat.
Eltrombopag	The metabolism of Morphine can be decreased when combined with Eltrombopag.
Eluxadoline	The risk or severity of constipation can be increased when Morphine is combined with Eluxadoline.
Elvitegravir	The metabolism of Morphine can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Morphine can be increased when combined with Emapalumab.
Empagliflozin	The risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.
Enalapril	The risk or severity of adverse effects can be increased when Morphine is combined with Enalapril.
Enalaprilat	The risk or severity of adverse effects can be increased when Morphine is combined with Enalaprilat.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Morphine.
Encorafenib	The serum concentration of Morphine can be increased when it is combined with Encorafenib.
Enflurane	The risk or severity of CNS depression can be increased when Enflurane is combined with Morphine.
Enfortumab vedotin	The serum concentration of Enfortumab vedotin can be increased when it is combined with Morphine.
Entacapone	The risk or severity of CNS depression can be increased when Morphine is combined with Entacapone.
Entrectinib	The serum concentration of Morphine can be increased when it is combined with Entrectinib.
Enzalutamide	The serum concentration of Morphine can be decreased when it is combined with Enzalutamide.
Epcoritamab	The serum concentration of Morphine can be increased when it is combined with Epcoritamab.
Epinastine	The risk or severity of CNS depression can be increased when Morphine is combined with Epinastine.
Eplerenone	The therapeutic efficacy of Eplerenone can be decreased when used in combination with Morphine.
Epoprostenol	The risk or severity of adverse effects can be increased when Morphine is combined with Epoprostenol.
Eprosartan	The risk or severity of adverse effects can be increased when Morphine is combined with Eprosartan.
Erdafitinib	The serum concentration of Morphine can be increased when it is combined with Erdafitinib.
Ergoloid mesylate	The risk or severity of CNS depression can be increased when Morphine is combined with Ergoloid mesylate.
Ergometrine	The risk or severity of CNS depression can be increased when Morphine is combined with Ergometrine.
Ergotamine	The metabolism of Morphine can be decreased when combined with Ergotamine.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Morphine.
Erythromycin	The serum concentration of Morphine can be increased when it is combined with Erythromycin.
Escitalopram	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Escitalopram.
Esketamine	The risk or severity of adverse effects can be increased when Morphine is combined with Esketamine.
Eslicarbazepine	The risk or severity of CNS depression can be increased when Morphine is combined with Eslicarbazepine.
Eslicarbazepine acetate	The risk or severity of CNS depression can be increased when Morphine is combined with Eslicarbazepine acetate.
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Morphine.
Estazolam	The risk or severity of adverse effects can be increased when Morphine is combined with Estazolam.
Estradiol	The metabolism of Estradiol can be decreased when combined with Morphine.
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Morphine.
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Morphine.
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Morphine.
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Morphine.
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Morphine.
Eszopiclone	The risk or severity of CNS depression can be increased when Morphine is combined with Eszopiclone.
Etacrynic acid	The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Morphine.
Etanercept	The metabolism of Morphine can be increased when combined with Etanercept.
Ethanol	Morphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol	The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Morphine.
Ethinylestradiol	Ethinylestradiol may increase the excretion rate of Morphine which could result in a lower serum level and potentially a reduction in efficacy.
Ethosuximide	The risk or severity of CNS depression can be increased when Morphine is combined with Ethosuximide.
Ethotoin	The risk or severity of CNS depression can be increased when Morphine is combined with Ethotoin.
Etomidate	The risk or severity of CNS depression can be increased when Etomidate is combined with Morphine.
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Morphine.
Etrasimod	The metabolism of Etrasimod can be decreased when combined with Morphine.
Everolimus	The serum concentration of Morphine can be increased when it is combined with Everolimus.
Ezogabine	The risk or severity of CNS depression can be increased when Morphine is combined with Ezogabine.
Favipiravir	The serum concentration of Morphine can be increased when it is combined with Favipiravir.
Fedratinib	The serum concentration of Morphine can be increased when it is combined with Fedratinib.
Felbamate	The risk or severity of CNS depression can be increased when Morphine is combined with Felbamate.
Felodipine	The metabolism of Morphine can be decreased when combined with Felodipine.
Fenfluramine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Fenfluramine.
Fenofibrate	The metabolism of Morphine can be decreased when combined with Fenofibrate.
Fenoldopam	The risk or severity of adverse effects can be increased when Morphine is combined with Fenoldopam.
Fenoterol	The risk or severity of adverse effects can be increased when Fenoterol is combined with Morphine.
Fentanyl	The risk or severity of adverse effects can be increased when Morphine is combined with Fentanyl.
Fesoterodine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Morphine.
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Morphine.
Finerenone	The metabolism of Finerenone can be decreased when combined with Morphine.
Flavoxate	The risk or severity of adverse effects can be increased when Flavoxate is combined with Morphine.
Flibanserin	The risk or severity of CNS depression can be increased when Morphine is combined with Flibanserin.
Fluconazole	The metabolism of Morphine can be decreased when combined with Fluconazole.
Flunarizine	The risk or severity of CNS depression can be increased when Morphine is combined with Flunarizine.
Flunitrazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Flunitrazepam.
Fluorouracil	The metabolism of Fluorouracil can be decreased when combined with Morphine.
Fluoxetine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Fluoxetine.
Flupentixol	The risk or severity of CNS depression can be increased when Morphine is combined with Flupentixol.
Fluphenazine	The risk or severity of hypotension and CNS depression can be increased when Fluphenazine is combined with Morphine.
Flurazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Flurazepam.
Flurbiprofen	The metabolism of Morphine can be decreased when combined with Flurbiprofen.
Fluspirilene	The risk or severity of CNS depression can be increased when Morphine is combined with Fluspirilene.
Fluticasone	The metabolism of Morphine can be decreased when combined with Fluticasone.
Fluticasone propionate	The metabolism of Morphine can be decreased when combined with Fluticasone propionate.
Fluvastatin	The metabolism of Morphine can be decreased when combined with Fluvastatin.
Fluvoxamine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Fluvoxamine.
Fosinopril	The risk or severity of adverse effects can be increased when Morphine is combined with Fosinopril.
Fosnetupitant	The metabolism of Morphine can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Fosphenytoin can be decreased when combined with Morphine.
Fospropofol	The risk or severity of CNS depression can be increased when Morphine is combined with Fospropofol.
Fostamatinib	The metabolism of Morphine can be decreased when combined with Fostamatinib.
Fostemsavir	The serum concentration of Fostemsavir can be increased when it is combined with Morphine.
Frangula purshiana bark	The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Morphine.
Frovatriptan	The risk or severity of CNS depression can be increased when Morphine is combined with Frovatriptan.
Fruquintinib	The metabolism of Fruquintinib can be decreased when combined with Morphine.
Furosemide	The therapeutic efficacy of Furosemide can be decreased when used in combination with Morphine.
Fusidic acid	The metabolism of Morphine can be decreased when combined with Fusidic acid.
Futibatinib	The serum concentration of Futibatinib can be increased when it is combined with Morphine.
Gabapentin	The serum concentration of Gabapentin can be increased when it is combined with Morphine.
Gabapentin enacarbil	The risk or severity of CNS depression can be increased when Morphine is combined with Gabapentin enacarbil.
Gallamine triethiodide	The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Morphine.
gamma-Hydroxybutyric acid	The risk or severity of CNS depression can be increased when Morphine is combined with gamma-Hydroxybutyric acid.
Ganaxolone	The risk or severity of sedation, somnolence, and CNS depression can be increased when Morphine is combined with Ganaxolone.
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Morphine.
Gemfibrozil	The metabolism of Morphine can be decreased when combined with Gemfibrozil.
Gepirone	The risk or severity of serotonin syndrome can be increased when Gepirone is combined with Morphine.
Gilteritinib	The serum concentration of Gilteritinib can be increased when it is combined with Morphine.
Glasdegib	The serum concentration of Morphine can be increased when it is combined with Glasdegib.
Glecaprevir	The serum concentration of Morphine can be increased when it is combined with Glecaprevir.
Glofitamab	The serum concentration of Morphine can be increased when it is combined with Glofitamab.
Gluconic Acid	The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Morphine.
Glutethimide	The risk or severity of CNS depression can be increased when Morphine is combined with Glutethimide.
Glycerin	The therapeutic efficacy of Glycerin can be decreased when used in combination with Morphine.
Glycopyrronium	The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Morphine.
Golimumab	The metabolism of Morphine can be increased when combined with Golimumab.
Granisetron	The risk or severity of CNS depression can be increased when Morphine is combined with Granisetron.
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Morphine.
Guanabenz	Morphine may increase the hypotensive activities of Guanabenz.
Guanadrel	Morphine may increase the hypotensive activities of Guanadrel.
Guanethidine	Morphine may increase the hypotensive activities of Guanethidine.
Guanfacine	The risk or severity of CNS depression can be increased when Morphine is combined with Guanfacine.
Guanoxan	Morphine may increase the hypotensive activities of Guanoxan.
Halazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Halazepam.
Halofantrine	The metabolism of Halofantrine can be decreased when combined with Morphine.
Haloperidol	The risk or severity of CNS depression can be increased when Haloperidol is combined with Morphine.
Halothane	The therapeutic efficacy of Morphine can be increased when used in combination with Halothane.
Hexafluronium	The risk or severity of adverse effects can be increased when Hexafluronium is combined with Morphine.
Hexocyclium	The risk or severity of adverse effects can be increased when Hexocyclium is combined with Morphine.
Homatropine methylbromide	The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Morphine.
Hydralazine	The risk or severity of adverse effects can be increased when Morphine is combined with Hydralazine.
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Morphine.
Hydrocodone	Morphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydrocortisone	The metabolism of Morphine can be increased when combined with Hydrocortisone.
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Morphine.
Hydromorphone	The risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.
Hydroxychloroquine	The metabolism of Hydroxychloroquine can be decreased when combined with Morphine.
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Morphine.
Ibuprofen	The metabolism of Ibuprofen can be decreased when combined with Morphine.
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Morphine.
Ifosfamide	The metabolism of Morphine can be increased when combined with Ifosfamide.
Iloperidone	The risk or severity of CNS depression can be increased when Morphine is combined with Iloperidone.
Iloprost	The risk or severity of adverse effects can be increased when Morphine is combined with Iloprost.
Imatinib	The metabolism of Imatinib can be decreased when combined with Morphine.
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Morphine.
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Morphine.
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Morphine.
Indinavir	The metabolism of Morphine can be decreased when combined with Indinavir.
Indomethacin	The metabolism of Morphine can be decreased when combined with Indomethacin.
Indoramin	The risk or severity of adverse effects can be increased when Morphine is combined with Indoramin.
Infliximab	The metabolism of Morphine can be increased when combined with Infliximab.
Iofetamine I-123	Iofetamine I-123 may increase the analgesic activities of Morphine.
Ipratropium	The risk or severity of adverse effects can be increased when Ipratropium is combined with Morphine.
Iptacopan	The metabolism of Iptacopan can be decreased when combined with Morphine.
Irbesartan	The metabolism of Morphine can be decreased when combined with Irbesartan.
Isavuconazole	The serum concentration of Morphine can be increased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Morphine can be increased when it is combined with Isavuconazonium.
Isocarboxazid	Isocarboxazid may increase the analgesic activities of Morphine.
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Morphine.
Isoniazid	The metabolism of Morphine can be decreased when combined with Isoniazid.
Isopropamide	The risk or severity of adverse effects can be increased when Isopropamide is combined with Morphine.
Isosorbide	The therapeutic efficacy of Isosorbide can be decreased when used in combination with Morphine.
Isosorbide dinitrate	The risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide dinitrate.
Isosorbide mononitrate	The risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide mononitrate.
Isoxsuprine	The risk or severity of adverse effects can be increased when Morphine is combined with Isoxsuprine.
Isradipine	The metabolism of Morphine can be decreased when combined with Isradipine.
Istradefylline	The serum concentration of Morphine can be increased when it is combined with Istradefylline.
Itraconazole	The metabolism of Morphine can be decreased when combined with Itraconazole.
Ivacaftor	The serum concentration of Morphine can be increased when it is combined with Ivacaftor.
Ivosidenib	The metabolism of Morphine can be increased when combined with Ivosidenib.
Ixabepilone	The serum concentration of Morphine can be increased when it is combined with Ixabepilone.
Ketamine	The risk or severity of CNS depression can be increased when Morphine is combined with Ketamine.
Ketazolam	The risk or severity of adverse effects can be increased when Morphine is combined with Ketazolam.
Ketoconazole	The metabolism of Morphine can be decreased when combined with Ketoconazole.
Ketoprofen	The metabolism of Morphine can be decreased when combined with Ketoprofen.
Ketorolac	The metabolism of Ketorolac can be decreased when combined with Morphine.
Labetalol	The risk or severity of adverse effects can be increased when Morphine is combined with Labetalol.
Lacidipine	Morphine may increase the hypotensive activities of Lacidipine.
Lactitol	The therapeutic efficacy of Lactitol can be decreased when used in combination with Morphine.
Lactulose	The therapeutic efficacy of Lactulose can be decreased when used in combination with Morphine.
Lamotrigine	The metabolism of Morphine can be increased when combined with Lamotrigine.
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Morphine.
Lapatinib	The serum concentration of Morphine can be increased when it is combined with Lapatinib.
Lasmiditan	The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Morphine.
Ledipasvir	The serum concentration of Morphine can be increased when it is combined with Ledipasvir.
Lefamulin	The serum concentration of Lefamulin can be increased when it is combined with Morphine.
Lemborexant	The risk or severity of CNS depression can be increased when Morphine is combined with Lemborexant.
Lenacapavir	The serum concentration of Lenacapavir can be increased when it is combined with Morphine.
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Morphine.
Lercanidipine	The risk or severity of adverse effects can be increased when Morphine is combined with Lercanidipine.
Letermovir	The metabolism of Morphine can be decreased when combined with Letermovir.
Levacetylmethadol	The risk or severity of adverse effects can be increased when Morphine is combined with Levacetylmethadol.
Levallorphan	The therapeutic efficacy of Morphine can be decreased when used in combination with Levallorphan.
Levamlodipine	Morphine may increase the hypotensive activities of Levamlodipine.
Levetiracetam	The risk or severity of CNS depression can be increased when Morphine is combined with Levetiracetam.
Levobupivacaine	The risk or severity of CNS depression can be increased when Morphine is combined with Levobupivacaine.
Levocetirizine	The risk or severity of CNS depression can be increased when Morphine is combined with Levocetirizine.
Levodopa	The risk or severity of hypotension and orthostatic hypotension can be increased when Morphine is combined with Levodopa.
Levoketoconazole	The metabolism of Morphine can be decreased when combined with Levoketoconazole.
Levomilnacipran	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Levomilnacipran.
Levorphanol	The risk or severity of adverse effects can be increased when Morphine is combined with Levorphanol.
Levosimendan	The risk or severity of adverse effects can be increased when Morphine is combined with Levosimendan.
Levothyroxine	The metabolism of Morphine can be decreased when combined with Levothyroxine.
Lidocaine	The risk or severity of CNS depression can be increased when Lidocaine is combined with Morphine.
Linaclotide	The therapeutic efficacy of Linaclotide can be decreased when used in combination with Morphine.
Linagliptin	The metabolism of Morphine can be decreased when combined with Linagliptin.
Linezolid	The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Morphine.
Linzagolix	The serum concentration of Morphine can be increased when it is combined with Linzagolix.
Lisdexamfetamine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Lisdexamfetamine.
Lisinopril	The risk or severity of adverse effects can be increased when Morphine is combined with Lisinopril.
Lisuride	The risk or severity of CNS depression can be increased when Morphine is combined with Lisuride.
Lithium carbonate	The risk or severity of CNS depression can be increased when Morphine is combined with Lithium carbonate.
Lofexidine	The therapeutic efficacy of Morphine can be increased when used in combination with Lofexidine.
Lomitapide	The serum concentration of Morphine can be increased when it is combined with Lomitapide.
Lonafarnib	The metabolism of Morphine can be decreased when combined with Lonafarnib.
Loncastuximab tesirine	The serum concentration of Loncastuximab tesirine can be increased when it is combined with Morphine.
Loperamide	The metabolism of Loperamide can be decreased when combined with Morphine.
Lopinavir	The metabolism of Morphine can be decreased when combined with Lopinavir.
Loratadine	The metabolism of Morphine can be decreased when combined with Loratadine.
Lorazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Lorazepam.
Lorcaserin	The risk or severity of CNS depression can be increased when Morphine is combined with Lorcaserin.
Lormetazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Lormetazepam.
Losartan	The metabolism of Morphine can be decreased when combined with Losartan.
Loxapine	The risk or severity of CNS depression can be increased when Morphine is combined with Loxapine.
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Morphine.
Lumacaftor	The serum concentration of Morphine can be decreased when it is combined with Lumacaftor.
Lumateperone	The risk or severity of CNS depression can be increased when Morphine is combined with Lumateperone.
Lurasidone	The risk or severity of CNS depression can be increased when Morphine is combined with Lurasidone.
Lusutrombopag	The serum concentration of Lusutrombopag can be increased when it is combined with Morphine.
Macitentan	Morphine may increase the hypotensive activities of Macitentan.
Magnesium	The therapeutic efficacy of Magnesium can be decreased when used in combination with Morphine.
Magnesium acetate	The therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Morphine.
Magnesium acetate tetrahydrate	The therapeutic efficacy of Magnesium acetate tetrahydrate can be decreased when used in combination with Morphine.
Magnesium carbonate	The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Morphine.
Magnesium cation	The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Morphine.
Magnesium citrate	The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Morphine.
Magnesium glycinate	The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Morphine.
Magnesium hydroxide	The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Morphine.
Magnesium oxide	The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Morphine.
Magnesium sulfate	The therapeutic efficacy of Morphine can be increased when used in combination with Magnesium sulfate.
Magnesium trisilicate	The therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Morphine.
Manidipine	Morphine may increase the hypotensive activities of Manidipine.
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Morphine.
Maprotiline	The risk or severity of adverse effects can be increased when Maprotiline is combined with Morphine.
Maribavir	The serum concentration of Morphine can be increased when it is combined with Maribavir.
Mavacamten	The serum concentration of Morphine can be decreased when it is combined with Mavacamten.
Mazindol	The risk or severity of CNS depression can be increased when Morphine is combined with Mazindol.
Mebeverine	The risk or severity of adverse effects can be increased when Mebeverine is combined with Morphine.
Mebutamate	The risk or severity of CNS depression can be increased when Morphine is combined with Mebutamate.
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.
Meclizine	The risk or severity of adverse effects can be increased when Meclizine is combined with Morphine.
Medifoxamine	The risk or severity of CNS depression can be increased when Morphine is combined with Medifoxamine.
Medroxyprogesterone acetate	The metabolism of Morphine can be decreased when combined with Medroxyprogesterone acetate.
Mefenamic acid	The metabolism of Morphine can be decreased when combined with Mefenamic acid.
Mefloquine	The serum concentration of Morphine can be increased when it is combined with Mefloquine.
Melatonin	The risk or severity of CNS depression can be increased when Morphine is combined with Melatonin.
Mepenzolate	The risk or severity of adverse effects can be increased when Mepenzolate is combined with Morphine.
Meperidine	The risk or severity of adverse effects can be increased when Morphine is combined with Meperidine.
Mephentermine	Mephentermine may increase the analgesic activities of Morphine.
Mephenytoin	The risk or severity of CNS depression can be increased when Morphine is combined with Mephenytoin.
Mepivacaine	The risk or severity of CNS depression can be increased when Morphine is combined with Mepivacaine.
Meprobamate	The risk or severity of CNS depression can be increased when Morphine is combined with Meprobamate.
Mepyramine	The risk or severity of CNS depression can be increased when Morphine is combined with Mepyramine.
Mesoridazine	The risk or severity of hypotension and CNS depression can be increased when Mesoridazine is combined with Morphine.
Mestranol	The metabolism of Mestranol can be decreased when combined with Morphine.
Metamfetamine	Metamfetamine may increase the analgesic activities of Morphine.
Metaxalone	The risk or severity of CNS depression can be increased when Morphine is combined with Metaxalone.
Metergoline	The risk or severity of CNS depression can be increased when Morphine is combined with Metergoline.
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Morphine.
Methantheline	The risk or severity of adverse effects can be increased when Methantheline is combined with Morphine.
Methazolamide	The therapeutic efficacy of Methazolamide can be decreased when used in combination with Morphine.
Methimazole	The metabolism of Morphine can be decreased when combined with Methimazole.
Methocarbamol	The risk or severity of CNS depression can be increased when Morphine is combined with Methocarbamol.
Methohexital	Methohexital may increase the hypotensive activities of Morphine.
Methotrimeprazine	Morphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane	The risk or severity of CNS depression can be increased when Morphine is combined with Methoxyflurane.
Methoxyphenamine	Methoxyphenamine may increase the analgesic activities of Morphine.
Methscopolamine	The risk or severity of adverse effects can be increased when Methscopolamine is combined with Morphine.
Methscopolamine bromide	The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Morphine.
Methsuximide	The risk or severity of CNS depression can be increased when Morphine is combined with Methsuximide.
Methylcellulose	The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Morphine.
Methyldopa	The risk or severity of adverse effects can be increased when Morphine is combined with Methyldopa.
Methylene blue	Morphine may increase the serotonergic activities of Methylene blue.
Methylnaltrexone	The therapeutic efficacy of Morphine can be decreased when used in combination with Methylnaltrexone.
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Morphine.
Methyprylon	The risk or severity of CNS depression can be increased when Morphine is combined with Methyprylon.
Methysergide	The risk or severity of CNS depression can be increased when Methysergide is combined with Morphine.
Meticrane	The therapeutic efficacy of Meticrane can be decreased when used in combination with Morphine.
Metixene	The risk or severity of adverse effects can be increased when Metixene is combined with Morphine.
Metoclopramide	The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Morphine.
Metocurine	The risk or severity of adverse effects can be increased when Metocurine is combined with Morphine.
Metocurine iodide	The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Morphine.
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Morphine.
Metoprolol	The risk or severity of adverse effects can be increased when Metoprolol is combined with Morphine.
Metreleptin	The metabolism of Morphine can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Morphine can be decreased when combined with Metronidazole.
Metyrosine	Morphine may increase the sedative activities of Metyrosine.
Mianserin	The risk or severity of CNS depression can be increased when Morphine is combined with Mianserin.
Miconazole	The metabolism of Morphine can be decreased when combined with Miconazole.
Midazolam	The risk or severity of respiratory depression can be increased when Midazolam is combined with Morphine.
Midostaurin	The metabolism of Morphine can be decreased when combined with Midostaurin.
Mifepristone	The serum concentration of Morphine can be increased when it is combined with Mifepristone.
Milnacipran	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Milnacipran.
Minaprine	Minaprine may increase the analgesic activities of Morphine.
Mineral oil	The therapeutic efficacy of Mineral oil can be decreased when used in combination with Morphine.
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Minoxidil	The risk or severity of adverse effects can be increased when Morphine is combined with Minoxidil.
Mirabegron	The serum concentration of Morphine can be increased when it is combined with Mirabegron.
Mirtazapine	Morphine may increase the serotonergic activities of Mirtazapine.
Mitapivat	The metabolism of Morphine can be increased when combined with Mitapivat.
Mitotane	The metabolism of Morphine can be increased when combined with Mitotane.
Mivacurium	The risk or severity of adverse effects can be increased when Mivacurium is combined with Morphine.
Moclobemide	Moclobemide may increase the analgesic activities of Morphine.
Moexipril	The risk or severity of adverse effects can be increased when Morphine is combined with Moexipril.
Molindone	The risk or severity of CNS depression can be increased when Morphine is combined with Molindone.
Mometasone furoate	The metabolism of Morphine can be decreased when combined with Mometasone furoate.
Monopotassium phosphate	The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Morphine.
Montelukast	The metabolism of Montelukast can be decreased when combined with Morphine.
Moricizine	The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Morphine.
Moxonidine	The risk or severity of adverse effects can be increased when Morphine is combined with Moxonidine.
Muzolimine	The therapeutic efficacy of Muzolimine can be decreased when used in combination with Morphine.
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Morphine.
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Nadolol	The risk or severity of adverse effects can be increased when Morphine is combined with Nadolol.
Nalbuphine	The therapeutic efficacy of Morphine can be decreased when used in combination with Nalbuphine.
Naldemedine	The therapeutic efficacy of Morphine can be decreased when used in combination with Naldemedine.
Nalmefene	The therapeutic efficacy of Morphine can be decreased when used in combination with Nalmefene.
Naloxegol	The risk or severity of adverse effects can be increased when Morphine is combined with Naloxegol.
Naloxone	The therapeutic efficacy of Morphine can be decreased when used in combination with Naloxone.
Naltrexone	The therapeutic efficacy of Morphine can be decreased when used in combination with Naltrexone.
Naphazoline	Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Naproxen	The metabolism of Naproxen can be decreased when combined with Morphine.
Naratriptan	The risk or severity of CNS depression can be increased when Morphine is combined with Naratriptan.
Nebivolol	The risk or severity of adverse effects can be increased when Morphine is combined with Nebivolol.
Nefazodone	The metabolism of Morphine can be decreased when combined with Nefazodone.
Nefopam	The therapeutic efficacy of Morphine can be increased when used in combination with Nefopam.
Nelfinavir	The metabolism of Morphine can be decreased when combined with Nelfinavir.
Neratinib	The serum concentration of Morphine can be increased when it is combined with Neratinib.
Nesiritide	The risk or severity of adverse effects can be increased when Morphine is combined with Nesiritide.
Netupitant	The metabolism of Morphine can be decreased when combined with Netupitant.
Nialamide	Nialamide may increase the analgesic activities of Morphine.
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Morphine.
Nicorandil	Nicorandil may increase the hypotensive activities of Morphine.
Nifedipine	The risk or severity of adverse effects can be increased when Morphine is combined with Nifedipine.
Nilotinib	The metabolism of Morphine can be decreased when combined with Nilotinib.
Nilutamide	The metabolism of Morphine can be decreased when combined with Nilutamide.
Nilvadipine	The metabolism of Morphine can be decreased when combined with Nilvadipine.
Nimodipine	The risk or severity of adverse effects can be increased when Morphine is combined with Nimodipine.
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Morphine.
Nirogacestat	The serum concentration of Morphine can be increased when it is combined with Nirogacestat.
Nisoldipine	The risk or severity of adverse effects can be increased when Morphine is combined with Nisoldipine.
Nitrazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Nitrazepam.
Nitrendipine	The risk or severity of adverse effects can be increased when Morphine is combined with Nitrendipine.
Nitric Oxide	The risk or severity of adverse effects can be increased when Morphine is combined with Nitric Oxide.
Nitroglycerin	The risk or severity of adverse effects can be increased when Morphine is combined with Nitroglycerin.
Nitroprusside	The risk or severity of adverse effects can be increased when Morphine is combined with Nitroprusside.
Nitrous acid	The risk or severity of adverse effects can be increased when Morphine is combined with Nitrous acid.
Nitrous oxide	The risk or severity of myocardial depression can be increased when Morphine is combined with Nitrous oxide.
Nomifensine	The risk or severity of CNS depression can be increased when Morphine is combined with Nomifensine.
Norgestimate	The serum concentration of Morphine can be increased when it is combined with Norgestimate.
Normethadone	The risk or severity of adverse effects can be increased when Morphine is combined with Normethadone.
Nortriptyline	The risk or severity of adverse effects can be increased when Nortriptyline is combined with Morphine.
Obinutuzumab	The risk or severity of adverse effects can be increased when Morphine is combined with Obinutuzumab.
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Morphine.
Oliceridine	The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Morphine is combined with Oliceridine.
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Morphine.
Olodaterol	The metabolism of Olodaterol can be decreased when combined with Morphine.
Omadacycline	The serum concentration of Omadacycline can be increased when it is combined with Morphine.
Omaveloxolone	The serum concentration of Morphine can be decreased when it is combined with Omaveloxolone.
Ombitasvir	The metabolism of Morphine can be decreased when combined with Ombitasvir.
Ondansetron	The risk or severity of CNS depression can be increased when Morphine is combined with Ondansetron.
Opicapone	The risk or severity of adverse effects can be increased when Morphine is combined with Opicapone.
Opium	The risk or severity of adverse effects can be increased when Morphine is combined with Opium.
Orphenadrine	Morphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Morphine.
Oxazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Oxazepam.
Oxcarbazepine	The risk or severity of CNS depression can be increased when Morphine is combined with Oxcarbazepine.
Oxitriptan	The risk or severity of CNS depression can be increased when Morphine is combined with Oxitriptan.
Oxprenolol	The risk or severity of CNS depression can be increased when Morphine is combined with Oxprenolol.
Oxybuprocaine	The risk or severity of CNS depression can be increased when Morphine is combined with Oxybuprocaine.
Oxybutynin	The risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.
Oxycodone	The risk or severity of adverse effects can be increased when Morphine is combined with Oxycodone.
Oxymorphone	The risk or severity of adverse effects can be increased when Morphine is combined with Oxymorphone.
Oxyphencyclimine	The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Morphine.
Oxyphenisatin acetate	The therapeutic efficacy of Oxyphenisatin acetate can be decreased when used in combination with Morphine.
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Morphine.
Ozanimod	The metabolism of Ozanimod can be decreased when combined with Morphine.
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Morphine.
Pacritinib	The serum concentration of Morphine can be increased when it is combined with Pacritinib.
Palbociclib	The serum concentration of Morphine can be increased when it is combined with Palbociclib.
Paliperidone	The risk or severity of CNS depression can be increased when Morphine is combined with Paliperidone.
Palonosetron	The risk or severity of CNS depression can be increased when Morphine is combined with Palonosetron.
Pancuronium	The risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Morphine.
Papaverine	The risk or severity of adverse effects can be increased when Morphine is combined with Papaverine.
Paraldehyde	Morphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paramethadione	The risk or severity of CNS depression can be increased when Morphine is combined with Paramethadione.
Pargyline	Pargyline may increase the analgesic activities of Morphine.
Paritaprevir	The metabolism of Morphine can be decreased when combined with Paritaprevir.
Paroxetine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Paroxetine.
Pazopanib	The metabolism of Pazopanib can be decreased when combined with Morphine.
Pegvisomant	The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.
Penbutolol	The risk or severity of CNS depression can be increased when Morphine is combined with Penbutolol.
Pentazocine	The therapeutic efficacy of Morphine can be decreased when used in combination with Pentazocine.
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Morphine.
Pentolinium	The risk or severity of adverse effects can be increased when Pentolinium is combined with Morphine.
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Perazine	The risk or severity of hypotension and CNS depression can be increased when Perazine is combined with Morphine.
Pergolide	The risk or severity of CNS depression can be increased when Morphine is combined with Pergolide.
Periciazine	The risk or severity of hypotension and CNS depression can be increased when Periciazine is combined with Morphine.
Perindopril	The risk or severity of adverse effects can be increased when Morphine is combined with Perindopril.
Perphenazine	The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Morphine.
Pexidartinib	The metabolism of Morphine can be decreased when combined with Pexidartinib.
Phenacemide	The risk or severity of CNS depression can be increased when Morphine is combined with Phenacemide.
Phendimetrazine	Phendimetrazine may increase the analgesic activities of Morphine.
Phenelzine	Phenelzine may increase the analgesic activities of Morphine.
Phenobarbital	The risk or severity of adverse effects can be increased when Phenobarbital is combined with Morphine.
Phenolphthalein	The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Morphine.
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Morphine is combined with Phenoxybenzamine.
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Morphine.
Phensuximide	The risk or severity of CNS depression can be increased when Morphine is combined with Phensuximide.
Phentermine	Phentermine may increase the analgesic activities of Morphine.
Phentolamine	The risk or severity of adverse effects can be increased when Morphine is combined with Phentolamine.
Phenytoin	The metabolism of Phenytoin can be decreased when combined with Morphine.
Pibrentasvir	The serum concentration of Morphine can be increased when it is combined with Pibrentasvir.
Picosulfuric acid	The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Morphine.
Pimozide	The risk or severity of CNS depression can be increased when Morphine is combined with Pimozide.
Pinacidil	Morphine may increase the hypotensive activities of Pinacidil.
Pindolol	The risk or severity of CNS depression can be increased when Morphine is combined with Pindolol.
Pioglitazone	The metabolism of Morphine can be decreased when combined with Pioglitazone.
Pipecuronium	The risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.
Pipotiazine	The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Morphine.
Pirenzepine	The risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.
Piretanide	The therapeutic efficacy of Piretanide can be decreased when used in combination with Morphine.
Piritramide	The risk or severity of adverse effects can be increased when Morphine is combined with Piritramide.
Piroxicam	The metabolism of Piroxicam can be decreased when combined with Morphine.
Pirtobrutinib	The metabolism of Morphine can be decreased when combined with Pirtobrutinib.
Pitolisant	The serum concentration of Morphine can be decreased when it is combined with Pitolisant.
Pizotifen	The risk or severity of adverse effects can be increased when Pizotifen is combined with Morphine.
Plantago ovata seed	The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Morphine.
Plantago seed	The therapeutic efficacy of Plantago seed can be decreased when used in combination with Morphine.
Plecanatide	The therapeutic efficacy of Plecanatide can be decreased when used in combination with Morphine.
Polyethylene glycol	The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Morphine.
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Morphine.
Pomalidomide	The risk or severity of CNS depression can be increased when Morphine is combined with Pomalidomide.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Morphine.
Posaconazole	The metabolism of Morphine can be decreased when combined with Posaconazole.
Potassium	The therapeutic efficacy of Potassium can be decreased when used in combination with Morphine.
Potassium cation	The therapeutic efficacy of Potassium cation can be decreased when used in combination with Morphine.
Potassium citrate	The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Morphine.
Potassium lactate	The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Morphine.
Potassium sulfate	The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Morphine.
Practolol	Morphine may increase the hypotensive activities of Practolol.
Pralsetinib	The serum concentration of Morphine can be increased when it is combined with Pralsetinib.
Pramipexole	Morphine may increase the sedative activities of Pramipexole.
Pramocaine	The risk or severity of CNS depression can be increased when Morphine is combined with Pramocaine.
Prasugrel	The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Morphine resulting in a loss in efficacy.
Pravastatin	The serum concentration of Morphine can be increased when it is combined with Pravastatin.
Prazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Prazepam.
Prazosin	The risk or severity of adverse effects can be increased when Morphine is combined with Prazosin.
Prednisolone phosphate	The metabolism of Morphine can be increased when combined with Prednisolone phosphate.
Pregabalin	The therapeutic efficacy of Morphine can be increased when used in combination with Pregabalin.
Pretomanid	The serum concentration of Morphine can be increased when it is combined with Pretomanid.
Prilocaine	The risk or severity of CNS depression can be increased when Morphine is combined with Prilocaine.
Primaquine	The metabolism of Morphine can be decreased when combined with Primaquine.
Primidone	The risk or severity of adverse effects can be increased when Primidone is combined with Morphine.
Probenecid	The metabolism of Morphine can be decreased when combined with Probenecid.
Procaine	Procaine may increase the analgesic activities of Morphine.
Procarbazine	Procarbazine may increase the analgesic activities of Morphine.
Prochlorperazine	The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Morphine.
Procyclidine	The risk or severity of adverse effects can be increased when Procyclidine is combined with Morphine.
Profenamine	The risk or severity of adverse effects can be increased when Profenamine is combined with Morphine.
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Morphine.
Promethazine	The risk or severity of adverse effects can be increased when Promethazine is combined with Morphine.
Propafenone	The serum concentration of Morphine can be increased when it is combined with Propafenone.
Propantheline	The risk or severity of adverse effects can be increased when Propantheline is combined with Morphine.
Propiomazine	The risk or severity of adverse effects can be increased when Propiomazine is combined with Morphine.
Propiverine	The risk or severity of adverse effects can be increased when Propiverine is combined with Morphine.
Propofol	Morphine may increase the sedative activities of Propofol.
Propranolol	The risk or severity of adverse effects can be increased when Morphine is combined with Propranolol.
Protriptyline	The risk or severity of CNS depression can be increased when Morphine is combined with Protriptyline.
Proxibarbal	The risk or severity of CNS depression can be increased when Morphine is combined with Proxibarbal.
Prucalopride	The therapeutic efficacy of Prucalopride can be decreased when used in combination with Morphine.
Pseudoephedrine	Pseudoephedrine may increase the analgesic activities of Morphine.
Pyrantel	The risk or severity of CNS depression can be increased when Morphine is combined with Pyrantel.
Pyrimethamine	The metabolism of Morphine can be decreased when combined with Pyrimethamine.
Quazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Quazepam.
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Morphine.
Quinapril	The risk or severity of adverse effects can be increased when Morphine is combined with Quinapril.
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Morphine.
Quinidine	The risk or severity of adverse effects can be increased when Quinidine is combined with Morphine.
Quinine	The risk or severity of CNS depression can be increased when Morphine is combined with Quinine.
Quinupramine	The risk or severity of CNS depression can be increased when Morphine is combined with Quinupramine.
Quizartinib	The serum concentration of Morphine can be increased when it is combined with Quizartinib.
Raloxifene	The metabolism of Morphine can be decreased when combined with Raloxifene.
Ramelteon	The risk or severity of CNS depression can be increased when Morphine is combined with Ramelteon.
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Morphine.
Ranolazine	The serum concentration of Morphine can be increased when it is combined with Ranolazine.
Rapacuronium	The risk or severity of adverse effects can be increased when Rapacuronium is combined with Morphine.
Rasagiline	Rasagiline may increase the analgesic activities of Morphine.
Reboxetine	The risk or severity of CNS depression can be increased when Reboxetine is combined with Morphine.
Regorafenib	The serum concentration of Morphine can be increased when it is combined with Regorafenib.
Relugolix	The serum concentration of Relugolix can be increased when it is combined with Morphine.
Remifentanil	The risk or severity of adverse effects can be increased when Morphine is combined with Remifentanil.
Remimazolam	The risk or severity of sedation can be increased when Morphine is combined with Remimazolam.
Remoxipride	The risk or severity of CNS depression can be increased when Morphine is combined with Remoxipride.
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Morphine.
Repotrectinib	The serum concentration of Morphine can be increased when it is combined with Repotrectinib.
Rescinnamine	Morphine may increase the hypotensive activities of Rescinnamine.
Reserpine	The risk or severity of CNS depression can be increased when Reserpine is combined with Morphine.
Resmetirom	The metabolism of Morphine can be decreased when combined with Resmetirom.
Revefenacin	The risk or severity of adverse effects can be increased when Revefenacin is combined with Morphine.
Ribociclib	The metabolism of Morphine can be decreased when combined with Ribociclib.
Rifabutin	The metabolism of Morphine can be increased when combined with Rifabutin.
Rifampin	The metabolism of Morphine can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Morphine can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Morphine can be increased when combined with Rifapentine.
Rilmenidine	Morphine may increase the hypotensive activities of Rilmenidine.
Rilonacept	The metabolism of Morphine can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Morphine can be decreased when combined with Rilpivirine.
Riluzole	The risk or severity of CNS depression can be increased when Morphine is combined with Riluzole.
Rimegepant	The serum concentration of Rimegepant can be increased when it is combined with Morphine.
Rimonabant	The risk or severity of adverse effects can be increased when Rimonabant is combined with Morphine.
Riociguat	The metabolism of Riociguat can be decreased when combined with Morphine.
Ripretinib	The serum concentration of Morphine can be increased when it is combined with Ripretinib.
Risperidone	Morphine may increase the hypotensive activities of Risperidone.
Ritlecitinib	The serum concentration of Morphine can be increased when it is combined with Ritlecitinib.
Ritonavir	The serum concentration of Morphine can be increased when it is combined with Ritonavir.
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Morphine.
Rizatriptan	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Rizatriptan.
Rocuronium	The risk or severity of adverse effects can be increased when Rocuronium is combined with Morphine.
Rofecoxib	The metabolism of Morphine can be decreased when combined with Rofecoxib.
Rolapitant	The serum concentration of Morphine can be increased when it is combined with Rolapitant.
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Morphine.
Ropeginterferon alfa-2b	The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Morphine.
Ropinirole	Morphine may increase the sedative activities of Ropinirole.
Ropivacaine	The risk or severity of CNS depression can be increased when Morphine is combined with Ropivacaine.
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Morphine.
Rotigotine	Morphine may increase the sedative activities of Rotigotine.
Roxadustat	The metabolism of Roxadustat can be decreased when combined with Morphine.
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Morphine.
Sacubitril	The risk or severity of adverse effects can be increased when Morphine is combined with Sacubitril.
Safinamide	Safinamide may increase the analgesic activities of Morphine.
Salmeterol	The metabolism of Morphine can be decreased when combined with Salmeterol.
Samidorphan	The risk or severity of CNS depression can be increased when Morphine is combined with Samidorphan.
Sapropterin	The serum concentration of Morphine can be increased when it is combined with Sapropterin.
Saquinavir	The metabolism of Morphine can be decreased when combined with Saquinavir.
Sarecycline	The serum concentration of Morphine can be increased when it is combined with Sarecycline.
Satralizumab	The serum concentration of Morphine can be decreased when it is combined with Satralizumab.
Scopolamine	The risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Morphine.
Secukinumab	The metabolism of Morphine can be increased when combined with Secukinumab.
Selegiline	Selegiline may increase the analgesic activities of Morphine.
Selexipag	The metabolism of Selexipag can be decreased when combined with Morphine.
Selpercatinib	The serum concentration of Morphine can be increased when it is combined with Selpercatinib.
Selumetinib	The metabolism of Selumetinib can be decreased when combined with Morphine.
Senna leaf	The therapeutic efficacy of Senna leaf can be decreased when used in combination with Morphine.
Sertindole	The risk or severity of CNS depression can be increased when Morphine is combined with Sertindole.
Sertraline	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Sertraline.
Sevoflurane	The risk or severity of CNS depression can be increased when Morphine is combined with Sevoflurane.
Sibutramine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Sibutramine.
Sildenafil	The serum concentration of Morphine can be increased when it is combined with Sildenafil.
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Morphine.
Siltuximab	The metabolism of Morphine can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Morphine can be decreased when combined with Simeprevir.
Simvastatin	The serum concentration of Morphine can be increased when it is combined with Simvastatin.
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Morphine.
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Morphine.
Sitaxentan	Morphine may increase the hypotensive activities of Sitaxentan.
Sodium ascorbate	The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Morphine.
Sodium aurothiomalate	The metabolism of Morphine can be decreased when combined with Sodium aurothiomalate.
Sodium ferric gluconate complex	The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Morphine.
Sodium fluorophosphate	The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Morphine.
Sodium oxybate	Morphine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium phosphate, dibasic	The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Morphine.
Sodium phosphate, dibasic, unspecified form	The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Morphine.
Sodium phosphate, monobasic	The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Morphine.
Sodium phosphate, monobasic, unspecified form	The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Morphine.
Sodium sulfate	The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Morphine.
Sodium tartrate	The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Morphine.
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Morphine.
Solifenacin	The risk or severity of adverse effects can be increased when Solifenacin is combined with Morphine.
Solriamfetol	The risk or severity of CNS depression can be increased when Morphine is combined with Solriamfetol.
Somatrogon	The metabolism of Morphine can be increased when combined with Somatrogon.
Sorafenib	The serum concentration of Morphine can be increased when it is combined with Sorafenib.
Sorbitol	The therapeutic efficacy of Sorbitol can be decreased when used in combination with Morphine.
Sotagliflozin	The serum concentration of Morphine can be increased when it is combined with Sotagliflozin.
Sotalol	The risk or severity of adverse effects can be increased when Morphine is combined with Sotalol.
Sotorasib	The serum concentration of Morphine can be decreased when it is combined with Sotorasib.
Sparsentan	The serum concentration of Morphine can be increased when it is combined with Sparsentan.
Spirapril	Morphine may increase the hypotensive activities of Spirapril.
Spironolactone	The risk or severity of orthostatic hypotension can be increased when Morphine is combined with Spironolactone.
St. John's Wort	The metabolism of Morphine can be increased when combined with St. John's Wort.
Stiripentol	The metabolism of Morphine can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Morphine.
Succinylcholine	The risk or severity of bradycardia can be increased when Succinylcholine is combined with Morphine.
Sufentanil	The risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Morphine.
Sulfaphenazole	The metabolism of Morphine can be decreased when combined with Sulfaphenazole.
Sulpiride	The risk or severity of CNS depression can be increased when Morphine is combined with Sulpiride.
Sulthiame	The risk or severity of CNS depression can be increased when Morphine is combined with Sulthiame.
Sultopride	The risk or severity of CNS depression can be increased when Morphine is combined with Sultopride.
Sumatriptan	The risk or severity of CNS depression can be increased when Morphine is combined with Sumatriptan.
Suvorexant	Morphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tacrolimus	The serum concentration of Morphine can be increased when it is combined with Tacrolimus.
Tadalafil	Morphine may increase the hypotensive activities of Tadalafil.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Morphine.
Talbutal	The risk or severity of adverse effects can be increased when Talbutal is combined with Morphine.
Tamoxifen	The metabolism of Morphine can be decreased when combined with Tamoxifen.
Tamsulosin	The risk or severity of adverse effects can be increased when Morphine is combined with Tamsulosin.
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Morphine.
Tasimelteon	The risk or severity of CNS depression can be increased when Morphine is combined with Tasimelteon.
Tazarotene	The metabolism of Tazarotene can be decreased when combined with Morphine.
Tazemetostat	The serum concentration of Tazemetostat can be increased when it is combined with Morphine.
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Morphine.
Tecovirimat	The metabolism of Morphine can be increased when combined with Tecovirimat.
Tegafur	The metabolism of Tegafur can be decreased when combined with Morphine.
Tegaserod	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Tegaserod.
Telaprevir	The metabolism of Morphine can be decreased when combined with Telaprevir.
Telithromycin	The metabolism of Morphine can be decreased when combined with Telithromycin.
Telmisartan	The risk or severity of adverse effects can be increased when Morphine is combined with Telmisartan.
Telotristat ethyl	The serum concentration of Morphine can be decreased when it is combined with Telotristat ethyl.
Temazepam	The risk or severity of adverse effects can be increased when Morphine is combined with Temazepam.
Temsirolimus	The serum concentration of Morphine can be increased when it is combined with Temsirolimus.
Tenofovir disoproxil	The serum concentration of Tenofovir disoproxil can be increased when it is combined with Morphine.
Tepotinib	The serum concentration of Morphine can be increased when it is combined with Tepotinib.
Terazosin	The risk or severity of adverse effects can be increased when Morphine is combined with Terazosin.
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Morphine.
Terfenadine	The metabolism of Morphine can be decreased when combined with Terfenadine.
Teriflunomide	The metabolism of Morphine can be decreased when combined with Teriflunomide.
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Morphine.
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Morphine.
Testosterone propionate	The metabolism of Morphine can be increased when combined with Testosterone propionate.
Tetracaine	The risk or severity of CNS depression can be increased when Morphine is combined with Tetracaine.
Tezacaftor	The serum concentration of Tezacaftor can be increased when it is combined with Morphine.
Thalidomide	Morphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline	The metabolism of Morphine can be decreased when combined with Theophylline.
Thiamylal	Thiamylal may increase the hypotensive activities of Morphine.
Thiethylperazine	The risk or severity of hypotension and CNS depression can be increased when Thiethylperazine is combined with Morphine.
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Morphine.
Thioridazine	The risk or severity of hypotension and CNS depression can be increased when Thioridazine is combined with Morphine.
Thiothixene	The risk or severity of CNS depression can be increased when Morphine is combined with Thiothixene.
Thonzylamine	The risk or severity of adverse effects can be increased when Thonzylamine is combined with Morphine.
Tiagabine	The risk or severity of CNS depression can be increased when Morphine is combined with Tiagabine.
Ticagrelor	The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Morphine.
Ticlopidine	The therapeutic efficacy of Ticlopidine can be decreased when used in combination with Morphine.
Timolol	The risk or severity of adverse effects can be increased when Morphine is combined with Timolol.
Tiotropium	The risk or severity of adverse effects can be increased when Tiotropium is combined with Morphine.
Tipranavir	The metabolism of Morphine can be decreased when combined with Tipranavir.
Tivozanib	The serum concentration of Tivozanib can be increased when it is combined with Morphine.
Tizanidine	The risk or severity of CNS depression can be increased when Morphine is combined with Tizanidine.
Tocilizumab	The metabolism of Morphine can be increased when combined with Tocilizumab.
Tolazoline	The risk or severity of adverse effects can be increased when Morphine is combined with Tolazoline.
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Morphine.
Tolcapone	The risk or severity of CNS depression can be increased when Morphine is combined with Tolcapone.
Tolterodine	The risk or severity of adverse effects can be increased when Tolterodine is combined with Morphine.
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Morphine.
Topiramate	The risk or severity of CNS depression can be increased when Topiramate is combined with Morphine.
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Morphine.
Torasemide	The metabolism of Morphine can be decreased when combined with Torasemide.
Toremifene	The serum concentration of Morphine can be increased when it is combined with Toremifene.
Tovorafenib	The metabolism of Tovorafenib can be decreased when combined with Morphine.
Tramadol	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Tramadol.
Trandolapril	The risk or severity of adverse effects can be increased when Morphine is combined with Trandolapril.
Tranylcypromine	Tranylcypromine may increase the analgesic activities of Morphine.
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Morphine.
Trazodone	The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Morphine.
Treprostinil	The metabolism of Treprostinil can be decreased when combined with Morphine.
Triamterene	The therapeutic efficacy of Triamterene can be decreased when used in combination with Morphine.
Triazolam	The risk or severity of adverse effects can be increased when Morphine is combined with Triazolam.
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Morphine.
Trichloroethylene	The risk or severity of CNS depression can be increased when Morphine is combined with Trichloroethylene.
Triclabendazole	The metabolism of Morphine can be decreased when combined with Triclabendazole.
Triclofos	The risk or severity of CNS depression can be increased when Morphine is combined with Triclofos.
Trifluoperazine	The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Morphine.
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Morphine.
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Morphine.
Trilaciclib	The serum concentration of Trilaciclib can be increased when it is combined with Morphine.
Trimebutine	The risk or severity of adverse effects can be increased when Trimebutine is combined with Morphine.
Trimethadione	The risk or severity of CNS depression can be increased when Morphine is combined with Trimethadione.
Trimethaphan	The risk or severity of adverse effects can be increased when Trimethaphan is combined with Morphine.
Trimethobenzamide	The risk or severity of CNS depression can be increased when Morphine is combined with Trimethobenzamide.
Trimethoprim	The metabolism of Morphine can be decreased when combined with Trimethoprim.
Trimipramine	The risk or severity of CNS depression can be increased when Morphine is combined with Trimipramine.
Triprolidine	The risk or severity of CNS depression can be increased when Morphine is combined with Triprolidine.
Troglitazone	The metabolism of Morphine can be decreased when combined with Troglitazone.
Troleandomycin	The metabolism of Morphine can be decreased when combined with Troleandomycin.
Tropisetron	The risk or severity of CNS depression can be increased when Morphine is combined with Tropisetron.
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Morphine.
Tryptophan	The risk or severity of CNS depression can be increased when Tryptophan is combined with Morphine.
Tubocurarine	The risk or severity of adverse effects can be increased when Tubocurarine is combined with Morphine.
Tucatinib	Tucatinib may decrease the excretion rate of Morphine which could result in a higher serum level.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Morphine.
Udenafil	The risk or severity of hypotension can be increased when Udenafil is combined with Morphine.
Umbralisib	The serum concentration of Morphine can be increased when it is combined with Umbralisib.
Umeclidinium	The risk or severity of adverse effects can be increased when Umeclidinium is combined with Morphine.
Urethane	The risk or severity of CNS depression can be increased when Morphine is combined with Urethane.
Vadadustat	The serum concentration of Morphine can be increased when it is combined with Vadadustat.
Valproate bismuth	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Valproate bismuth.
Valproic acid	The risk or severity of CNS depression can be increased when Morphine is combined with Valproic acid.
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Morphine.
Vandetanib	The serum concentration of Morphine can be increased when it is combined with Vandetanib.
Vardenafil	The serum concentration of Morphine can be increased when it is combined with Vardenafil.
Vecuronium	The risk or severity of adverse effects can be increased when Vecuronium is combined with Morphine.
Velpatasvir	The serum concentration of Morphine can be increased when it is combined with Velpatasvir.
Vemurafenib	The serum concentration of Morphine can be increased when it is combined with Vemurafenib.
Venetoclax	The metabolism of Morphine can be decreased when combined with Venetoclax.
Venlafaxine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Venlafaxine.
Verapamil	The metabolism of Morphine can be decreased when combined with Verapamil.
Vericiguat	The risk or severity of adverse effects can be increased when Morphine is combined with Vericiguat.
Vigabatrin	The risk or severity of CNS depression can be increased when Morphine is combined with Vigabatrin.
Vilazodone	The risk or severity of CNS depression can be increased when Morphine is combined with Vilazodone.
Viloxazine	The metabolism of Morphine can be decreased when combined with Viloxazine.
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Morphine.
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Morphine.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Morphine.
Voclosporin	The serum concentration of Morphine can be increased when it is combined with Voclosporin.
Vorapaxar	The serum concentration of Morphine can be increased when it is combined with Vorapaxar.
Voriconazole	The metabolism of Morphine can be decreased when combined with Voriconazole.
Vortioxetine	The risk or severity of CNS depression can be increased when Morphine is combined with Vortioxetine.
Voxilaprevir	The serum concentration of Morphine can be increased when it is combined with Voxilaprevir.
Yohimbine	The risk or severity of CNS depression can be increased when Morphine is combined with Yohimbine.
Zaleplon	The risk or severity of CNS depression can be increased when Morphine is combined with Zaleplon.
Ziconotide	The risk or severity of adverse effects can be increased when Morphine is combined with Ziconotide.
Zidovudine	The metabolism of Morphine can be increased when combined with Zidovudine.
Zimelidine	The risk or severity of serotonin syndrome can be increased when Morphine is combined with Zimelidine.
Ziprasidone	The risk or severity of adverse effects can be increased when Morphine is combined with Ziprasidone.
Zofenopril	Morphine may increase the hypotensive activities of Zofenopril.
Zolmitriptan	The risk or severity of CNS depression can be increased when Morphine is combined with Zolmitriptan.
Zolpidem	Morphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide	The risk or severity of CNS depression can be increased when Morphine is combined with Zonisamide.
Zopiclone	The risk or severity of adverse effects can be increased when Morphine is combined with Zopiclone.
Zotepine	The risk or severity of CNS depression can be increased when Morphine is combined with Zotepine.
Zuclopenthixol	The risk or severity of CNS depression can be increased when Morphine is combined with Zuclopenthixol.
Zuranolone	The risk or severity of CNS depression can be increased when Zuranolone is combined with Morphine.

Food Interactions

Avoid alcohol. Concomitant use may lead to profound sedation, respiratory depression, coma, and death.
Take with or without food. There is no significant different in the AUC or Cmax of oral extended release tablets when taken with or without food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Morphine acetate	VEO43W5229	596-15-6	CLDOGJORCNORLA-VYKNHSEDSA-N
Morphine hydrochloride	J28GE0ROVX	52-26-6	XCKKIKBIPZJUET-VYKNHSEDSA-N
Morphine hydrochloride trihydrate	Q5F3AS69LF	6055-06-7	XELXKCKNPPSFNN-BJWPBXOKSA-N
Morphine mesylate	QXB8THK8QY	335328-17-1	MHEMFNFIWLUDDJ-VYKNHSEDSA-N
Morphine nitrate	DV2P23JCWV	596-16-7	VHBDDUMTLJSZDR-VYKNHSEDSA-N
Morphine phosphate	1LQ9207LZE	596-17-8	KZSZGTYWWBPNKB-VYKNHSEDSA-N
Morphine sulfate	DY70C97N30	64-31-3	USAHOPJHPJHUNS-IFCNUISUSA-N
Morphine sulfate pentahydrate	X3P646A2J0	6211-15-0	GRVOTVYEFDAHCL-RTSZDRIGSA-N
Morphine tartrate	U3NSU23LHD	302-31-8	SVTKSKRNLMAUKF-HAIKCVHQSA-N

International/Other Brands

Kapanol (Mayne Pharma/Glaxo) / MSIR (Purdue Pharma) / Oramorph (Boeringher Ingelheim)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Arymo ER	Tablet, film coated, extended release	15 mg/1	Oral	Zyla Life Sciences US Inc.	2017-02-01	Not applicable
Arymo ER	Tablet, film coated, extended release	60 mg/1	Oral	Zyla Life Sciences US Inc.	2017-02-01	Not applicable
Arymo ER	Tablet, film coated, extended release	30 mg/1	Oral	Zyla Life Sciences US Inc.	2017-02-01	Not applicable
Avinza	Capsule, extended release	30 mg/1	Oral	Ligand Pharmaceuticals Incorporated	2006-08-08	Not applicable
Avinza	Capsule, extended release	120 mg/1	Oral	Physicians Total Care, Inc.	2004-10-15	2012-06-30
Avinza	Capsule, extended release	30 mg/1	Oral	Stat Rx USA	2002-03-20	Not applicable
Avinza	Capsule, extended release	30 mg/1	Oral	Physicians Total Care, Inc.	2003-11-10	2012-06-30
Avinza	Capsule, extended release	90 mg/1	Oral	Ligand Pharmaceuticals Incorporated	2006-08-08	Not applicable
Avinza	Capsule, extended release	75 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2002-03-20	2015-11-30
Avinza	Capsule, extended release	90 mg/1	Oral	bryant ranch prepack	2002-03-20	2010-09-01
Avinza	Capsule, extended release	30 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2002-03-20	2015-08-31
Avinza	Capsule, coated, extended release	60 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-10-25	2015-07-10
Avinza	Capsule, extended release	90 mg/1	Oral	Physicians Total Care, Inc.	2003-10-30	2012-06-30
Avinza	Capsule, extended release	120 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2002-03-20	2017-01-31
Avinza	Capsule, extended release	60 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2002-03-20	2017-01-31
Avinza	Capsule, extended release	90 mg/1	Oral	Stat Rx USA	2002-03-20	Not applicable
Avinza	Capsule, extended release	60 mg/1	Oral	Ligand Pharmaceuticals Incorporated	2006-08-08	Not applicable
Avinza	Capsule, extended release	120 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-10-25	2015-06-01
Avinza	Capsule, extended release	60 mg/1	Oral	Stat Rx USA	2002-03-20	Not applicable
Avinza	Capsule, extended release	60 mg/1	Oral	Physicians Total Care, Inc.	2003-10-30	2012-06-30
Avinza	Capsule, extended release	30 mg/1	Oral	bryant ranch prepack	2002-03-20	2010-07-15
Avinza	Capsule, extended release	90 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2002-03-20	2017-01-31
Avinza	Capsule, extended release	45 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2002-03-20	2015-11-30
Avinza	Capsule, extended release	60 mg/1	Oral	bryant ranch prepack	2002-03-20	2014-03-01
Avinza	Capsule, extended release	90 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-10-25	2015-07-10
Avinza	Capsule, extended release	120 mg/1	Oral	Ligand Pharmaceuticals Incorporated	2006-08-08	Not applicable
DepoDur	Injection, lipid complex	20 mg/2mL	Epidural	Endo Pharmaceuticals	2006-07-21	Not applicable
DepoDur	Injection, lipid complex	15 mg/1.5mL	Epidural	Endo Pharmaceuticals	2006-07-21	Not applicable
DepoDur	Injection, lipid complex	10 mg/1mL	Epidural	Endo Pharmaceuticals	2006-07-21	Not applicable
Doloral Sirop	Syrup	5 mg / mL	Oral	Laboratoire Atlas Inc	1991-12-31	Not applicable
Doloral Sirop	Syrup	1 mg / mL	Oral	Laboratoire Atlas Inc	1985-12-31	Not applicable
Duramorph	Injection	1 mg/1mL	Epidural; Intrathecal; Intravenous	Hikma Pharmaceuticals USA Inc.	1984-09-18	Not applicable
Duramorph	Injection, solution	1 mg/1mL	Epidural; Intrathecal; Intravenous	Baxter Laboratories	2010-05-31	2015-02-28
Duramorph	Injection	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Hikma Pharmaceuticals USA Inc.	1984-09-18	Not applicable
Duramorph	Injection, solution	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Baxter Laboratories	2010-05-31	2015-02-28
Infumorph 200	Injection, solution	10 mg/1mL	Epidural; Intrathecal	Hikma Pharmaceuticals USA Inc.	1984-09-18	Not applicable
Infumorph 200/Infumorph 500	Injection, solution	10 mg/1mL	Epidural; Intrathecal	Baxter Laboratories	2013-10-01	2014-10-31
Infumorph 200/Infumorph 500	Injection, solution	25 mg/1mL	Epidural; Intrathecal	Baxter Laboratories	2013-10-01	2014-09-30
Infumorph 500	Injection, solution	25 mg/1mL	Epidural; Intrathecal	Hikma Pharmaceuticals USA Inc.	1984-09-18	Not applicable
Kadian	Capsule, extended release	60 mg/1	Oral	Stat Rx USA	2009-04-07	Not applicable
Kadian	Capsule, extended release	30 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2020-02-29
Kadian	Capsule, extended release	60 mg/1	Oral	Physicians Total Care, Inc.	2008-01-16	Not applicable
Kadian	Capsule, extended release	80 mg/1	Oral	Allergan, Inc.	2009-04-07	2023-02-28
Kadian	Capsule, extended release	10 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2012-02-29	2014-07-11
Kadian	Capsule, extended release	20 mg/1	Oral	Stat Rx USA	2009-04-07	Not applicable
Kadian	Capsule, extended release	20 mg/1	Oral	Physicians Total Care, Inc.	2001-11-07	Not applicable
Kadian	Capsule, extended release	40 mg/1	Oral	Allergan, Inc.	2012-05-07	2022-06-30
Kadian	Capsule, extended release	130 mg/1	Oral	Actavis Kadian LLC	2012-05-07	2017-07-01
Kadian	Capsule, extended release	10 mg/1	Oral	Allergan, Inc.	2009-04-07	2023-06-30
Kadian	Capsule, extended release	50 mg	Oral	Bgp Pharma Ulc	1996-10-23	Not applicable
Kadian	Capsule, extended release	70 mg/1	Oral	Actavis Kadian LLC	2012-05-07	2017-07-01
Kadian	Capsule, extended release	100 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	60 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2012-02-29	2014-07-11
Kadian	Capsule, extended release	40 mg/1	Oral	Actavis Kadian LLC	2012-05-07	2017-07-01
Kadian	Capsule, extended release	50 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	100 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2020-07-31
Kadian	Capsule, extended release	30 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-12-21	2014-07-11
Kadian	Capsule, extended release	10 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	50 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2020-02-29
Kadian	Capsule, extended release	100 mg/1	Oral	Stat Rx USA	2009-04-07	Not applicable
Kadian	Capsule, extended release	10 mg/1	Oral	Physicians Total Care, Inc.	2008-11-19	Not applicable
Kadian	Capsule, extended release	200 mg/1	Oral	Allergan, Inc.	2009-04-07	2023-03-31
Kadian	Capsule, extended release	20 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2020-02-29
Kadian	Capsule, extended release	50 mg/1	Oral	Stat Rx USA	2009-04-07	Not applicable
Kadian	Capsule, extended release	30 mg/1	Oral	bryant ranch prepack	2009-04-07	2014-05-01
Kadian	Capsule, extended release	50 mg/1	Oral	Physicians Total Care, Inc.	2001-11-07	Not applicable
Kadian	Capsule, extended release	60 mg/1	Oral	Allergan, Inc.	2009-04-07	2023-02-28
Kadian	Capsule, extended release	200 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	30 mg/1	Oral	Allergan, Inc.	2009-04-07	2022-06-30
Kadian	Capsule, extended release	200 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	80 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2020-07-31
Kadian	Capsule, extended release	10 mg	Oral	Bgp Pharma Ulc	2001-12-11	Not applicable
Kadian	Capsule, extended release	100 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	100 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2012-02-29	2014-07-11
Kadian	Capsule, extended release	80 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	40 mg/1	Oral	Actavis Pharma, Inc.	2012-05-07	2019-05-31
Kadian	Capsule, extended release	20 mg	Oral	Bgp Pharma Ulc	1996-10-25	Not applicable
Kadian	Capsule, extended release	80 mg/1	Oral	Stat Rx USA	2009-04-07	Not applicable
Kadian	Capsule, extended release	60 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	50 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2012-02-29	2014-07-11
Kadian	Capsule, extended release	60 mg/1	Oral	bryant ranch prepack	2009-04-07	2014-02-01
Kadian	Capsule, extended release	30 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	10 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2020-06-30
Kadian	Capsule, extended release	30 mg/1	Oral	Stat Rx USA	2009-04-07	Not applicable
Kadian	Capsule, extended release	30 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-12-21	2014-07-11
Kadian	Capsule, extended release	150 mg/1	Oral	Actavis Kadian LLC	2012-05-07	2017-07-01
Kadian	Capsule, extended release	20 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2009-04-07	2017-06-01
Kadian	Capsule, extended release	80 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	100 mg/1	Oral	Physicians Total Care, Inc.	2008-11-20	Not applicable
Kadian	Capsule, extended release	100 mg/1	Oral	Allergan, Inc.	2009-04-07	2023-02-23
Kadian	Capsule, extended release	10 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	100 mg	Oral	Bgp Pharma Ulc	1996-10-25	Not applicable
Kadian	Capsule, extended release	50 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	30 mg/1	Oral	Physicians Total Care, Inc.	2004-01-16	Not applicable
Kadian	Capsule, extended release	50 mg/1	Oral	Allergan, Inc.	2009-04-07	2023-02-28
Kadian	Capsule, extended release	60 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	200 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2019-09-30
Kadian	Capsule, extended release	20 mg/1	Oral	Actavis Kadian LLC	2009-04-07	2017-07-01
Kadian	Capsule, extended release	20 mg/1	Oral	Allergan, Inc.	2009-04-07	2022-06-30
Kadian	Capsule, extended release	20 mg/1	Oral	Alpharma Pharmaceuticals LLC	1996-07-03	2008-12-29
Kadian	Capsule, extended release	20 mg/1	Oral	bryant ranch prepack	2009-04-07	2012-11-01
Kadian	Capsule, extended release	200 mg/1	Oral	Stat Rx USA	2009-04-07	Not applicable
Kadian	Capsule, extended release	60 mg/1	Oral	Actavis Pharma, Inc.	2009-04-07	2020-02-29
Kadian	Capsule, extended release	80 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2012-02-29	2014-07-11
Kadian	Capsule, extended release	30 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2009-04-07	2017-06-01
Kadian ER	Capsule, extended release	20 mg/1	Oral	St. Marys Medical Park Pharmacy	2010-12-21	2018-01-02
M-ediat	Capsule	10 mg	Oral	Ethypharm	2016-09-06	Not applicable
M-ediat	Capsule	30 mg	Oral	Ethypharm	2016-09-06	Not applicable
M-ediat	Capsule	5 mg	Oral	Ethypharm	2016-09-06	Not applicable
M-ediat	Capsule	20 mg	Oral	Ethypharm	2016-09-06	Not applicable
M-eslon	Capsule, extended release	100 mg	Oral	Ethypharm	1993-12-31	Not applicable
M-eslon	Capsule, extended release	10 mg	Oral	Ethypharm	1993-12-31	Not applicable
M-eslon	Capsule, extended release	30 mg	Oral	Ethypharm	1993-12-31	Not applicable
M-eslon	Capsule, extended release	15 mg	Oral	Ethypharm	1995-12-31	Not applicable
M-eslon	Capsule, extended release	60 mg	Oral	Ethypharm	1993-12-31	Not applicable
M-eslon	Capsule, extended release	200 mg	Oral	Ethypharm	1995-12-31	Not applicable
M.O.S. 10 Syrup 10mg/ml	Syrup	10 mg / mL	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1985-12-31	2014-07-30
M.O.S. 10 Tablets 10mg	Tablet	10 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1986-12-31	2014-07-30
M.O.S. 20 Concentrate 20mg/ml	Syrup	20 mg / mL	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1985-12-31	2014-07-30
M.O.S. SR Tablets 30mg	Tablet, extended release	30 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1988-12-31	2016-07-08
M.O.S. SR Tablets 60mg	Tablet, extended release	60 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1988-12-31	2016-07-08
M.O.S. Sulphate 10mg Tab	Tablet	10 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1993-12-31	2016-07-08
M.O.S. Sulphate 25mg Tab	Tablet	25 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1993-12-31	2016-07-08
M.O.S. Sulphate 50mg Tab	Tablet	50 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1993-12-31	2016-07-08
M.O.S. Sulphate 5mg Tab	Tablet	5 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1993-12-31	2016-07-08
M.O.S. Syrup 1.0 mg/ml	Syrup	1 mg / mL	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1980-12-31	2014-07-30
M.O.S. Syrup 5mg/ml	Syrup	5 mg / mL	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1981-12-31	2014-07-30
M.O.S.- 10	Suppository	10 mg	Rectal	Valeant Canada Lp Valeant Canada S.E.C.	1984-12-31	2014-07-30
M.O.S.- 20	Suppository	20 mg	Rectal	Valeant Canada Lp Valeant Canada S.E.C.	1984-12-31	2014-07-30
M.O.S.- 30	Suppository	30 mg	Rectal	Valeant Canada Lp Valeant Canada S.E.C.	1985-12-31	2014-07-30
M.O.S.-20 Tab 20mg	Tablet	20 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1986-12-31	2014-07-30
M.O.S.-40 Tab 40mg	Tablet	40 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1986-12-31	2014-07-30
M.O.S.-50 Concentrate Liq 50mg/ml	Syrup	50 mg / mL	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1986-12-31	2014-07-30
M.O.S.-60 Tab 60mg	Tablet	60 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1986-12-31	2014-07-30
MorphaBond	Tablet, extended release	100 mg/1	Oral	Inspirion Delivery Technologies, Llc	2016-04-02	2017-03-02
MorphaBond	Tablet, extended release	15 mg/1	Oral	Inspirion Delivery Technologies, Llc	2016-04-02	2017-03-02
MorphaBond	Tablet, extended release	60 mg/1	Oral	Inspirion Delivery Technologies, Llc	2016-04-02	2017-03-02
MorphaBond	Tablet, extended release	30 mg/1	Oral	Inspirion Delivery Technologies, Llc	2016-04-02	2017-03-02
MorphaBond ER	Tablet, extended release	60 mg/1	Oral	Daiichi Sankyo Inc.	2017-03-02	2021-01-22
MorphaBond ER	Tablet, extended release	30 mg/1	Oral	Daiichi Sankyo Inc.	2017-03-02	2021-01-22
MorphaBond ER	Tablet, extended release	100 mg/1	Oral	Daiichi Sankyo Inc.	2017-03-02	2021-01-22
MorphaBond ER	Tablet, extended release	15 mg/1	Oral	Daiichi Sankyo Inc.	2017-03-02	2021-01-22
Morphine Extra-forte	Solution	50 mg / mL	Intramuscular; Intravenous; Subcutaneous	Pfizer Canada Ulc	1990-12-31	2020-01-06
Morphine Forte	Solution	25 mg / mL	Intramuscular; Intravenous; Subcutaneous	Pfizer Canada Ulc	1990-12-31	2019-03-04
Morphine Hp 25 - 25mg/ml	Solution	25 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	1986-12-31	2023-07-28
Morphine Hp 50	Solution	50 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	1987-12-31	Not applicable
Morphine Lp Epidural	Solution	1 mg / mL	Epidural; Intravenous; Subcutaneous	Sandoz Canada Incorporated	1993-12-31	Not applicable
Morphine Lp Epidural	Solution	0.5 mg / mL	Epidural; Intravenous; Subcutaneous	Sandoz Canada Incorporated	1993-12-31	Not applicable
Morphine SR	Tablet, extended release	200 mg	Oral	Sanis Health Inc	2011-03-01	2014-08-01
Morphine SR	Tablet, extended release	60 mg	Oral	Sanis Health Inc	2011-03-02	2021-06-22
Morphine SR	Tablet, extended release	100 mg	Oral	Sanis Health Inc	2011-03-01	2014-08-01
Morphine SR	Tablet, extended release	30 mg	Oral	Sanis Health Inc	2011-03-01	2021-03-16
Morphine SR	Tablet, extended release	15 mg	Oral	Sanis Health Inc	2011-03-01	2020-12-23
Morphine Sulfate	Solution	100 mg/5mL	Oral	Hikma Pharmaceuticals USA Inc.	2008-03-17	2021-10-31
Morphine Sulfate	Solution	10 mg/0.5mL	Oral	Precision Dose, Inc.	2020-11-01	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Atlantic Biologicals Corp.	2008-03-17	Not applicable
Morphine Sulfate	Capsule, extended release	20 mg/1	Oral	Par Pharmaceutical	2012-11-09	2018-11-30
Morphine Sulfate	Suppository	20 mg/1	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Injection, solution	15 mg/1mL	Intravenous	Hospira, Inc.	2012-08-20	2015-09-01
Morphine Sulfate	Injection, solution	1 mg/1mL	Intravenous	Cantrell Drug Company	2013-05-01	Not applicable
Morphine Sulfate	Tablet	15 mg/1	Oral	Avera McKennan Hospital	2015-12-22	2017-05-24
Morphine Sulfate	Injection, solution, concentrate	25 mg/1mL	Intravenous	Hospira, Inc.	2005-07-28	2019-07-01
Morphine Sulfate	Injection, solution	40 mg/1mL	Intrathecal	Cantrell Drug Company	2012-08-24	2015-03-13
Morphine Sulfate	Injection, solution	5 mg/1mL	Intravenous	REMEDYREPACK INC.	2018-04-11	2020-05-09
Morphine Sulfate	Solution	100 mg/5mL	Oral	Precision Dose, Inc.	2022-09-30	Not applicable
Morphine Sulfate	Injection	15 mg/1mL	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-05-31
Morphine Sulfate	Tablet	30 mg/1	Oral	Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC	2011-12-13	Not applicable
Morphine Sulfate	Injection, solution	4 mg/1mL	Intravenous	Hospira, Inc.	2012-08-07	Not applicable
Morphine Sulfate	Injection	10 mg/1mL	Intramuscular; Intravenous; Subcutaneous	Physicians Total Care, Inc.	2000-05-24	2013-01-15
Morphine Sulfate	Injection, solution	10 mg/10mL	Intravenous; Subcutaneous	Amphastar Pharmaceuticals, Inc.	2000-08-11	2010-09-23
Morphine Sulfate	Injection, solution	1 mg/1mL	Intravenous	Hospira, Inc.	2006-11-28	2019-08-01
Morphine Sulfate	Injection, solution	10 mg/1mL	Intravenous	Hospira, Inc.	1997-06-09	2014-03-01
Morphine Sulfate	Solution	20 mg/1mL	Oral	Roxane Laboratories, Inc	2008-10-01	2009-09-30
Morphine Sulfate	Injection	8 mg/1mL	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2016-06-30
Morphine Sulfate	Injection, solution	8 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi USA, LLC	2018-04-10	Not applicable
Morphine Sulfate	Injection	1 mg/1mL	Intravenous	International Medication Systems, Limited	1987-03-27	2023-10-31
Morphine Sulfate	Injection, solution	10 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi, Usa Llc	2013-10-30	Not applicable
Morphine Sulfate	Injection, solution	8 mg/1mL	Intravenous	Hospira, Inc.	1997-06-09	2013-10-01
Morphine Sulfate	Solution, concentrate	100 mg/5mL	Oral	Lannett Company, Inc.	2011-06-23	Not applicable
Morphine Sulfate	Injection, solution	1 mg/1mL	Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid	Hospira, Inc.	2006-06-15	2006-06-15
Morphine Sulfate	Tablet	15 mg/1	Oral	Stat Rx USA	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	2 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi USA, LLC	2018-04-10	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Atlantic Biologicals Corp.	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	4 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi, Usa Llc	2013-10-30	Not applicable
Morphine Sulfate	Capsule, extended release	100 mg/1	Oral	Par Pharmaceutical	2012-11-09	2019-02-28
Morphine Sulfate	Tablet	30 mg/1	Oral	H.J. Harkins Company	2008-03-17	Not applicable
Morphine Sulfate	Suppository	10 mg/1	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Physicians Total Care, Inc.	2009-05-29	Not applicable
Morphine Sulfate	Suppository	20 mg/1	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Injection, solution	10 mg/1mL	Intravenous	Hospira, Inc.	2012-08-20	Not applicable
Morphine Sulfate	Capsule, extended release	50 mg/1	Oral	Par Pharmaceutical	2012-11-09	2018-07-31
Morphine Sulfate	Injection, solution	30 mg/30mL	Intravenous; Subcutaneous	Amphastar Pharmaceuticals, Inc.	1987-03-27	2010-09-23
Morphine Sulfate	Tablet	15 mg/1	Oral	Quality Care Products LLC	2012-03-19	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	Precision Dose Inc.	2016-02-29	Not applicable
Morphine Sulfate	Injection	8 mg/1mL	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-01-31
Morphine Sulfate	Injection, solution	2 mg/1mL	Intravenous	Hospira, Inc.	2012-08-23	Not applicable
Morphine sulfate	Injection, solution	50 mg/1mL	Intravenous	Hospira, Inc.	2023-11-20	2023-11-20
Morphine Sulfate	Injection, solution	2 mg/1mL	Epidural; Intramuscular; Intrathecal; Intravenous	Cantrell Drug Company	2012-02-22	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Precision Dose Inc.	2014-06-04	2017-09-30
Morphine Sulfate	Injection, solution	25 mg/1mL	Intravenous	Hospira, Inc.	1991-04-11	2015-09-01
Morphine Sulfate	Solution	10 mg/5mL	Oral	Hikma Pharmaceuticals USA Inc.	2008-03-17	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Directrx	2019-03-04	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	PAI Holdings, LLC	2017-03-17	Not applicable
Morphine Sulfate	Injection, solution	5 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi USA, LLC	2018-04-10	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Precision Dose, Inc.	2023-08-15	Not applicable
Morphine Sulfate	Injection, solution	5 mg/1mL	Intravenous	Cantrell Drug Company	2013-10-25	Not applicable
Morphine Sulfate	Injection	10 mg/1mL	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-04-30
Morphine Sulfate	Injection, solution, concentrate	50 mg/1mL	Intravenous	Hospira, Inc.	2005-08-11	Not applicable
Morphine Sulfate	Injection, solution	0.5 mg/1mL	Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid	Hospira, Inc.	2006-06-15	2006-06-15
Morphine Sulfate	Tablet	15 mg/1	Oral	bryant ranch prepack	2008-03-17	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	Physicians Total Care, Inc.	2005-09-12	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Dispensing Solutions, Inc.	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	0.5 mg/1mL	Intravenous	Hospira, Inc.	2004-08-01	2004-09-01
Morphine Sulfate	Solution	20 mg/5mL	Oral	Atlantic Biologicals Corp.	2016-09-06	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Watson Pharmaceuticals	2006-04-12	Not applicable
Morphine Sulfate	Injection	5 mg/1mL	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-05-31
Morphine Sulfate	Injection	15 mg/1mL	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-10-31
Morphine Sulfate	Suppository	5 mg/1	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Capsule, extended release	80 mg/1	Oral	Par Pharmaceutical	2012-11-09	2018-11-30
Morphine Sulfate	Tablet	15 mg/1	Oral	H.J. Harkins Company	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	2 mg/1mL	Intravenous	Hospira, Inc.	1980-05-01	2013-09-01
Morphine Sulfate	Solution	10 mg/5mL	Oral	Atlantic Biologicals Corp.	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	8 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi, Usa Llc	2013-10-30	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Hikma Pharmaceuticals USA Inc.	2008-03-17	Not applicable
Morphine Sulfate	Injection	5 mg/1mL	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-10-31
Morphine Sulfate	Solution	100 mg/5mL	Oral	Atlantic Biologicals Corp.	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	50 mg/1mL	Intravenous	Hospira, Inc.	2023-11-20	Not applicable
Morphine Sulfate	Capsule, extended release	30 mg/1	Oral	Par Pharmaceutical	2012-11-09	2019-02-28
Morphine Sulfate	Injection, solution	4 mg/1mL	Intravenous	Hospira, Inc.	1997-06-09	2013-09-01
Morphine Sulfate	Solution	100 mg/5mL	Oral	Hikma Pharmaceuticals USA Inc.	2008-03-17	Not applicable
Morphine Sulfate	Solution, concentrate	100 mg/5mL	Oral	Lohxa	2018-05-29	Not applicable
Morphine Sulfate	Injection, solution	2 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi, Usa Llc	2013-10-30	Not applicable
Morphine Sulfate	Suppository	30 mg/1	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	American Health Packaging	2023-08-01	Not applicable
Morphine Sulfate	Injection	10 mg/0.7mL	Intramuscular	Meridian Medical Technologies, Inc.	1990-07-12	Not applicable
Morphine Sulfate	Injection	15 mg/1mL	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-02-28
Morphine Sulfate	Solution	20 mg/5mL	Oral	Hikma Pharmaceuticals USA Inc.	2008-03-17	Not applicable
Morphine Sulfate	Tablet	15 mg/1	Oral	Physicians Total Care, Inc.	2008-01-07	Not applicable
Morphine Sulfate	Injection, solution	8 mg/1mL	Intravenous	Hospira, Inc.	2012-09-24	Not applicable
Morphine Sulfate	Suppository	5 mg/1	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Glenmark Generics, Inc. USA	2006-08-01	2009-06-26
Morphine Sulfate	Solution	20 mg/5mL	Oral	Atlantic Biologicals Corp.	2008-03-17	Not applicable
Morphine Sulfate	Injection	10 mg/1mL	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-04-30
Morphine Sulfate	Injection, solution	10 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi USA, LLC	2018-04-10	Not applicable
Morphine Sulfate	Injection	1 mg/1mL	Parenteral	Amphastar Pharmaceuticals, Inc.	1993-06-01	2009-12-18
Morphine Sulfate	Solution	100 mg/5mL	Oral	Precision Dose Inc.	2013-08-16	2021-10-31
Morphine Sulfate	Injection, solution	15 mg/1mL	Intravenous	Hospira, Inc.	1997-06-09	2013-06-01
Morphine Sulfate	Solution, concentrate	100 mg/5mL	Oral	Lannett Company, Inc.	2011-06-23	Not applicable
Morphine Sulfate	Injection, solution	0.5 mg/1mL	Intrathecal; Intravenous	Cantrell Drug Company	2012-01-23	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Stat Rx USA	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	4 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi USA, LLC	2018-04-10	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Atlantic Biologicals Corp.	2018-11-21	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	bryant ranch prepack	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	1 mg/1mL	Epidural; Intramuscular; Intrathecal; Intravenous	Cantrell Drug Company	2013-09-09	2017-12-06
Morphine Sulfate	Solution, concentrate	20 mg/1mL	Oral	Physicians Total Care, Inc.	2006-01-23	2013-01-15
Morphine Sulfate	Injection, solution	5 mg/1mL	Intravenous	Hospira, Inc.	2006-05-02	2019-03-01
Morphine Sulfate	Solution, concentrate	20 mg/1mL	Oral	Lehigh Valley Technologies, Inc.	2010-05-12	2010-07-22
Morphine Sulfate	Suppository	10 mg/1	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Injection	10 mg/1mL	Intramuscular; Intravenous; Subcutaneous	Physicians Total Care, Inc.	2003-03-11	2011-06-30
Morphine Sulfate	Tablet	15 mg/1	Oral	RedPharm Drug, Inc.	2008-03-17	Not applicable
Morphine Sulfate	Injection	10 mg/1mL	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-11-30
Morphine Sulfate	Suppository	30 mg/1	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Precision Dose, Inc.	2023-11-30	Not applicable
Morphine Sulfate	Capsule, extended release	60 mg/1	Oral	Par Pharmaceutical	2012-11-09	2019-02-28
Morphine Sulfate	Tablet	15 mg/1	Oral	Hikma Pharmaceuticals USA Inc.	2008-03-17	Not applicable
Morphine Sulfate	Injection, solution	25 mg/1mL	Intravenous	Hospira, Inc.	1991-04-11	2015-02-01
Morphine Sulfate	Tablet	15 mg/1	Oral	Glenmark Generics, Inc. USA	2006-08-01	2009-06-26
Morphine Sulfate	Injection, solution	5 mg/1mL	Intramuscular; Intravenous	Fresenius Kabi, Usa Llc	2013-10-30	Not applicable
Morphine Sulfate	Solution	20 mg/1mL	Oral	Paddock Laboratories, Inc.	2009-10-08	2011-10-31
Morphine Sulfate Inj 10mg/ml USP	Liquid	10 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	1978-12-31	Not applicable
Morphine Sulfate Inj 15mg/ml USP	Liquid	15 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	1978-12-31	Not applicable
Morphine Sulfate Inj 1mg/ml USP	Solution	1 mg / mL	Intravenous; Subcutaneous	Sandoz Canada Incorporated	1992-12-31	2021-04-21
Morphine Sulfate Inj 2mg/ml USP	Solution	2 mg / mL	Intravenous; Subcutaneous	Sandoz Canada Incorporated	1992-12-31	2021-04-21
Morphine Sulfate Inj 5mg/ml USP	Solution	5 mg / mL	Intravenous; Subcutaneous	Sandoz Canada Incorporated	1992-12-31	2021-04-21
Morphine Sulfate Injection	Solution	2 mg / mL	Intramuscular; Intravenous; Subcutaneous	Jamp Pharma Corporation	2021-04-29	Not applicable
Morphine Sulfate Injection	Solution	15 mg / mL	Intramuscular; Intravenous; Subcutaneous	Jamp Pharma Corporation	2021-04-29	Not applicable
Morphine Sulfate Injection	Solution	10 mg / mL	Intramuscular; Intravenous; Subcutaneous	Jamp Pharma Corporation	2021-04-29	Not applicable
Morphine Sulfate Injection BP	Solution	10 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sterimax Inc	2018-09-21	Not applicable
Morphine Sulfate Injection BP	Solution	15 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sterimax Inc	Not applicable	Not applicable
Morphine Sulfate Injection Epidural	Solution	1 mg / mL	Epidural	Sterimax Inc	2021-06-02	Not applicable
Morphine Sulfate Injection Epidural	Solution	0.5 mg / mL	Epidural	Sterimax Inc	2021-05-21	Not applicable
Morphine Sulfate Injection Sdz	Solution	1 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	Not applicable	Not applicable
Morphine Sulfate Injection Sdz	Solution	15 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	Not applicable	Not applicable
Morphine Sulfate Injection Sdz	Solution	10 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	2012-10-18	Not applicable
Morphine Sulfate Injection Sdz	Solution	2 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	Not applicable	Not applicable
Morphine Sulfate Injection USP	Solution	15 mg / mL	Intramuscular; Intravenous; Subcutaneous	Pfizer Canada Ulc	1989-12-31	2020-01-10
Morphine Sulfate Injection USP	Solution	1 mg / mL	Intravenous	Icu Medical Canada Inc	1986-12-31	2020-05-04
Morphine Sulfate Injection USP	Solution	100 mg / 100 mL	Intravenous	Sterinova Inc.	2020-08-25	Not applicable
Morphine Sulfate Injection USP	Solution	10 mg / mL	Intramuscular; Intravenous; Subcutaneous	Pfizer Canada Ulc	1988-12-31	2020-01-06
Morphine Sulfate Injection USP	Solution	50 mg / 50 mL	Intravenous	Sterinova Inc.	Not applicable	Not applicable
Morphine Sulfate Injection USP	Solution	2 mg / mL	Intramuscular; Intravenous; Subcutaneous	Pfizer Canada Ulc	1989-12-31	Not applicable
Morphine Sulfate Injection USP	Solution	5 mg / mL	Intravenous	Icu Medical Canada Inc	1986-12-31	2019-10-14
Morphine Sulfate Injection USP	Liquid	2 mg / mL	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	2000-12-12	Not applicable
Morphine Sulfate Injection, USP	Solution	4 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	Not applicable	Not applicable
Morphine Sulfate Injection, USP	Solution	8 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	Not applicable	Not applicable
Morphine Sulfate Injection, USP	Solution	2 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	2019-12-17	Not applicable
Morphine Sulfate Injection, USP	Solution	2 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	Not applicable	Not applicable
Morphine Sulfate Injection, USP	Solution	5 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	Not applicable	Not applicable
Morphine Sulfate Injection, USP	Solution	10 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	Not applicable	Not applicable
Morphine Sulfate Injection, USP	Solution	10 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	2019-12-17	Not applicable
Morphine Sulfate Injection, USP	Solution	4 mg / 1 mL	Intramuscular; Intravenous; Subcutaneous	Fresenius Kabi	Not applicable	Not applicable
Morphine Sulphate Inj 1mg/ml BP	Liquid	1 mg / mL	Intravenous; Subcutaneous	David Bull Laboratories (Canada) Inc.	1993-12-31	1998-08-13
Morphine Sulphate Injection 1mg/ml	Liquid	1 mg / mL	Intravenous; Subcutaneous	Hospira Healthcare Ulc	1997-09-04	2020-01-06
Morphine Sulphate Injection 2mg/ml	Liquid	2 mg / mL	Intravenous; Subcutaneous	Hospira Healthcare Ulc	1997-09-04	2018-11-30
Morphine Sulphate Injection 50mg/ml	Liquid	50 mg / mL	Intramuscular; Intravenous; Subcutaneous	Hospira Healthcare Ulc	1997-09-11	2018-11-30
Morphine Sulphate Injection B.P. 25mg/ml	Liquid	25 mg / mL	Intramuscular; Intravenous; Subcutaneous	David Bull Laboratories (Canada) Inc.	1994-12-31	1997-08-14
Morphine Sulphate Injection B.P. 50mg/ml	Liquid	50 mg / mL	Intramuscular; Intravenous; Subcutaneous	David Bull Laboratories (Canada) Inc.	1994-12-31	1998-08-13
Morphine Sulphate Injection Bp 2mg/ml	Liquid	2 mg / mL	Intravenous; Subcutaneous	David Bull Laboratories (Canada) Inc.	1993-12-31	1998-08-13
Morphine Sulphate Injection, USP	Liquid	25 mg / mL	Intravenous	International Medication Systems, Limited	1993-12-31	1997-08-15
Morphine Sulphate Injection, USP Liq50mg/ml	Liquid	50 mg / mL	Intravenous	International Medication Systems, Limited	1993-12-31	1997-08-15
Morphine Sulphate Injection,usp Liq 1.1mg/ml	Liquid	1.1 mg / mL	Intravenous	International Medication Systems, Limited	1993-12-31	1997-08-15
Morphine-epd	Solution	0.5 mg / mL	Epidural	Pfizer Canada Ulc	1992-12-31	2020-01-06
Morphine-epd	Solution	1 mg / mL	Epidural	Pfizer Canada Ulc	1992-12-31	2019-03-04
MS Contin	Tablet, film coated, extended release	100 mg/1	Oral	Purdue Pharma LP	1987-07-01	Not applicable
MS Contin	Tablet, film coated, extended release	15 mg/1	Oral	Purdue Pharma LP	1987-07-01	Not applicable
MS Contin	Tablet, extended release	60 mg	Oral	Purdue Pharma	1993-12-31	Not applicable
MS Contin	Tablet	100 mg/1	Oral	Rhodes Pharmaceuticals L.P.	2017-05-15	Not applicable
MS Contin	Tablet, film coated, extended release	30 mg/1	Oral	Physicians Total Care, Inc.	2003-11-04	2011-06-30
MS Contin	Tablet, extended release	200 mg	Oral	Purdue Pharma	1993-12-31	Not applicable
MS Contin	Tablet	15 mg/1	Oral	Rhodes Pharmaceuticals L.P.	2017-05-15	Not applicable
Ms Contin	Tablet, film coated, extended release	60 mg/1	Oral	Cardinal Health	1987-07-01	2012-03-31
MS Contin	Tablet, extended release	100 mg	Oral	Purdue Pharma	1993-12-31	Not applicable
MS Contin	Tablet, film coated, extended release	15 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-01-31	2014-01-01
MS Contin	Tablet, film coated, extended release	60 mg/1	Oral	Purdue Pharma LP	1987-07-01	Not applicable
MS Contin	Tablet	60 mg/1	Oral	Rhodes Pharmaceuticals L.P.	2017-05-15	Not applicable
MS Contin	Tablet, film coated, extended release	15 mg/1	Oral	Physicians Total Care, Inc.	1994-11-03	2011-06-30
Ms Contin	Tablet, film coated, extended release	30 mg/1	Oral	Cardinal Health	1987-07-01	2012-05-31
MS Contin	Tablet, extended release	15 mg	Oral	Purdue Pharma	1993-12-31	Not applicable
MS Contin	Tablet	200 mg/1	Oral	Rhodes Pharmaceuticals L.P.	2017-05-15	Not applicable
MS Contin	Tablet, extended release	30 mg	Oral	Purdue Pharma	1993-12-31	Not applicable
MS Contin	Tablet, film coated, extended release	200 mg/1	Oral	Purdue Pharma LP	1987-07-01	Not applicable
Ms Contin	Tablet, film coated, extended release	100 mg/1	Oral	Cardinal Health	1987-07-01	2012-05-31
MS Contin	Tablet	30 mg/1	Oral	Rhodes Pharmaceuticals L.P.	2017-05-15	Not applicable
MS Contin	Tablet, film coated, extended release	30 mg/1	Oral	Purdue Pharma LP	1987-07-01	Not applicable
Ms Contin CR	Tablet, film coated, extended release	60 mg/1	Oral	Stat Rx USA	1987-07-01	Not applicable
Ms Contin Suppositories - 100mg	Suppository, extended release	100 mg / sup	Rectal	Purdue Pharma	1995-12-31	2003-07-29
Ms Contin Suppositories - 200mg	Suppository, extended release	200 mg / sup	Rectal	Purdue Pharma	1995-12-31	2003-07-29
Ms Contin Suppositories - 30mg	Suppository, extended release	30 mg / sup	Rectal	Purdue Pharma	1995-12-31	2003-07-29
Ms Contin Suppositories - 60mg	Suppository, extended release	60 mg / sup	Rectal	Purdue Pharma	1995-12-31	2003-07-29
Ms Contin Tablets	Tablet, extended release	5 mg / tab	Oral	Purdue Pharma	Not applicable	Not applicable
Ms Contin XL Capsules	Capsule, extended release	90 mg / src	Oral	Purdue Pharma	Not applicable	Not applicable
Ms Contin XL Capsules	Capsule, extended release	120 mg / src	Oral	Purdue Pharma	Not applicable	Not applicable
Ms Contin XL Capsules	Capsule, extended release	60 mg / src	Oral	Purdue Pharma	Not applicable	Not applicable
Ms Contin XL Capsules	Capsule, extended release	200 mg / src	Oral	Purdue Pharma	Not applicable	Not applicable
Ms Contin XL Capsules	Capsule, extended release	30 mg / src	Oral	Purdue Pharma	Not applicable	Not applicable
Ms Contin XL Capsules	Capsule, extended release	150 mg / src	Oral	Purdue Pharma	Not applicable	Not applicable
Ms Ir Sup 10mg	Suppository	10 mg / sup	Rectal	Purdue Pharma	1991-12-31	2003-07-29
Ms Ir Sup 20mg	Suppository	20 mg / sup	Rectal	Purdue Pharma	1991-12-31	2003-07-29
Ms Ir Sup 30mg	Suppository	30 mg / sup	Rectal	Purdue Pharma	1991-12-31	2003-07-29
Ms.ir	Tablet, multilayer, extended release	30 mg	Oral	Purdue Pharma	1991-12-31	Not applicable
Ms.ir	Tablet, multilayer, extended release	10 mg	Oral	Purdue Pharma	1993-12-31	Not applicable
Ms.ir	Tablet, multilayer, extended release	20 mg	Oral	Purdue Pharma	1991-12-31	Not applicable
Ms.ir	Tablet, multilayer, extended release	5 mg	Oral	Purdue Pharma	1991-12-31	Not applicable
Opium	Tincture	10 mg/1mL	Oral	Paddock Laboratories, Inc.	2011-01-28	2013-04-30
Opium Tincture	Tincture	10 mg / mL	Oral	D.C. Labs Limited	1951-12-31	2003-07-11
Opium Tincture Deodorized	Solution	10 g/1000mL	Oral	bryant ranch prepack	2011-02-25	Not applicable
Opium Tincture Deodorized	Solution	10 mg/1mL	Oral	Marathon Pharmaceuticals	2008-09-17	2016-08-10
Opium Tincture Deodorized	Solution	1 g/100mL	Oral	ANI Pharmaceuticals, Inc.	2011-02-25	Not applicable
Opium Tincture Deodorized	Solution	10 mg/1mL	Oral	Valeant Pharmaceuticals North America	2008-09-17	Not applicable
Opium Tincture Deodorized	Tincture	10 mg/1mL	Oral	Edenbridge Pharmaceuticals Llc	2010-07-15	Not applicable
Oramorph SR Sustained Release	Tablet	15 mg/1	Oral	Xanodyne Pharmaceuticals	2007-05-07	2012-02-29
Oramorph SR Sustained Release	Tablet	60 mg/1	Oral	Xanodyne Pharmaceuticals	2007-05-07	2012-03-31
Oramorph SR Sustained Release	Tablet	30 mg/1	Oral	Xanodyne Pharmaceuticals	2007-05-07	2011-12-31
Oramorph SR Sustained Release	Tablet	100 mg/1	Oral	Xanodyne Pharmaceuticals	2007-05-07	2012-06-30
Oramorph SR Tablets 100mg	Tablet, extended release	100 mg / tab	Oral	Roxane Labs, Division Of Boehringer Ingelheim	1992-12-31	2001-07-30
Oramorph SR Tablets 30mg	Tablet, extended release	30 mg	Oral	Roxane Labs, Division Of Boehringer Ingelheim	1992-12-31	2002-07-25
Oramorph SR Tablets 60mg	Tablet, extended release	60 mg	Oral	Roxane Labs, Division Of Boehringer Ingelheim	1992-12-31	2002-07-25
Paregoric	Liquid	2 mg/5mL	Oral	Hi-Tech Pharmacal Co., Inc.	2012-08-06	Not applicable
Paregoric	Liquid	2 mg/5mL	Oral	Physicians Total Care, Inc.	2012-07-01	2012-09-01
Roxanol	Solution, concentrate	20 mg/1mL	Oral	Physicians Total Care, Inc.	1994-11-03	2006-06-30
Statex Dps 50mg/ml	Solution / drops	50 mg / mL	Oral	Paladin Labs Inc.	1986-12-31	2018-12-07
Statex Drops 20mg/ml	Solution / drops	20 mg / mL	Oral	Paladin Labs Inc.	1984-12-31	2018-09-18
Statex Suppositories 20mg	Suppository	20 mg	Rectal	Paladin Labs Inc.	1985-12-31	2021-12-23
Statex Suppositories 30mg	Suppository	30 mg	Rectal	Paladin Labs Inc.	1997-08-04	2022-02-10
Statex Suppositories 5mg	Suppository	5 mg	Rectal	Paladin Labs Inc.	1997-08-04	2021-03-05
Statex Syrup 10mg/ml	Syrup	10 mg / mL	Oral	Paladin Labs Inc.	1987-12-31	2018-09-18
Statex Syrup 1mg/ml	Syrup	1 mg / mL	Oral	Paladin Labs Inc.	1984-12-31	2019-05-31
Statex Syrup 5mg/ml	Syrup	5 mg / mL	Oral	Paladin Labs Inc.	1984-12-31	2018-09-18
Statex Tab 10mg	Tablet	10 mg	Oral	Paladin Labs Inc.	1985-12-31	Not applicable
Statex Tab 5mg	Tablet	5 mg	Oral	Paladin Labs Inc.	1985-12-31	Not applicable
Statex Tablet 25mg	Tablet	25 mg	Oral	Paladin Labs Inc.	1985-12-31	2023-02-20
Statex Tablets 50mg	Tablet	50 mg	Oral	Paladin Labs Inc.	1986-12-31	2023-02-20
Statex-suppositories 10mg	Suppository	10 mg	Rectal	Paladin Labs Inc.	1985-12-31	2021-01-07
Zomorph	Capsule, extended release	60 mg	Oral	Ethypharm	Not applicable	Not applicable
Zomorph	Capsule, extended release	200 mg	Oral	Ethypharm	Not applicable	Not applicable
Zomorph	Capsule, extended release	40 mg	Oral	Ethypharm	Not applicable	Not applicable
Zomorph	Capsule, extended release	120 mg	Oral	Ethypharm	Not applicable	Not applicable
Zomorph	Capsule, extended release	20 mg	Oral	Ethypharm	Not applicable	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Astramorph	Injection	1 mg/1mL	Epidural; Intrathecal; Intravenous	Astra Zeneca Lp	1990-09-30	2013-03-31
Astramorph	Injection	1 mg/1mL	Epidural; Intrathecal; Intravenous	Astra Zeneca Lp	1990-10-01	2013-04-30
Astramorph	Injection	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Astra Zeneca Lp	1990-10-01	2013-02-28
Astramorph	Injection	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Astra Zeneca Lp	1990-10-01	2012-11-30
Astramorph	Injection	1 mg/1mL	Epidural; Intrathecal; Intravenous	Astra Zeneca Lp	1990-10-01	2012-06-30
Astramorph	Injection	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Astra Zeneca Lp	1990-10-01	2012-08-31
Astramorph PF	Injection, solution	1 mg/1mL	Epidural; Intrathecal; Intravenous	Fresenius Kabi	2009-09-28	2013-05-10
Astramorph PF	Injection, solution	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Fresenius Kabi	2009-09-28	2013-05-10
Bar-morphine SR	Tablet, extended release	100 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-morphine SR	Tablet, extended release	15 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-morphine SR	Tablet, extended release	60 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-morphine SR	Tablet, extended release	200 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Bar-morphine SR	Tablet, extended release	30 mg	Oral	Bard Pharmaceuticals (1990) Inc	Not applicable	Not applicable
Mitigo	Injection	200 mg/20mL	Epidural; Intrathecal	Piramal Critical Care, Inc.	2019-02-25	Not applicable
Mitigo	Injection	500 mg/20mL	Epidural; Intrathecal	Piramal Critical Care, Inc.	2018-10-15	Not applicable
Morphine Sulfate	Capsule, extended release	50 mg/1	Oral	Par Pharmaceutical	2011-11-10	Not applicable
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	St Marys Medical Park Pharmacy	2016-04-01	2020-01-31
Morphine Sulfate	Tablet	30 mg/1	Oral	bryant ranch prepack	2021-02-11	Not applicable
Morphine Sulfate	Solution	20 mg/5mL	Oral	ANI Pharmaceuticals, Inc.	2018-07-09	2022-07-31
Morphine sulfate	Capsule, extended release	100 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2023-02-28
Morphine sulfate	Tablet, film coated, extended release	100 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Ethex Corporation	2009-12-03	Not applicable
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	Zydus Pharmaceuticals (USA) Inc.	2015-07-09	Not applicable
Morphine sulfate	Capsule, extended release	45 mg/1	Oral	Actavis Pharma, Inc.	2014-02-04	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Core Pharma, Llc	2016-06-23	2016-06-23
Morphine Sulfate	Tablet, extended release	15 mg/1	Oral	Physicians Total Care, Inc.	2004-08-10	Not applicable
Morphine Sulfate	Injection	10 mg/1mL	Intravenous	Hikma Pharmaceuticals USA Inc.	2015-06-03	Not applicable
Morphine Sulfate	Capsule, extended release	80 mg/1	Oral	Upsher-Smith Laboratories, LLC	2013-06-30	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Actavis Pharma Company	1987-05-01	2018-03-28
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Mylan Pharmaceuticals Inc.	2011-10-18	2019-07-31
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	bryant ranch prepack	2015-10-26	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Winder Laboratories Llc	2019-05-15	Not applicable
Morphine sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-05-11	Not applicable
Morphine sulfate	Capsule, extended release	50 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2023-02-28
Morphine Sulfate	Tablet	15 mg/1	Oral	SpecGx LLC	2023-09-01	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Directrx	2015-01-01	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Lupin Pharmaceuticals,Inc.	2015-12-16	Not applicable
Morphine Sulfate	Tablet, film coated	100 mg/1	Oral	IVAX Pharmaceuticals Inc	2010-07-19	2010-07-20
Morphine Sulfate	Solution	100 mg/5mL	Oral	Akorn	2017-07-06	Not applicable
Morphine Sulfate	Capsule, extended release	30 mg/1	Oral	Upsher-Smith Laboratories, LLC	2013-06-30	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1987-05-01	2018-04-12
Morphine Sulfate	Solution	10 mg/5mL	Oral	Vistapharm, Inc.	2012-03-01	Not applicable
Morphine Sulfate	Tablet, extended release	60 mg/1	Oral	bryant ranch prepack	2010-10-21	2012-04-01
Morphine Sulfate	Capsule, extended release	100 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2016-04-12	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Ascend Laboratories, LLC	2021-02-11	Not applicable
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-05-11	Not applicable
Morphine sulfate	Capsule, extended release	10 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2023-06-30
Morphine Sulfate	Injection	1 mg/30mL	Intravenous	International Medication Systems, Limited	2022-01-20	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Lupin Pharmaceuticals,Inc.	2015-12-16	Not applicable
Morphine Sulfate	Capsule, extended release	20 mg/1	Oral	Quality Care Products LLC	2013-06-30	Not applicable
Morphine Sulfate	Solution	20 mg/5mL	Oral	Caraco Pharmaceutical Laboratories, Ltd.	2012-01-31	2016-01-31
Morphine Sulfate	Tablet, film coated	15 mg/1	Oral	IVAX Pharmaceuticals Inc	2010-07-19	2010-07-20
Morphine Sulfate	Tablet, extended release	100 mg/1	Oral	SpecGx LLC	2003-07-03	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Upsher-Smith Laboratories, LLC	2019-07-22	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1987-05-01	2018-04-12
Morphine Sulfate	Tablet, extended release	100 mg/1	Oral	Par Pharmaceutical	1998-10-31	2019-10-31
Morphine Sulfate	Capsule, extended release	60 mg/1	Oral	Actavis Pharma, Inc.	2011-11-10	2013-11-30
Morphine Sulfate	Capsule, extended release	50 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2016-04-12	Not applicable
Morphine sulfate	Tablet, film coated, extended release	200 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Mayne Pharma Commercial LLC	2016-11-01	Not applicable
Morphine Sulfate	Solution	20 mg/1mL	Oral	bryant ranch prepack	2015-09-21	Not applicable
Morphine Sulfate	Injection, solution	1 mg/1mL	Epidural; Intrathecal; Intravenous	Barr Laboratories	1990-09-30	2011-03-31
Morphine sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Actavis Pharma, Inc.	2015-10-26	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Mylan Pharmaceuticals Inc.	2011-10-18	2019-07-31
Morphine Sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Ethex Corporation	2010-04-22	Not applicable
Morphine Sulfate	Tablet, extended release	15 mg/1	Oral	SpecGx LLC	2003-07-31	Not applicable
Morphine Sulfate	Tablet, extended release	100 mg/1	Oral	Zydus Pharmaceuticals (USA) Inc.	2015-07-09	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	200 mg/1	Oral	Core Pharma, Llc	2016-06-23	2016-06-23
Morphine Sulfate	Tablet, extended release	15 mg/1	Oral	Par Pharmaceutical	1998-10-31	2019-10-31
Morphine Sulfate	Capsule, extended release	100 mg/1	Oral	Nortec Development Associates, Inc.	2009-04-07	Not applicable
Morphine Sulfate	Capsule, extended release	20 mg/1	Oral	Actavis Pharma, Inc.	2011-11-10	2013-12-31
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Injection, solution	1 mg/1mL	Epidural; Intrathecal; Intravenous	Hospira, Inc.	2005-06-29	Not applicable
Morphine Sulfate	Solution	20 mg/1mL	Oral	Safecor Health, LLC	2013-01-17	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Mylan Pharmaceuticals Inc.	2011-10-18	2019-07-31
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	RedPharm Drug, Inc.	2015-10-26	Not applicable
Morphine Sulfate	Tablet, extended release	15 mg/1	Oral	Zydus Pharmaceuticals (USA) Inc.	2015-07-09	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Core Pharma, Llc	2016-06-23	2016-06-23
Morphine Sulfate	Tablet, extended release	100 mg/1	Oral	American Health Packaging	2011-09-02	2018-10-31
Morphine Sulfate	Capsule, extended release	50 mg/1	Oral	Nortec Development Associates, Inc.	2009-04-07	Not applicable
Morphine Sulfate	Injection	8 mg/1mL	Intravenous	Hikma Pharmaceuticals USA Inc.	2015-06-03	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	Tris Pharma Inc	2015-09-21	2021-09-10
Morphine Sulfate	Solution	10 mg/5mL	Oral	Atlantic Biologicals Corp.	2018-07-09	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	H.J. Harkins Company	2011-01-14	Not applicable
Morphine Sulfate	Tablet, extended release	100 mg/1	Oral	Novel Laboratories, Inc.	2015-12-16	Not applicable
Morphine Sulfate	Solution	20 mg/5mL	Oral	Rhodes Pharmaceuticals L.P.	2016-07-12	Not applicable
Morphine sulfate	Tablet, film coated, extended release	200 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Capsule, extended release	80 mg/1	Oral	Par Pharmaceutical	2011-11-10	Not applicable
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Lupin Pharmaceuticals,Inc.	2015-12-16	Not applicable
Morphine Sulfate	Solution	20 mg/5mL	Oral	Qualitest	2015-10-30	2015-10-30
Morphine Sulfate	Tablet, extended release	15 mg/1	Oral	American Health Packaging	2011-09-01	2019-10-31
Morphine Sulfate	Solution	20 mg/1mL	Oral	SpecGx LLC	2011-07-15	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Actavis Pharma Company	1987-05-01	2018-03-28
Morphine sulfate	Capsule, extended release	75 mg/1	Oral	Actavis Pharma, Inc.	2014-02-04	Not applicable
Morphine Sulfate	Tablet, extended release	60 mg/1	Oral	Physicians Total Care, Inc.	2004-04-26	Not applicable
Morphine Sulfate	Tablet, extended release	15 mg/1	Oral	Novel Laboratories, Inc.	2015-12-16	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	ANI Pharmaceuticals, Inc.	2018-07-09	2022-07-31
Morphine sulfate	Capsule, extended release	80 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2023-02-28
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Tablet, extended release	60 mg/1	Oral	Par Pharmaceutical	1998-10-31	2019-10-31
Morphine Sulfate	Capsule, extended release	30 mg/1	Oral	Par Pharmaceutical	2011-11-10	Not applicable
Morphine sulfate	Tablet, film coated, extended release	60 mg/1	Oral	bryant ranch prepack	2015-10-26	Not applicable
Morphine sulfate	Tablet, film coated, extended release	200 mg/1	Oral	Actavis Pharma, Inc.	2015-10-26	Not applicable
Morphine Sulfate	Solution	20 mg/1mL	Oral	bryant ranch prepack	2015-09-21	Not applicable
Morphine Sulfate	Tablet, extended release	60 mg/1	Oral	SpecGx LLC	2003-07-31	Not applicable
Morphine Sulfate	Tablet, extended release	15 mg/1	Oral	McKesson Corporation dba SKY Packaging	2015-07-09	2019-04-30
Morphine sulfate	Capsule, extended release	30 mg/1	Oral	Actavis Pharma, Inc.	2014-02-04	Not applicable
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	bryant ranch prepack	2003-07-31	Not applicable
Morphine Sulfate	Capsule, extended release	60 mg/1	Oral	Upsher-Smith Laboratories, LLC	2013-06-30	Not applicable
Morphine sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-05-11	Not applicable
Morphine sulfate	Capsule, extended release	30 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2023-02-28
Morphine sulfate	Tablet, film coated, extended release	60 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Solution	20 mg/5mL	Oral	Nostrum Laboratories, Inc.	2014-02-05	Not applicable
Morphine Sulfate	Capsule, extended release	80 mg/1	Oral	Nortec Development Associates, Inc.	2009-04-07	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	PAI Holdings, LLC	2016-11-14	Not applicable
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Actavis Pharma, Inc.	2015-10-26	Not applicable
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2015-10-26	Not applicable
Morphine Sulfate	Solution	20 mg/5mL	Oral	Winder Laboratories Llc	2019-05-15	Not applicable
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Quality Care Products, LLC	2019-12-15	Not applicable
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2010-04-07	2017-06-01
Morphine Sulfate	Capsule, extended release	100 mg/1	Oral	Actavis Pharma, Inc.	2011-11-10	2014-08-31
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2015-10-26	Not applicable
Morphine Sulfate	Tablet, film coated	60 mg/1	Oral	IVAX Pharmaceuticals Inc	2010-07-19	2010-07-20
Morphine Sulfate	Capsule, extended release	20 mg/1	Oral	Upsher-Smith Laboratories, LLC	2013-06-30	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Mayne Pharma Commercial LLC	2022-01-14	Not applicable
Morphine Sulfate	Tablet, extended release	60 mg/1	Oral	American Health Packaging	2011-09-02	2018-12-31
Morphine Sulfate	Capsule, extended release	30 mg/1	Oral	Nortec Development Associates, Inc.	2009-04-07	Not applicable
Morphine Sulfate	Injection, solution	1 mg/1mL	Epidural; Intrathecal; Intravenous	Barr Laboratories	1990-09-30	2010-10-31
Morphine Sulfate	Capsule, extended release	80 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2016-04-12	Not applicable
Morphine Sulfate	Injection	4 mg/1mL	Intravenous	Civica, Inc.	2019-11-11	Not applicable
Morphine Sulfate	Tablet	15 mg/1	Oral	Ascend Laboratories, LLC	2021-02-11	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	RedPharm Drug, Inc.	2011-01-14	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Mayne Pharma Commercial LLC	2016-11-01	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1987-05-01	2018-04-12
Morphine Sulfate	Capsule, extended release	50 mg/1	Oral	Actavis Pharma, Inc.	2011-11-10	2014-09-30
Morphine Sulfate	Tablet, film coated, extended release	200 mg/1	Oral	Ethex Corporation	2009-01-01	Not applicable
Morphine Sulfate	Tablet	15 mg/1	Oral	Upsher-Smith Laboratories, LLC	2019-07-22	Not applicable
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	St Marys Medical Park Pharmacy	2016-04-01	2020-01-31
Morphine Sulfate	Tablet	15 mg/1	Oral	bryant ranch prepack	2021-02-11	Not applicable
Morphine Sulfate	Injection, solution	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Barr Laboratories	1990-09-30	2011-06-30
Morphine Sulfate	Capsule, extended release	30 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2016-04-12	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	Rhodes Pharmaceuticals L.P.	2017-06-22	Not applicable
Morphine sulfate	Capsule, extended release	200 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2011-11-11
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Capsule, extended release	60 mg/1	Oral	Par Pharmaceutical	2011-11-10	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	200 mg/1	Oral	Actavis Pharma Company	1987-05-01	2018-03-28
Morphine sulfate	Tablet, film coated, extended release	100 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine sulfate	Tablet, film coated, extended release	60 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Mayne Pharma Commercial LLC	2016-11-01	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Core Pharma, Llc	2016-06-23	2016-06-23
Morphine Sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Mylan Pharmaceuticals Inc.	2011-10-18	2019-07-31
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Ethex Corporation	2010-04-22	Not applicable
Morphine Sulfate	Tablet, extended release	60 mg/1	Oral	Zydus Pharmaceuticals (USA) Inc.	2015-07-09	Not applicable
Morphine Sulfate	Tablet	30 mg/1	Oral	Quality Care Products, LLC	2021-03-18	Not applicable
Morphine Sulfate	Injection, solution	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Hospira, Inc.	2005-08-10	Not applicable
Morphine sulfate	Tablet, film coated, extended release	200 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-05-11	Not applicable
Morphine sulfate	Capsule, extended release	60 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2023-02-28
Morphine Sulfate	Tablet	30 mg/1	Oral	SpecGx LLC	2023-09-01	Not applicable
Morphine Sulfate	Capsule, extended release	20 mg/1	Oral	Par Pharmaceutical	2011-11-10	Not applicable
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	bryant ranch prepack	2015-10-26	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Core Pharma, Llc	2016-06-23	2016-06-23
Morphine Sulfate	Injection	4 mg/1mL	Intravenous	Hikma Pharmaceuticals USA Inc.	2015-06-03	Not applicable
Morphine Sulfate	Solution	20 mg/5mL	Oral	Vistapharm, Inc.	2012-03-01	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	200 mg/1	Oral	Lupin Pharmaceuticals,Inc.	2015-12-16	Not applicable
Morphine sulfate	Capsule, extended release	120 mg/1	Oral	Actavis Pharma, Inc.	2014-02-04	Not applicable
Morphine Sulfate	Solution	10 mg/5mL	Oral	Winder Laboratories Llc	2019-05-15	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	H.J. Harkins Company	2011-01-14	Not applicable
Morphine Sulfate	Tablet, extended release	60 mg/1	Oral	Novel Laboratories, Inc.	2015-12-16	Not applicable
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Sun Pharmaceutical Industries, Inc.	2012-05-11	Not applicable
Morphine sulfate	Capsule, extended release	20 mg/1	Oral	Actavis Pharma, Inc.	2011-11-11	2023-02-28
Morphine Sulfate	Tablet	30 mg/1	Oral	bryant ranch prepack	2021-02-11	Not applicable
Morphine sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Quality Care Products, LLC	2020-06-06	Not applicable
Morphine Sulfate	Capsule, extended release	40 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2018-10-05	Not applicable
Morphine sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2015-10-26	2019-10-11
Morphine Sulfate	Solution	10 mg/5mL	Oral	Qualitest	2015-11-25	2015-11-25
Morphine Sulfate	Tablet, extended release	200 mg/1	Oral	SpecGx LLC	2003-07-03	Not applicable
Morphine Sulfate	Tablet, extended release	200 mg/1	Oral	Par Pharmaceutical	1998-10-31	2019-10-31
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Lupin Pharmaceuticals,Inc.	2015-12-16	Not applicable
Morphine sulfate	Capsule, extended release	60 mg/1	Oral	Actavis Pharma, Inc.	2014-02-04	Not applicable
Morphine Sulfate	Tablet	15 mg/1	Oral	RedPharm Drug, Inc.	2019-07-22	Not applicable
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	Physicians Total Care, Inc.	2005-06-30	Not applicable
Morphine Sulfate	Capsule, extended release	100 mg/1	Oral	Upsher-Smith Laboratories, LLC	2013-06-30	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	60 mg/1	Oral	Mayne Pharma Commercial LLC	2016-11-01	Not applicable
Morphine Sulfate	Tablet	15 mg/1	Oral	Mayne Pharma Commercial LLC	2022-01-14	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	Actavis Pharma Company	1987-05-01	2018-03-28
Morphine Sulfate	Injection, solution	0.5 mg/1mL	Epidural; Intrathecal; Intravenous	Barr Laboratories	1990-09-30	2010-10-31
Morphine Sulfate	Capsule, extended release	60 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2016-04-12	Not applicable
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	SpecGx LLC	2003-07-31	Not applicable
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	Par Pharmaceutical	1998-10-31	2019-10-31
Morphine Sulfate	Tablet	15 mg/1	Oral	American Health Packaging	2021-10-18	2025-01-31
Morphine sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Actavis Pharma, Inc.	2015-10-26	Not applicable
Morphine sulfate	Tablet, film coated, extended release	60 mg/1	Oral	bryant ranch prepack	2012-05-11	Not applicable
Morphine Sulfate	Tablet, film coated	200 mg/1	Oral	IVAX Pharmaceuticals Inc	2010-07-19	2010-07-20
Morphine Sulfate	Capsule, extended release	50 mg/1	Oral	Upsher-Smith Laboratories, LLC	2013-06-30	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Paddock Laboratories, LLC	2012-08-17	2020-02-29
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	McKesson Corporation dba SKY Packaging	2015-07-09	2019-04-30
Morphine Sulfate	Capsule, extended release	20 mg/1	Oral	Amneal Pharmaceuticals of New York Llc	2016-04-12	Not applicable
Morphine Sulfate	Capsule, extended release	30 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2013-06-30	Not applicable
Morphine Sulfate	Capsule, extended release	60 mg/1	Oral	Nortec Development Associates, Inc.	2009-04-07	Not applicable
Morphine sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Actavis Pharma, Inc.	2015-10-26	Not applicable
Morphine Sulfate	Solution	20 mg/1mL	Oral	Tris Pharma Inc	2015-09-21	Not applicable
Morphine Sulfate	Tablet, film coated	30 mg/1	Oral	IVAX Pharmaceuticals Inc	2010-07-19	2010-07-20
Morphine Sulfate	Capsule, extended release	10 mg/1	Oral	Upsher-Smith Laboratories, LLC	2013-06-30	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1987-05-01	2018-04-12
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Stat Rx USA	2011-01-14	Not applicable
Morphine Sulfate	Capsule, extended release	80 mg/1	Oral	Actavis Pharma, Inc.	2011-11-10	2014-08-31
Morphine Sulfate	Tablet, extended release	200 mg/1	Oral	Novel Laboratories, Inc.	2015-12-16	Not applicable
Morphine Sulfate	Capsule, extended release	50 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2017-08-18	Not applicable
Morphine Sulfate	Capsule, extended release	100 mg/1	Oral	Par Pharmaceutical	2011-11-10	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	Direct_Rx	2019-07-17	Not applicable
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	American Health Packaging	2011-09-01	2019-10-31
Morphine Sulfate	Capsule, extended release	20 mg/1	Oral	Nortec Development Associates, Inc.	2009-04-07	Not applicable
Morphine Sulfate	Solution	100 mg/5mL	Oral	Rhodes Pharmaceuticals L.P.	2017-06-22	Not applicable
Morphine Sulfate	Solution	20 mg/1mL	Oral	bryant ranch prepack	2015-09-21	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Ethex Corporation	2009-01-01	Not applicable
Morphine Sulfate	Tablet, extended release	200 mg/1	Oral	Zydus Pharmaceuticals (USA) Inc.	2015-07-09	Not applicable
Morphine sulfate	Capsule, extended release	90 mg/1	Oral	Actavis Pharma, Inc.	2014-02-04	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	30 mg/1	Oral	bryant ranch prepack	2011-01-14	Not applicable
Morphine Sulfate	Tablet, extended release	100 mg/1	Oral	Physicians Total Care, Inc.	2006-05-17	Not applicable
Morphine Sulfate	Capsule, extended release	30 mg/1	Oral	Actavis Pharma, Inc.	2011-11-10	2014-09-30
Morphine Sulfate	Tablet, extended release	30 mg/1	Oral	Novel Laboratories, Inc.	2015-12-16	Not applicable
Morphine Sulfate	Tablet, film coated, extended release	100 mg/1	Oral	Actavis Pharma Company	1987-05-01	2018-03-28
Morphine Sulfate	Tablet, film coated, extended release	200 mg/1	Oral	Mylan Pharmaceuticals Inc.	2011-10-18	2018-11-30
Morphine Sulfate	Tablet, film coated, extended release	15 mg/1	Oral	bryant ranch prepack	1987-05-01	2017-12-31
Morphine Sulfate ER	Tablet, film coated, extended release	15 mg/1	Oral	bryant ranch prepack	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	60 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-01-14	2018-07-20
Morphine Sulfate Extended Release	Tablet, film coated, extended release	200 mg/1	Oral	bryant ranch prepack	2011-01-14	2013-06-01
Morphine Sulfate Extended Release	Tablet, film coated, extended release	30 mg/1	Oral	Major Pharmaceuticals	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	200 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2011-01-14	2014-12-31
Morphine Sulfate Extended Release	Tablet, film coated, extended release	60 mg/1	Oral	American Health Packaging	2013-08-05	2015-08-31
Morphine Sulfate Extended Release	Tablet, film coated, extended release	100 mg/1	Oral	Rhodes Pharmaceuticals L. P.	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	15 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	15 mg/1	Oral	Rhodes Pharmaceuticals L. P.	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	200 mg/1	Oral	bryant ranch prepack	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, extended release	60 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2011-12-13	2014-06-01
Morphine Sulfate Extended Release	Tablet, film coated, extended release	30 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-07-21	2018-07-20
Morphine Sulfate Extended Release	Tablet, film coated, extended release	100 mg/1	Oral	bryant ranch prepack	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	100 mg/1	Oral	Major Pharmaceuticals	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	60 mg/1	Oral	Rhodes Pharmaceuticals L. P.	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	200 mg/1	Oral	bryant ranch prepack	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	15 mg/1	Oral	Major Pharmaceuticals	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, extended release	15 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2010-09-17	2014-06-01
Morphine Sulfate Extended Release	Tablet, film coated, extended release	30 mg/1	Oral	American Health Packaging	2013-08-27	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	15 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-01-14	2018-07-20
Morphine Sulfate Extended Release	Tablet, film coated, extended release	30 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	60 mg/1	Oral	Major Pharmaceuticals	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	100 mg/1	Oral	Avera McKennan Hospital	2015-04-27	2017-05-24
Morphine Sulfate Extended Release	Tablet, film coated, extended release	100 mg/1	Oral	American Health Packaging	2013-08-05	2015-05-08
Morphine Sulfate Extended Release	Tablet, film coated, extended release	100 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-01-14	2017-06-01
Morphine Sulfate Extended Release	Tablet, film coated, extended release	60 mg/1	Oral	bryant ranch prepack	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	200 mg/1	Oral	Rhodes Pharmaceuticals L. P.	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	60 mg/1	Oral	Lake Erie Medical DBA Quality Care Products LLC	2011-01-14	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	15 mg/1	Oral	American Health Packaging	2013-10-21	Not applicable
Morphine Sulfate Extended Release	Tablet, film coated, extended release	30 mg/1	Oral	Rhodes Pharmaceuticals L. P.	2011-01-14	Not applicable
Morphine Sulfate Extended-release	Tablet, extended release	100 mg/1	Oral	Lake Erie Medical Surgical & Supply DBA Quality Care Products LLC	2011-07-28	2018-01-04
Morphine Sulfate Extended-Release	Tablet	60 mg/1	Oral	Sun Pharmaceutical Industries Limited	2016-09-13	Not applicable
Morphine Sulfate Extended-release	Tablet, extended release	30 mg/1	Oral	Stat Rx USA	2010-10-21	Not applicable
Morphine Sulfate Extended-release	Tablet	200 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-20	2014-01-01
Morphine Sulfate Extended-Release	Tablet	200 mg/1	Oral	Sun Pharmaceutical Industries Limited	2016-09-13	Not applicable
Morphine Sulfate Extended-Release	Tablet	30 mg/1	Oral	Sun Pharmaceutical Industries Limited	2016-09-13	Not applicable
Morphine Sulfate Extended-release	Tablet, extended release	15 mg/1	Oral	Stat Rx USA	2010-10-21	Not applicable
Morphine Sulfate Extended-Release	Tablet	100 mg/1	Oral	Sun Pharmaceutical Industries Limited	2016-09-13	Not applicable
Morphine Sulfate Extended-Release	Tablet	15 mg/1	Oral	Sun Pharmaceutical Industries Limited	2016-09-13	Not applicable
Morphine Sulfate Oral Solution	Solution	10 mg/5mL	Oral	Caraco Pharmaceutical Laboratories, Ltd.	2012-01-31	2016-02-29
Morphine Sulfate Oral Solution	Solution	10 mg/5mL	Oral	Nostrum Laboratories, Inc.	2014-02-05	Not applicable
Morphine Sulfate Oral Solution CII	Solution	100 mg/5mL	Oral	Nostrum Laboratories, Inc.	2016-10-06	Not applicable
Morphine sulfate solution	Solution	20 mg/5mL	Oral	Tris Pharma Inc	2017-06-15	2019-01-30
Ntp-morphine SR	Tablet, extended release	100 mg	Oral	TEVA Canada Limited	Not applicable	Not applicable
Ntp-morphine SR	Tablet, extended release	30 mg	Oral	TEVA Canada Limited	Not applicable	Not applicable
Ntp-morphine SR	Tablet, extended release	60 mg	Oral	TEVA Canada Limited	Not applicable	Not applicable
Ntp-morphine SR	Tablet, extended release	15 mg	Oral	TEVA Canada Limited	Not applicable	Not applicable
Ntp-morphine SR	Tablet, extended release	200 mg	Oral	TEVA Canada Limited	Not applicable	Not applicable
PMS-morphine Sulfate SR 100 mg	Tablet, extended release	100 mg	Oral	Pharmascience Inc	2007-12-17	2012-11-09
PMS-morphine Sulfate SR 15 mg	Tablet, extended release	15 mg	Oral	Pharmascience Inc	2002-02-20	2012-11-09
PMS-morphine Sulfate SR 200 mg	Tablet, extended release	200 mg	Oral	Pharmascience Inc	2007-12-17	2012-11-09
PMS-morphine Sulfate SR 30 mg	Tablet, extended release	30 mg	Oral	Pharmascience Inc	2002-02-20	2012-11-09
PMS-morphine Sulfate SR 60 mg	Tablet, extended release	60 mg	Oral	Pharmascience Inc	2002-02-20	2012-11-09
Ratio-morphine	Syrup	5 mg / mL	Oral	TEVA Canada Limited	1985-12-31	2018-05-18
Ratio-morphine	Syrup	10 mg / mL	Oral	TEVA Canada Limited	1986-12-31	2018-05-18
Ratio-morphine	Syrup	1 mg / mL	Oral	TEVA Canada Limited	1984-12-31	2018-05-18
Ratio-morphine	Syrup	20 mg / mL	Oral	TEVA Canada Limited	1986-12-31	2018-05-18
Sandoz Morphine SR	Tablet, extended release	60 mg	Oral	Sandoz Canada Incorporated	2001-11-14	Not applicable
Sandoz Morphine SR	Tablet, extended release	30 mg	Oral	Sandoz Canada Incorporated	2001-11-14	Not applicable
Sandoz Morphine SR	Tablet, extended release	200 mg	Oral	Sandoz Canada Incorporated	2018-12-19	Not applicable
Sandoz Morphine SR	Tablet, extended release	15 mg	Oral	Sandoz Canada Incorporated	2001-11-14	Not applicable
Sandoz Morphine SR	Tablet, extended release	100 mg	Oral	Sandoz Canada Incorporated	2018-12-19	Not applicable
Teva-morphine SR	Tablet, extended release	15 mg	Oral	TEVA Canada Limited	2009-03-25	Not applicable
Teva-morphine SR	Tablet, extended release	60 mg	Oral	TEVA Canada Limited	2008-04-01	Not applicable
Teva-morphine SR	Tablet, extended release	200 mg	Oral	TEVA Canada Limited	2008-04-01	Not applicable
Teva-morphine SR	Tablet, extended release	30 mg	Oral	TEVA Canada Limited	2009-03-25	Not applicable
Teva-morphine SR	Tablet, extended release	100 mg	Oral	TEVA Canada Limited	2008-04-01	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Embeda	Morphine sulfate pentahydrate (20 mg/1) + Naltrexone hydrochloride (.8 mg/1)	Capsule, extended release	Oral	Stat Rx USA	2009-08-13	Not applicable
Embeda	Morphine sulfate pentahydrate (80 mg/1) + Naltrexone hydrochloride (3.2 mg/1)	Capsule, extended release	Oral	Pfizer Laboratories Div Pfizer Inc	2009-08-13	Not applicable
Embeda	Morphine sulfate pentahydrate (30 mg/1) + Naltrexone hydrochloride (1.2 mg/1)	Capsule, extended release	Oral	Pfizer Laboratories Div Pfizer Inc	2009-08-13	Not applicable
Embeda	Morphine sulfate pentahydrate (60 mg/1) + Naltrexone hydrochloride (2.4 mg/1)	Capsule, extended release	Oral	Pfizer Laboratories Div Pfizer Inc	2009-08-13	Not applicable
Embeda	Morphine sulfate pentahydrate (20 mg/1) + Naltrexone hydrochloride (0.8 mg/1)	Capsule, extended release	Oral	Pfizer Laboratories Div Pfizer Inc	2009-08-13	Not applicable
Embeda	Morphine sulfate pentahydrate (100 mg/1) + Naltrexone hydrochloride (4 mg/1)	Capsule, extended release	Oral	Pfizer Laboratories Div Pfizer Inc	2009-08-13	Not applicable
Embeda	Morphine sulfate pentahydrate (50 mg/1) + Naltrexone hydrochloride (2 mg/1)	Capsule, extended release	Oral	Pfizer Laboratories Div Pfizer Inc	2009-08-13	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Morphine Sulfate	Morphine sulfate pentahydrate (15 mg/1)	Tablet	Oral	Glenmark Generics, Inc. USA	2006-08-01	2009-06-26
Morphine Sulfate	Morphine sulfate pentahydrate (20 mg/1mL)	Solution	Oral	Paddock Laboratories, Inc.	2009-10-08	2011-10-31
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/10mL)	Injection, solution	Intravenous; Subcutaneous	Amphastar Pharmaceuticals, Inc.	2000-08-11	2010-09-23
Morphine Sulfate	Morphine sulfate pentahydrate (30 mg/1)	Suppository	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (1 mg/1mL)	Injection, solution	Intravenous	Cantrell Drug Company	2013-05-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (1 mg/1mL)	Injection	Intravenous	International Medication Systems, Limited	1987-03-27	2023-10-31
Morphine Sulfate	Morphine sulfate pentahydrate (5 mg/1)	Suppository	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	Physicians Total Care, Inc.	2000-05-24	2013-01-15
Morphine Sulfate	Morphine sulfate pentahydrate (8 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-01-31
Morphine Sulfate	Morphine sulfate pentahydrate (20 mg/1mL)	Solution, concentrate	Oral	Lehigh Valley Technologies, Inc.	2010-05-12	2010-07-22
Morphine Sulfate	Morphine sulfate pentahydrate (5 mg/1)	Suppository	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-04-30
Morphine Sulfate	Morphine sulfate pentahydrate (25 mg/1mL)	Injection, solution, concentrate	Intravenous	Hospira, Inc.	2005-07-28	2019-07-01
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1mL)	Injection, solution	Intravenous	Hospira, Inc.	1997-06-09	2014-03-01
Morphine Sulfate	Morphine sulfate pentahydrate (5 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-05-31
Morphine Sulfate	Morphine sulfate pentahydrate (20 mg/1)	Suppository	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (8 mg/1mL)	Injection, solution	Intravenous	Hospira, Inc.	1997-06-09	2013-10-01
Morphine Sulfate	Morphine sulfate pentahydrate (25 mg/1mL)	Injection, solution	Intravenous	Hospira, Inc.	1991-04-11	2015-02-01
Morphine Sulfate	Morphine sulfate pentahydrate (2 mg/1mL)	Injection, solution	Epidural; Intramuscular; Intrathecal; Intravenous	Cantrell Drug Company	2012-02-22	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (30 mg/30mL)	Injection, solution	Intravenous; Subcutaneous	Amphastar Pharmaceuticals, Inc.	1987-03-27	2010-09-23
Morphine Sulfate	Morphine sulfate pentahydrate (15 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-02-28
Morphine Sulfate	Morphine sulfate pentahydrate (5 mg/1mL)	Injection, solution	Intravenous	Cantrell Drug Company	2013-10-25	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (15 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-10-31
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-04-30
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1)	Suppository	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	Physicians Total Care, Inc.	2003-03-11	2011-06-30
Morphine Sulfate	Morphine sulfate pentahydrate (5 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-10-31
Morphine Sulfate	Morphine sulfate pentahydrate (1 mg/1mL)	Injection, solution	Epidural; Intramuscular; Intrathecal; Intravenous	Cantrell Drug Company	2013-09-09	2017-12-06
Morphine Sulfate	Morphine sulfate pentahydrate (30 mg/1)	Suppository	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (30 mg/1)	Tablet	Oral	Glenmark Generics, Inc. USA	2006-08-01	2009-06-26
Morphine Sulfate	Morphine sulfate pentahydrate (25 mg/1mL)	Injection, solution	Intravenous	Hospira, Inc.	1991-04-11	2015-09-01
Morphine Sulfate	Morphine sulfate pentahydrate (50 mg/1mL)	Injection, solution, concentrate	Intravenous	Hospira, Inc.	2005-08-11	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (2 mg/1mL)	Injection, solution	Intravenous	Hospira, Inc.	1980-05-01	2013-09-01
Morphine Sulfate	Morphine sulfate pentahydrate (1 mg/1mL)	Injection	Parenteral	Amphastar Pharmaceuticals, Inc.	1993-06-01	2009-12-18
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1)	Suppository	Rectal	Padagis US LLC	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (4 mg/1mL)	Injection, solution	Intravenous	Hospira, Inc.	1997-06-09	2013-09-01
Morphine Sulfate	Morphine sulfate pentahydrate (10 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	Baxter Laboratories	2002-12-02	2013-11-30
Morphine Sulfate	Morphine sulfate pentahydrate (0.5 mg/1mL)	Injection, solution	Intrathecal; Intravenous	Cantrell Drug Company	2012-01-23	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (15 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2017-05-31
Morphine Sulfate	Morphine sulfate pentahydrate (20 mg/1mL)	Solution, concentrate	Oral	Physicians Total Care, Inc.	2006-01-23	2013-01-15
Morphine Sulfate	Morphine sulfate pentahydrate (40 mg/1mL)	Injection, solution	Intrathecal	Cantrell Drug Company	2012-08-24	2015-03-13
Morphine Sulfate	Morphine sulfate pentahydrate (8 mg/1mL)	Injection	Intramuscular; Intravenous; Subcutaneous	West-Ward Pharmaceuticals Corp.	1971-01-01	2016-06-30
Morphine Sulfate	Morphine sulfate pentahydrate (20 mg/1)	Suppository	Rectal	bryant ranch prepack	1990-09-01	Not applicable
Morphine Sulfate	Morphine sulfate pentahydrate (15 mg/1mL)	Injection, solution	Intravenous	Hospira, Inc.	1997-06-09	2013-06-01
Opium	Morphine (10 mg/1mL)	Tincture	Oral	Paddock Laboratories, Inc.	2011-01-28	2013-04-30
Opium Tincture Deodorized	Morphine (10 mg/1mL)	Tincture	Oral	Edenbridge Pharmaceuticals Llc	2010-07-15	Not applicable
Opium Tincture Deodorized	Morphine (10 g/1000mL)	Solution	Oral	bryant ranch prepack	2011-02-25	Not applicable
Opium Tincture Deodorized	Morphine (1 g/100mL)	Solution	Oral	ANI Pharmaceuticals, Inc.	2011-02-25	Not applicable
Opium Tincture Deodorized	Morphine (10 mg/1mL)	Solution	Oral	Marathon Pharmaceuticals	2008-09-17	2016-08-10
Opium Tincture Deodorized	Morphine (10 mg/1mL)	Solution	Oral	Valeant Pharmaceuticals North America	2008-09-17	Not applicable
Paregoric	Morphine (2 mg/5mL)	Liquid	Oral	Physicians Total Care, Inc.	2012-07-01	2012-09-01
Paregoric	Morphine (2 mg/5mL)	Liquid	Oral	Hi-Tech Pharmacal Co., Inc.	2012-08-06	Not applicable
Roxanol	Morphine sulfate pentahydrate (20 mg/1mL)	Solution, concentrate	Oral	Physicians Total Care, Inc.	1994-11-03	2006-06-30

Chemical Identifiers

UNII: 76I7G6D29C
CAS number: 57-27-2
InChI Key: BQJCRHHNABKAKU-KBQPJGBKSA-N
InChI: InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
IUPAC Name: (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O

References

Synthesis Reference

US4764615

General References

Pacifici GM: Metabolism and pharmacokinetics of morphine in neonates: A review. Clinics (Sao Paulo). 2016 Aug;71(8):474-80. doi: 10.6061/clinics/2016(08)11. [Article]
Kim J, Ham S, Hong H, Moon C, Im HI: Brain Reward Circuits in Morphine Addiction. Mol Cells. 2016 Sep;39(9):645-53. doi: 10.14348/molcells.2016.0137. Epub 2016 Aug 9. [Article]
Beltran-Campos V, Silva-Vera M, Garcia-Campos ML, Diaz-Cintra S: Effects of morphine on brain plasticity. Neurologia. 2015 Apr;30(3):176-80. doi: 10.1016/j.nrl.2014.08.004. Epub 2014 Nov 11. [Article]
Klimas R, Mikus G: Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth. 2014 Dec;113(6):935-44. doi: 10.1093/bja/aeu186. Epub 2014 Jul 1. [Article]
Lotsch J: Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005 May;29(5 Suppl):S90-103. doi: 10.1016/j.jpainsymman.2005.01.012. [Article]
Hoskin PJ, Hanks GW: Morphine: pharmacokinetics and clinical practice. Br J Cancer. 1990 Nov;62(5):705-7. [Article]
Glare PA, Walsh TD: Clinical pharmacokinetics of morphine. Ther Drug Monit. 1991 Jan;13(1):1-23. [Article]
Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML: The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol. 2000 Mar;49(3):207-14. [Article]
Shigeev S: Severity of opiate intoxication to gender and age. Soud Lek. 2007 Jan;52(1):21-4. [Article]
FDA approvals [Link]
NIH [Link]
FDA Approved Drug Products: Infumorph Morphine Sulfate Injection [Link]
FDA Approved Drug Products: Morphine Sulfate Oral Tablets [Link]
FDA Approved Drug Products: Morphine Sulfate Oral Solution [Link]
FDA Approved Drug Products: MS Contin (Morphine Sulfate) Oral Extended Release Tablet [Link]
FDA Approved Drug Products: Kadian (Morphine Sulfate) Oral Extended Release Capsules [Link]
FDA Approved Drug Products: INFUMORPH (morphine sulfate), Preservative-free, injectable solution, for intrathecal or epidural infusion, using a continuous microinfusion device, CII [Link]

External Links

Human Metabolome Database: HMDB0014440
KEGG Drug: D08233
KEGG Compound: C01516
PubChem Compound: 5288826
PubChem Substance: 46505161
ChemSpider: 4450907
BindingDB: 50000092
RxNav: 7052
ChEBI: 17303
ChEMBL: CHEMBL70
ZINC: ZINC000003812983
Therapeutic Targets Database: DAP000071
PharmGKB: PA450550
PDBe Ligand: MOI
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Morphine

PDB Entries

1q0y / 7u62 / 8ef6

FDA label

Download (277 KB)

MSDS

Download (52.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Prevention	Pain / Postpartum Depression	1
4	Active Not Recruiting	Treatment	Chronic Pain	1
4	Completed	Not Available	Abdominal Pain	1
4	Completed	Not Available	Acute Coronary Syndrome (ACS)	1
4	Completed	Basic Science	Chronic Lower Back Pain (CLBP)	1
4	Completed	Basic Science	Healthy Volunteers (HV)	1
4	Completed	Basic Science	Pain	1
4	Completed	Basic Science	Pharyngeal Dysfunction / Pharyngeal Swallowing	1
4	Completed	Diagnostic	Abdominal Cancer	1
4	Completed	Diagnostic	Appendicitis	1
4	Completed	Diagnostic	Chronic Lower Back Pain (CLBP) / Opioid Induced Hyperalgesia	1
4	Completed	Diagnostic	Pruritus	1
4	Completed	Diagnostic	Sphincter of Oddi Dysfunction	1
4	Completed	Health Services Research	Intestinal Obstruction	1
4	Completed	Health Services Research	Retraction of Colostomy	1
4	Completed	Other	Cardiovascular Disease (CVD)	1
4	Completed	Other	Chronic Lower Back Pain (CLBP) / Neck Pain Chronic	1
4	Completed	Other	Neonatal drug withdrawal syndrome / Neonatal Opioid Withdrawal Syndrome	1
4	Completed	Other	Sleep Apnea	1
4	Completed	Prevention	Analgesia / Dexmedetomidine / Elderly / Postoperative Complications / Sleeping Quality / Surgery	1
4	Completed	Prevention	Chronic Post-Procedural Pain	1
4	Completed	Prevention	Delirium	1
4	Completed	Prevention	Neurogenic Bladder / Overactive Bladder Syndrome (OABS) / Painful Bladder Syndrome (PBS) / Urinary Urge Incontinence (UUI)	1
4	Completed	Prevention	Pain	1
4	Completed	Prevention	Post Operative Nausea and Vomiting (PONV) / Postoperative pain	1
4	Completed	Prevention	Postoperative pain	2
4	Completed	Supportive Care	Abdominal Cancer / Age Problems	1
4	Completed	Supportive Care	Analgesia	1
4	Completed	Supportive Care	Appendicitis	1
4	Completed	Supportive Care	Arthropathy of Hip	1
4	Completed	Supportive Care	Cancer Pain	1
4	Completed	Supportive Care	Femoracetabular Impingement / Postoperative pain	1
4	Completed	Supportive Care	Gastrostomy / Pain, Breakthrough / Upper Aerodigestive Tract Neoplasms	1
4	Completed	Supportive Care	Hysterectomy (MeSH nr: E04.950.300.399)	1
4	Completed	Supportive Care	Obstructive Sleep Apnea (OSA)	1
4	Completed	Supportive Care	Pain Management / Posterior Spinal Fusion	1
4	Completed	Supportive Care	Pain / Unspecified Adult Solid Tumor, Protocol Specific	1
4	Completed	Supportive Care	Postoperative pain	2
4	Completed	Supportive Care	Sickle Cell Disease (SCD)	1
4	Completed	Treatment	Abdominal Aorta Aneurysm / Abdominal Aorta Atheroma / Postoperative pain / Surgery	1
4	Completed	Treatment	Abdominal Hysterectomy (& Wertheim)	1
4	Completed	Treatment	Acute Abdomen / Back pain / Flank Pain / Musculoskeletal Pain / Other Acute Pain	1
4	Completed	Treatment	Acute Coronary Syndrome (ACS)	1
4	Completed	Treatment	Acute Myocardial Infarction (AMI)	1
4	Completed	Treatment	Acute Pain	3
4	Completed	Treatment	Acute Pain Following Decompressive Lumbar Spinal Surgery	1
4	Completed	Treatment	Acute Pain Management / Renal Colic	1
4	Completed	Treatment	Acute Pain / Arthritis of the Knee Joint / Knee Disease	1
4	Completed	Treatment	Acute Pain / Sickle Cell Crisis	1
4	Completed	Treatment	Adenotonsillectomy / Analgesia	1
4	Completed	Treatment	Analgesia	2
4	Completed	Treatment	Analgesia / Analgesics, Opioids / Central Nervous System Depressants / Morphine / Narcotics / Physiological Effects of Drugs	1
4	Completed	Treatment	Analgesia / Anesthesia therapy / Epidural / Postoperative Period / Quality of Life (QOL) / Quality of Recovery / Radical Prostatectomy / Recovery Period, Anesthesia / Satisfaction, Patient	1
4	Completed	Treatment	Analgesia / Chronic Pain / Postoperative pain	1
4	Completed	Treatment	Analgesia / Chronic Pain / Postoperative pain / Satisfaction, Patient	1
4	Completed	Treatment	Analgesia / Head And Neck Cancer	1
4	Completed	Treatment	Analgesia / Postoperative pain	1
4	Completed	Treatment	Analgesics, Opioids / Postoperative pain / Surgery, Colorectal	1
4	Completed	Treatment	Anesthesia, Caudal	1
4	Completed	Treatment	Anesthesia; Functional	1
4	Completed	Treatment	Anxiety / Chronic Lower Back Pain (CLBP) / Depression / Intervertebral Disc, Degenerative	1
4	Completed	Treatment	Arthroplasty / Osteoarthritis (OA)	1
4	Completed	Treatment	Back Pain Lower Back	1
4	Completed	Treatment	Back pain / Chronic Pain / Chronic, Non Malignant Pain / Leg Pain	1
4	Completed	Treatment	Bariatric Surgery Candidates / Decreased carbohydrate and glucose tolerance / Resistance, Insulin	1
4	Completed	Treatment	Bariatric Surgery Candidates / Obesity, Morbid	1
4	Completed	Treatment	Block	1
4	Completed	Treatment	Bone Fractures / Postoperative pain	1
4	Completed	Treatment	Brain Neoplasm	1
4	Completed	Treatment	Bupivacaine Adverse Reaction / Complications; Cesarean Section / Regional Anesthesia Morbidity	1
4	Completed	Treatment	Caesarian Section	1
4	Completed	Treatment	Cancer / Cancer Pain	1
4	Completed	Treatment	Cesarean Sections / Hypotension / Pregnancy / Spinal Anesthesia therapy	1
4	Completed	Treatment	Cesarean Sections / Neuropathic Pain / Pain Management	1
4	Completed	Treatment	Cesarean Sections / Obstetrical analgesia therapy	1
4	Completed	Treatment	Cesarean Sections / Post Operative Nausea and Vomiting (PONV) / Spinal Anesthesia therapy	1
4	Completed	Treatment	Cesarean Sections / Postoperative pain	1
4	Completed	Treatment	Children / Postoperative pain / Recovery of Function	1
4	Completed	Treatment	Chlorzoxazone / Postoperative pain	1
4	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Completed	Treatment	Chronic Pain	3
4	Completed	Treatment	Chronic Pain / Intractable Pain / Pain, Breakthrough	1
4	Completed	Treatment	Chronic Pain / Osteoarthritis (OA)	1
4	Completed	Treatment	Circulating Tumor Cells (CTCs) / Colorectal Cancer	2
4	Completed	Treatment	Colon Cancer / Minimal Residual Disease	1
4	Completed	Treatment	Consumption / Nausea and Vomiting Following Administration of Anaesthetic Agent / Postoperative pain / Pruritus	1
4	Completed	Treatment	Coronary Artery Disease (CAD)	1
4	Completed	Treatment	CRP	1
4	Completed	Treatment	Disk Prolapse / Intervertebral Disk Displacement	1
4	Completed	Treatment	Dissecting Aneurysm of the Thoracic Aorta	1
4	Completed	Treatment	Drug Interaction Potentiation / Myocardial Infarction	1
4	Completed	Treatment	Dyspnea / Interstitial Lung Disease / Morphine	1
4	Completed	Treatment	Dyspnea / Lung Neoplasm	1
4	Completed	Treatment	Elective Cesarean Section / Pain Management	1
4	Completed	Treatment	Epidermylosis Bullosa	1
4	Completed	Treatment	Epidural; Analgesia / Intravenous Drug Delivery Systems / Morphine / Patient Controlled Analgesia / Spinal Anesthesia therapy / Surgery, Colorectal	1
4	Completed	Treatment	Femur Fractures / Postoperative pain	1
4	Completed	Treatment	Fracture, Ankle / Postoperative pain	1
4	Completed	Treatment	Gall Stone Disease	1
4	Completed	Treatment	Gastric Cancer	1
4	Completed	Treatment	Heart; Dysfunction Postoperative, Cardiac Surgery	1
4	Completed	Treatment	Hip Arthroplasty	2
4	Completed	Treatment	Hip Fracture	1
4	Completed	Treatment	Hysterectomy / Myoma / Opioids / Postoperative pain	1
4	Completed	Treatment	Hysterectomy / Surgery, Laparoscopic	1
4	Completed	Treatment	Inguinal Hernias / Nausea / Postoperative pain / Pruritus / Vomiting	1
4	Completed	Treatment	Injections, Spinal / Morphine / Prostatectomy / Satisfaction, Patient	1
4	Completed	Treatment	Lung Disorder / Solitary Mass	1
4	Completed	Treatment	Morphine	1
4	Completed	Treatment	Morphine / S-ketamine	2
4	Completed	Treatment	Mucositis / Pain	1
4	Completed	Treatment	Neonatal drug withdrawal syndrome	3
4	Completed	Treatment	Nerve Block / Orthopedic Surgery / Shoulder	1
4	Completed	Treatment	Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Segment Elevation Myocardial Infarction (STEMI) / VA Drug Interactions [VA Drug Interaction]	1
4	Completed	Treatment	Numeric Pain Rating Scale > 5 / 10 / Severe Traumatic Pain	1
4	Completed	Treatment	Opioid Consumption / Post Partum Pain / Postpartum Depression	1
4	Completed	Treatment	Opioids Use / Postoperative pain	1
4	Completed	Treatment	Osteoarthritis (OA)	1
4	Completed	Treatment	Osteoarthritis (OA) / Postoperative pain	1
4	Completed	Treatment	Osteoarthritis of the Knee	2
4	Completed	Treatment	Otitis Media (OM)	1
4	Completed	Treatment	Pain	15
4	Completed	Treatment	Pain Management / Scoliosis / Spine Fusion	1
4	Completed	Treatment	Pain, Labor	1
4	Completed	Treatment	Pain, Obstetric	1
4	Completed	Treatment	Pain / Patient Controlled Analgesia / Postoperative pain	1
4	Completed	Treatment	Pain / Sickle Cell Disease (SCD)	1
4	Completed	Treatment	Pediatric Adenotonsillectomy / Postoperative Analgesia	1
4	Completed	Treatment	Pertrochanteric Fractures	1
4	Completed	Treatment	Post Operative Nausea and Vomiting (PONV) / Postoperative Function Level / Postoperative pain	1
4	Completed	Treatment	Postoperative pain	17
4	Completed	Treatment	Postoperative Pain, Acute	1
4	Completed	Treatment	Postoperative pain / Total Hip Arthroplasty (THA)	1
4	Completed	Treatment	Postoperative pain / Total Knee Replacement Surgery	1
4	Completed	Treatment	Postoperative pain / Video-assisted Thoracoscopic Surgery (VATS)	1
4	Completed	Treatment	Renal Colic	1
4	Completed	Treatment	Renal Colic / Urinary Calculi	1
4	Completed	Treatment	Sedation	1
4	Completed	Treatment	Severe, Acute Pain in a Pre-hospital Setting	1
4	Completed	Treatment	Surgery	1
4	Completed	Treatment	Surgical Remove of Hemorrhoids	1
4	Completed	Treatment	Total Knee Arthroplasty (TKA)	1
4	Completed	Treatment	Unstable Angina Pectoris	3
4	Completed	Treatment	Urolithiasis	1
4	Completed	Treatment	Video-assisted Thoracoscopic Surgery (VATS)	1
4	Not Yet Recruiting	Prevention	Post Operative Nausea and Vomiting (PONV)	1
4	Not Yet Recruiting	Treatment	Ablation / Pulmonary Nodules	1
4	Not Yet Recruiting	Treatment	Analgesia / Thoracic, Diseases	1
4	Not Yet Recruiting	Treatment	Osteoarthritis of the Knee	1
4	Not Yet Recruiting	Treatment	Postoperative pain	1
4	Recruiting	Other	Opioids Use / Symptoms, Affective	1
4	Recruiting	Prevention	Postoperative pain	2
4	Recruiting	Treatment	Ablation / Nalbuphine Allergy / Safety	1
4	Recruiting	Treatment	Acute Pain / Anesthesia therapy / Hepatic Resection / Local Anaesthesia therapy	1
4	Recruiting	Treatment	Adductor Canal Block / Arthroscopic Anterior Cruciate Ligament Reconstruction / Intrathecal Morphine / Quality of Recovery	1
4	Recruiting	Treatment	Anesthesia therapy / Opioids Use / Sleep disorders and disturbances / Surgery / Tonsillitis	1
4	Recruiting	Treatment	Back Pain Lower Back	1
4	Recruiting	Treatment	Back pain / Methadone / Opioids Use / Postoperative pain / Spondylolisthesis, Degenerative / Stenosis, Spinal	1
4	Recruiting	Treatment	Burns / Wound of Skin	1
4	Recruiting	Treatment	Cancer Pain / Cost Analysis / Epidural Route / Morphine-ropivacaine Association / Opioids Use / Palliatives Treatments / Quality of Life (QOL) / Rational Use of Medication	1
4	Recruiting	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Recruiting	Treatment	Intrathecal Morphine / Pain Management / Pediatric / Ureteral Reimplantation	1
4	Recruiting	Treatment	Neonatal drug withdrawal syndrome	1
4	Recruiting	Treatment	Opioid Use Disorder (OUD)	1
4	Recruiting	Treatment	Patient Controlled Analgesia	1
4	Recruiting	Treatment	Proximal Femur Fractures	1
4	Recruiting	Treatment	Sickle Cell Disease (SCD) / Vaso-Occlusive Pain Episode in Sickle Cell Disease	1
4	Suspended	Prevention	Postdural Puncture Headache	1
4	Suspended	Treatment	Chronic Pain	1
4	Terminated	Not Available	Chronic Pain	1
4	Terminated	Health Services Research	Intestinal Obstruction	3
4	Terminated	Prevention	Anesthesia therapy / Hip Fracture	1
4	Terminated	Prevention	Morphine / Postoperative pain / Rachianesthesia / Sufentanil / Video-assisted Thoracoscopic Surgery (VATS)	1
4	Terminated	Prevention	Post-operative Pain Management / Scheduled Cesarean Sections / Side Effects	1
4	Terminated	Supportive Care	Diseases, Chronic / Pain	1
4	Terminated	Supportive Care	Impaired Renal Function / Pain / Terminal Illness	1
4	Terminated	Supportive Care	Postoperative pain	1
4	Terminated	Treatment	Acute Pulmonary Edema	1
4	Terminated	Treatment	Analgesia / Fascia / Femoral Fractures / Humans / Local Anaesthesia therapy / Medicine, Emergency / Morphine / Pain / Pain Management / Patient Controlled Analgesia / Ultrasonography	1
4	Terminated	Treatment	Arthroplasties, Replacement, Knee	1
4	Terminated	Treatment	Cardiovascular Disease (CVD)	1
4	Terminated	Treatment	Chronic Neuropathic Pain	1
4	Terminated	Treatment	Fracture of Neck of Femur (Hip)	1
4	Terminated	Treatment	Hip Arthroplasty	1
4	Terminated	Treatment	Morphine Adverse Reaction / Pain	1
4	Terminated	Treatment	Narcotic Abuse / Opiate Addiction / Opioid Related Disorders / Substance Abuse	1
4	Terminated	Treatment	Osteoarthritis (OA) / Postoperative pain	1
4	Terminated	Treatment	Pain	1
4	Terminated	Treatment	Pectus Excavatum	1
4	Terminated	Treatment	Postoperative Analgesia	1
4	Terminated	Treatment	Postoperative pain	1
4	Terminated	Treatment	Postoperative Pain, Acute	1
4	Terminated	Treatment	Postoperative pain / Recovery Period, Anesthesia	1
4	Terminated	Treatment	Rib Fractures	1
4	Terminated	Treatment	Sickle Cell Disease (SCD)	1
4	Unknown Status	Not Available	Acute Pain	1
4	Unknown Status	Diagnostic	Liver Disease	1
4	Unknown Status	Prevention	Hyperalgesia	1
4	Unknown Status	Supportive Care	Bypass Complications	1
4	Unknown Status	Supportive Care	Colon Cancer / Colon Diverticulosis / Colon Neoplasm / Constipation / Diverticulitis, Colonic / Drug Induced Constipation / Ileus / Ileus; Mechanical / Paralytic Ileus / Postoperative pain / Rectal Cancer / Rectal Neoplasms	1
4	Unknown Status	Supportive Care	Ventricular Dysfunction, Right	1
4	Unknown Status	Treatment	Acute Pain	1
4	Unknown Status	Treatment	Acute Pain / Chronic Pain / Mastectomy / Wound Infusion	1
4	Unknown Status	Treatment	Back Pain Lower Back	2
4	Unknown Status	Treatment	Fracture of Neck of Femur (Hip)	1
4	Unknown Status	Treatment	Gynecology / Surgery, Laparoscopic	1
4	Unknown Status	Treatment	Hallux Valgus (Bunions)	1
4	Unknown Status	Treatment	Head And Neck Cancer / Nasopharyngeal Carcinoma (NPC) / Pain / Radiation Mucositis	1
4	Unknown Status	Treatment	Hysterectomy, Vaginal / Pain	1
4	Unknown Status	Treatment	Inflammatory Disorder of Immune System / Sepsis	1
4	Unknown Status	Treatment	Obesity, Morbid	1
4	Unknown Status	Treatment	Pain	1
4	Unknown Status	Treatment	Post-Cesarean Section / Postoperative pain	1
4	Unknown Status	Treatment	Postoperative pain	8
4	Unknown Status	Treatment	Primary Osteoarthritis Requiring Total Hip Replacement	1
4	Unknown Status	Treatment	Renal Colic	2
4	Unknown Status	Treatment	Rib Fracture Multiple / Rib Fractures	1
4	Unknown Status	Treatment	Sciatica	1
4	Unknown Status	Treatment	ST Segment Elevation Myocardial Infarction (STEMI)	1
4	Unknown Status	Treatment	Supratentorial Brain Tumors	1
4	Unknown Status	Treatment	Tendon Injuries	1
4	Unknown Status	Treatment	Total Hip Arthroplasty (THA)	1
4	Unknown Status	Treatment	Total Knee Replacement Surgery	1
4	Withdrawn	Basic Science	Opioid Use Disorder (OUD) / Suicidal Thoughts	1
4	Withdrawn	Basic Science	Sickle Cell Disease (SCD)	1
4	Withdrawn	Prevention	Autogenous Bone Grafts	1
4	Withdrawn	Supportive Care	Bone Fractures / Lower Limb Injuries	1
4	Withdrawn	Treatment	Acute Pain / Postoperative pain / Surgery, Colorectal	1
4	Withdrawn	Treatment	Arthroplasties, Replacement, Knee / Osteoarthritis (OA) / Postoperative pain	1
4	Withdrawn	Treatment	Arthroplasties, Replacement, Knee / Osteoarthritis of the Knee	1
4	Withdrawn	Treatment	Chronic Pain	1
4	Withdrawn	Treatment	Obesity / Postoperative pain / Respiratory Insufficiency	1
4	Withdrawn	Treatment	Pain	2
4	Withdrawn	Treatment	Renal Colic	1
4	Withdrawn	Treatment	Total Knee Arthroplasty (TKA)	1
4	Withdrawn	Treatment	Traumatic Vaginal Delivery	1
3	Active Not Recruiting	Treatment	Neonatal drug withdrawal syndrome	1
3	Active Not Recruiting	Treatment	Neonatal Opioid Withdrawal Syndrome	1
3	Active Not Recruiting	Treatment	Pain Management	1
3	Completed	Basic Science	Prostate Cancer	1
3	Completed	Other	Fracture Acetabular / Local Anaesthesia therapy / Neuropathic Pain / Postoperative pain	1
3	Completed	Prevention	Acute Myeloid Leukemia / Leukemia Stem Cell	1
3	Completed	Supportive Care	Cancer Pain	1
3	Completed	Supportive Care	Chronic Myeloproliferative Disorders / Leukemias / Lymphoma / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndrome / Pain / Precancerous/Nonmalignant Condition / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
3	Completed	Treatment	Abdominal Pain	1
3	Completed	Treatment	Abdominal Pain / Analgesia / Appendicitis / Children, Only / Emergency	1
3	Completed	Treatment	Abscesses / Pain	1
3	Completed	Treatment	Acute Myocardial Infarction (AMI)	1
3	Completed	Treatment	Acute Pain	3
3	Completed	Treatment	Acute Pain Due to Trauma / Trauma, Multiple	1
3	Completed	Treatment	Acute Pain / Ambulances	1
3	Completed	Treatment	Acute Pain / Bunionectomy / Pain / Postoperative pain	1
3	Completed	Treatment	Acute Traumatic Pain	1
3	Completed	Treatment	Analgesia / Postoperative pain	1
3	Completed	Treatment	Analgesics, Opioids / Pain	1
3	Completed	Treatment	Blunt Injury of Thorax	1
3	Completed	Treatment	Cancer	2
3	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD) / Dyspnea	1
3	Completed	Treatment	Chronic Pain / Opioids Use	1
3	Completed	Treatment	Chronic Pain / Osteoarthritis (OA)	1
3	Completed	Treatment	Chronic, Non Malignant Pain	1
3	Completed	Treatment	Hallucinations / Hyperalgesia / Nausea / Pain Intensity / Vomiting / Wound Care	1
3	Completed	Treatment	Herpes Zoster / Pain	1
3	Completed	Treatment	Hysterectomy / Postoperative	1
3	Completed	Treatment	Idiopathic Pulmonary Fibrosis (IPF)	1
3	Completed	Treatment	Kidney Stones	1
3	Completed	Treatment	Moderate to Severe Postoperative Pain	1
3	Completed	Treatment	Neonatal drug withdrawal syndrome	2
3	Completed	Treatment	Neonatal drug withdrawal syndrome / Neonatal Opioid Withdrawal Syndrome	1
3	Completed	Treatment	Neoplasm	1
3	Completed	Treatment	Newborn, Infant / Pain	1
3	Completed	Treatment	Obesity	1
3	Completed	Treatment	Opiate Dependent	1
3	Completed	Treatment	Opioid Dependence	1
3	Completed	Treatment	Opioid Free Anesthesia / Surgery, Cardiac	1
3	Completed	Treatment	Other Acute Postoperative Pain	1
3	Completed	Treatment	Pain	3
3	Completed	Treatment	Pain, Labor	1
3	Completed	Treatment	Pain / Scoliosis	1
3	Completed	Treatment	Pain / Sickle Cell Disease (SCD)	1
3	Completed	Treatment	Pain / Tumor	1
3	Completed	Treatment	Post Caesarean Analgesia	1
3	Completed	Treatment	Postoperative pain	15
3	Completed	Treatment	Postoperative pain / Radical Prostatectomy	1
3	Completed	Treatment	Posttraumatic Pain	1
3	Completed	Treatment	Pregnancy, Ceasarian Section, Anaesthesia	1
3	Completed	Treatment	Pregnant Women	1
3	Completed	Treatment	Procedural Pain	1
3	Completed	Treatment	Pruritus	1
3	Completed	Treatment	Renal Colic	1
3	Completed	Treatment	Scoliosis	1
3	Completed	Treatment	Sedation	1
3	Completed	Treatment	Total Hip Replacements	1
3	Not Yet Recruiting	Treatment	Cancer Pain	1
3	Not Yet Recruiting	Treatment	Postoperative pain	1
3	Not Yet Recruiting	Treatment	Sickle-Cell Disease With Crisis	1
3	Not Yet Recruiting	Treatment	Vaso-occlusive Crisis	1
3	Recruiting	Treatment	Abdominal Pain / Acute Abdomen / Acute Pain / Appendicitis / Children, Only / Emergency	1
3	Recruiting	Treatment	Acute Pain / Anesthesia therapy / Chronic Pain / Postoperative pain	1
3	Recruiting	Treatment	Anaesthesia / Back pain / Local Anaesthesia therapy / Nerve Block / Postoperative pain / Spine Fusion / Surgery	1
3	Recruiting	Treatment	Benign neoplasm of ureter / Calculus of Kidney and Ureter / Congenital ureteric anomaly / Other Specified Disorders of Kidney and Ureter / Renal Benign Neoplasm / Renal Cancer / Ureteral Cancer / Ureteric Reflux	1
3	Recruiting	Treatment	Bone Metastases / Lymphoma / Multiple Myeloma (MM) / Opioids Use / Pain	1
3	Recruiting	Treatment	Cancer Pain	1
3	Recruiting	Treatment	Complications; Cesarean Section	1
3	Recruiting	Treatment	Hematopoietic and Lymphoid System Neoplasm / Malignant Solid Neoplasms	1
3	Recruiting	Treatment	Non-STEMI Acute Coronary Syndrome / ST Segment Elevation Myocardial Infarction (STEMI)	1
3	Recruiting	Treatment	Perioperative Optimization	1
3	Recruiting	Treatment	Postoperative pain	1
3	Suspended	Supportive Care	Abortion in First Trimester	1
3	Terminated	Supportive Care	Obstructive Sleep Apnea (OSA)	1
3	Terminated	Treatment	Acute Pain	1
3	Terminated	Treatment	Advanced Malignant Neoplasm / Solid Tumors	1
3	Terminated	Treatment	Cancer Pain	1
3	Terminated	Treatment	Cancer Related Pain (Breakthrough Pain) / Cancer: Extreme Pain on Movement	1
3	Terminated	Treatment	Cancer / Neoplasm / Pain	1
3	Terminated	Treatment	Chronic Pain / Neoplasm / Pain	1
3	Terminated	Treatment	Chronic Wounds / Localized pain	1
3	Terminated	Treatment	Colorectal Cancer / Other Complications / Pain	1
3	Terminated	Treatment	Emergency / Injury / Pain	1
3	Terminated	Treatment	Fentanyl / Methadone / Morphine / Opiate Substitution Treatment / Opioid Related Disorders	1
3	Terminated	Treatment	Pain	1
3	Terminated	Treatment	Pain Management	1
3	Terminated	Treatment	Parecoxib / Rib Fractures	1
3	Terminated	Treatment	Sickle Cell Disease (SCD)	1
3	Unknown Status	Other	Acute Traumatic Pain	1
3	Unknown Status	Supportive Care	Intractable Pain	1
3	Unknown Status	Supportive Care	Sigmoidal Tumour	1
3	Unknown Status	Treatment	Abdominal Aortic Aneurysm (AAA) / Local Anaesthesia therapy / Pain	1
3	Unknown Status	Treatment	Acute Pain / Emergency / Morphine	1
3	Unknown Status	Treatment	Cancer	1
3	Unknown Status	Treatment	Cancer Pain	1
3	Unknown Status	Treatment	Cancer Related Pain (Breakthrough Pain)	1
3	Unknown Status	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
3	Unknown Status	Treatment	Idiopathic Pulmonary Fibrosis (IPF)	1
3	Unknown Status	Treatment	Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive	1
3	Unknown Status	Treatment	Osteoarthritis (OA) / Pain	1
3	Unknown Status	Treatment	Osteoarthritis (OA) / Pain Management / Total Knee Replacement Surgery	1
3	Unknown Status	Treatment	Pediatric Obstructive Sleep Apnea Syndrome	1
3	Unknown Status	Treatment	Wound	1
3	Withdrawn	Treatment	Adenocarcinomas / Cancer Pain	1
3	Withdrawn	Treatment	Cancer / Pain	1
3	Withdrawn	Treatment	Chronic Obstructive Pulmonary Disease (COPD) / Dyspnea	1
3	Withdrawn	Treatment	Intervertebral Disc, Degenerative / Lumbar Spine Disc Herniation / Spondylolisthesis	1
3	Withdrawn	Treatment	Opioid Related Disorders / Opioid Withdrawal (Disorder)	1
3	Withdrawn	Treatment	Opioids Use / Shoulder Pain	1
3	Withdrawn	Treatment	Orthopedic Disorder of Spine	1
3	Withdrawn	Treatment	Pain / Skin Transplantations	1
3	Withdrawn	Treatment	SBS / Short Bowel Syndrome (SBS) / Short Gut / Short Gut Syndrome	1
3	Withdrawn	Treatment	SBS / Short Bowel / Short Bowel Syndrome (SBS) / Short Gut / Short Gut Syndrome	1
2	Active Not Recruiting	Basic Science	Autonomic Failure / Diabetes Mellitus / Hypoglycemia	1
2	Active Not Recruiting	Treatment	Respiratory Depression	1
2	Completed	Other	Addiction / Pain / Polymorphism, Genetic	1
2	Completed	Other	Healthy Volunteers (HV)	1
2	Completed	Prevention	Coagulation Defect; Bleeding	1
2	Completed	Prevention	Postoperative pain	1
2	Completed	Prevention	Pruritus	1
2	Completed	Supportive Care	Cancer / Pain	1
2	Completed	Supportive Care	Erector Spinae Plane Block / Scoliosis Idiopathic / Scoliosis; Adolescence	1
2	Completed	Supportive Care	Metastatic Cancer / Pain / Unspecified Adult Solid Tumor, Protocol Specific	1
2	Completed	Supportive Care	Mucositis	1
2	Completed	Supportive Care	Pain	1
2	Completed	Supportive Care	Pain / Unspecified Adult Solid Tumor, Protocol Specific	1
2	Completed	Treatment	Acute Pain	2
2	Completed	Treatment	Acute Pain / Chronic Pain	1
2	Completed	Treatment	Acute Respiratory Failure	1
2	Completed	Treatment	Adenotonsillitis / Tonsillitis	1
2	Completed	Treatment	Amputations / Chronic Pain	1
2	Completed	Treatment	Analgesia / Nephrectomy	1
2	Completed	Treatment	Cancer Pain	1
2	Completed	Treatment	Cancer / Dyspnea, Paroxysmal	1
2	Completed	Treatment	Cesarean Sections / Pain	1
2	Completed	Treatment	Chronic Diarrhea	1
2	Completed	Treatment	Hallux Valgus (Bunions)	1
2	Completed	Treatment	Heroin Dependence / Opioid Related Disorders / Substance Related Disorders	1
2	Completed	Treatment	Hysterectomy	1
2	Completed	Treatment	Neonatal drug withdrawal syndrome / Neonatal Withdrawal Syndrome	1
2	Completed	Treatment	Neuropathic Pain / Spinal Cord Injuries	1
2	Completed	Treatment	Opioid Related Disorders	3
2	Completed	Treatment	Osteoarthritis of the Knee	1
2	Completed	Treatment	Pain	6
2	Completed	Treatment	Pain Management	1
2	Completed	Treatment	POCD - Postoperative Cognitive Dysfunction	1
2	Completed	Treatment	Posterior Fossa Tumors	1
2	Completed	Treatment	Postoperative pain	7
2	Completed	Treatment	Postoperative pain / Third Molars Extraction	1
2	Completed	Treatment	Pregnant Women	2
2	Completed	Treatment	Premature Neonates	1
2	Completed	Treatment	Progressive Infantile Idiopathic Scoliosis	1
2	Completed	Treatment	Radicular syndrome / Sciatica	1
2	Completed	Treatment	Renal Colic	1
2	Recruiting	Basic Science	Benzodiazepine Abuse / Opioid Abuse / Polysubstance Abuse	1
2	Recruiting	Basic Science	Opioid Craving / Opioid Use Disorder (OUD) / Opioid Withdrawal (Disorder)	1
2	Recruiting	Health Services Research	Postoperative pain	1
2	Recruiting	Prevention	Nausea, Postoperative / Postoperative pain / Pruritus / Vomiting, Postoperative	1
2	Recruiting	Supportive Care	Acute Pancreatitis	1
2	Recruiting	Supportive Care	Cancer Debulking / Disease, Adnexal / Enlarged Uterus / Fibroid Uterus	1
2	Recruiting	Supportive Care	Pericapsular Nerve Group Block	1
2	Recruiting	Treatment	Acute Pain	1
2	Recruiting	Treatment	Back Injuries / Back pain / Chronic Lower Back Pain (CLBP) / Chronic Pain / Narcotics Use / Opioid Dependence / Opioid Use Disorder (OUD) / Opioids Use	1
2	Recruiting	Treatment	Breast Cancer / Cancer Pain / Head And Neck Cancer / Wounds and Injuries	1
2	Recruiting	Treatment	Cancer / Cancer Related Pain (Breakthrough Pain)	1
2	Recruiting	Treatment	HIE - Hypoxic - Ischemic Encephalopathy / Pain	1
2	Terminated	Supportive Care	Referred Pain	1
2	Terminated	Treatment	Analgesia	1
2	Terminated	Treatment	Neonatal drug withdrawal syndrome	1
2	Terminated	Treatment	Neonatal Opioid Withdrawal Syndrome	1
2	Terminated	Treatment	Neoplasm / Pain	1
2	Terminated	Treatment	Pain	1
2	Terminated	Treatment	Postoperative pain	2
2	Unknown Status	Prevention	Rotator Cuff Tears	1
2	Unknown Status	Supportive Care	Anesthesia therapy / Block / Surgery / Thoracic Injury	1
2	Unknown Status	Supportive Care	Metastatic Cancer	1
2	Unknown Status	Treatment	Chronic Obstructive Pulmonary Disease (COPD) / Interstitial Lung Disease	1
2	Unknown Status	Treatment	Neuropathic Pain	1
2	Unknown Status	Treatment	Pain	1
2	Unknown Status	Treatment	Pulmonary Arterial Hypertension (PAH)	1
2	Unknown Status	Treatment	ST Segment Elevation Myocardial Infarction (STEMI)	1
2	Withdrawn	Treatment	Acute Pain	2
2	Withdrawn	Treatment	Chronic Pain	2
2	Withdrawn	Treatment	Hb-SS Disease With Vasoocclusive Pain / Hemoglobin SS Disease With Crisis / Hemoglobin SS Disease With Vasoocclusive Crisis / Other Sickle Cell Disease With Vaso-Occlusive Pain / Sickle Cell Disease (SCD)	1
2	Withdrawn	Treatment	Pain	1
2, 3	Active Not Recruiting	Treatment	Arthritis of the Knee Joint	1
2, 3	Active Not Recruiting	Treatment	Pain / Respiratory Depression	1
2, 3	Completed	Other	Pain	1
2, 3	Completed	Prevention	Postoperative pain	1
2, 3	Completed	Prevention	Pruritus	1
2, 3	Completed	Supportive Care	Chronic Obstructive Pulmonary Disease (COPD)	1
2, 3	Completed	Treatment	Acute Pain	1
2, 3	Completed	Treatment	Agitation / Dementia / Pain	1
2, 3	Completed	Treatment	Anesthesia therapy	1
2, 3	Completed	Treatment	Closed Multiple Fractures of Upper and Lower Limbs	1
2, 3	Completed	Treatment	Diabetes / Hypertension / Obesity / Sleep Apnea	1
2, 3	Completed	Treatment	Obesity, Morbid / Postoperative Ambulation / Postoperative Bowel Functions / Postoperative pain	1
2, 3	Completed	Treatment	Pain	2
2, 3	Completed	Treatment	Patient Controlled Analgesia / Stenosis, Spinal	1
2, 3	Completed	Treatment	Postoperative pain	4
2, 3	Completed	Treatment	Sedation	1
2, 3	Completed	Treatment	Sickle Cell Anemia in Children / Sickle Cell Disease (SCD) / Vaso-occlusive Crisis	1
2, 3	Completed	Treatment	Stomatitis	1
2, 3	Not Yet Recruiting	Treatment	Cesarean Sections / Chronic Postoperative Pain / Postoperative pain	1
2, 3	Recruiting	Treatment	Chronic Pain	1
2, 3	Recruiting	Treatment	Pain	1
2, 3	Terminated	Treatment	Critically Ill Patients	1
2, 3	Terminated	Treatment	Postoperative pain	1
2, 3	Unknown Status	Diagnostic	Breast Cancer	1
2, 3	Unknown Status	Treatment	Flail Chest	1
2, 3	Unknown Status	Treatment	Postoperative pain	1
1	Active Not Recruiting	Treatment	Back Pain Lower Back	1
1	Completed	Not Available	Gastric Emptying / Healthy Volunteers (HV)	1
1	Completed	Not Available	Healthy Volunteers (HV)	3
1	Completed	Not Available	Pain	1
1	Completed	Not Available	Postoperative pain	1
1	Completed	Basic Science	Analgesia / Chronic Pain / Narcotic Abuse / Opioid Related Disorders	1
1	Completed	Basic Science	Drug Induced Constipation	1
1	Completed	Basic Science	Effect of Drugs	1
1	Completed	Basic Science	Healthy Volunteers (HV)	6
1	Completed	Basic Science	Nondependent Opioid Abuse, Episodic	1
1	Completed	Diagnostic	Fatty Liver	1
1	Completed	Other	Morphine / Organic Cation Transporter 1	1
1	Completed	Treatment	Acute Pain	1
1	Completed	Treatment	Cancer / Pain	1
1	Completed	Treatment	Healthy Volunteers (HV)	1
1	Completed	Treatment	Neonatal drug withdrawal syndrome	2
1	Completed	Treatment	Nephrectomy	1
1	Completed	Treatment	Opioid Substitution Treatment	1
1	Completed	Treatment	Opioid Use Disorder (OUD)	2
1	Completed	Treatment	Renal Colic	1
1	Completed	Treatment	Restless Legs Syndrome (RLS)	1
1	Not Yet Recruiting	Treatment	Cardiac Arrest	1
1	Recruiting	Basic Science	CBD / Chronic Pain	1
1	Recruiting	Diagnostic	Opioid Use Disorder (OUD)	1
1	Recruiting	Other	Cannabidiol / Drug Drug Interaction (DDI) / Drug Induced Liver Injury	1
1	Terminated	Supportive Care	Cancer	1
1	Unknown Status	Not Available	Healthy Volunteers (HV)	1
1	Unknown Status	Treatment	Obstructive Sleep Apnea of Adult	1
1	Unknown Status	Treatment	Pain	1
1	Withdrawn	Treatment	Opioid Use Disorder, Moderate	1
1, 2	Active Not Recruiting	Treatment	Immune System Suppression	1
1, 2	Completed	Basic Science	Healthy Volunteers (HV)	2
1, 2	Completed	Basic Science	Heroin Dependence / Opioid Use Disorder (OUD)	1
1, 2	Completed	Supportive Care	Intubation; Complication	1
1, 2	Completed	Supportive Care	Pain, Breakthrough	1
1, 2	Completed	Treatment	Acute Pain	2
1, 2	Completed	Treatment	Colon Cancer / Diverticulitis / Inflammatory Bowel Diseases (IBD)	1
1, 2	Completed	Treatment	Opioid Abuse / Opioid Dependence	1
1, 2	Completed	Treatment	Pain	1
1, 2	Completed	Treatment	Postoperative pain	1
1, 2	Completed	Treatment	Renal Colic	1
1, 2	Recruiting	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
1, 2	Recruiting	Treatment	Postoperative Pain, Acute	1
1, 2	Unknown Status	Not Available	Closed Head Injury / Craniocerebral Injuries / Subarachnoid Hemorrhage	1
1, 2	Unknown Status	Treatment	Acute Pain / Chronic Pain	1
1, 2	Unknown Status	Treatment	Rheumatic Diseases	1
1, 2	Withdrawn	Basic Science	Effect of Drugs / Pain	1
0	Active Not Recruiting	Treatment	Anesthesia therapy	1
0	Active Not Recruiting	Treatment	Tibial Plateau Fractures	1
0	Completed	Diagnostic	Erector Spinae Plane Block	1
0	Completed	Supportive Care	Cervical Cancer / Ovarian Cancer / Uterine Endometrial Cancer	1
0	Completed	Supportive Care	Hematopoietic and Lymphoid System Neoplasm / Malignant Solid Neoplasms / Metastatic Malignant Solid Neoplasms	1
0	Completed	Treatment	Acute Pain	1
0	Completed	Treatment	Anesthesia therapy	1
0	Completed	Treatment	Cesarean Sections	1
0	Completed	Treatment	Pain	1
0	Completed	Treatment	Postoperative pain	1
0	Completed	Treatment	Renal Colic	1
0	Enrolling by Invitation	Treatment	Fracture, Ankle	1
0	Not Yet Recruiting	Health Services Research	Postoperative pain	1
0	Recruiting	Treatment	Fentanyl / Platelet Reactivity	1
0	Unknown Status	Diagnostic	Vasoplegia	1
0	Unknown Status	Supportive Care	Perineal Tears	1
0	Unknown Status	Treatment	Rib Fracture Multiple	1
Not Available	Active Not Recruiting	Prevention	Acute Pain / Analgesia / Chronic Pain / Morphine / Neuropathic Pain / Postoperative pain / S-ketamine	1
Not Available	Active Not Recruiting	Prevention	Analgesia / Dexmedetomidine / Elderly / Long Term Outcomes / Surgery	1
Not Available	Active Not Recruiting	Treatment	Postoperative pain	1
Not Available	Completed	Not Available	Abdominal Injuries / Analgesia / Local Anaesthetic / Postoperative pain	1
Not Available	Completed	Not Available	Abdominal Pain	1
Not Available	Completed	Not Available	Abdominal Surgeries / Hepatic dysfunction / Kidney Failure / Multi-organ Failure / Respiratory Failure	1
Not Available	Completed	Not Available	Adverse Drug Reaction (ADR) / Opioids Use / Postoperative pain	1
Not Available	Completed	Not Available	Analgesia / Anesthesia therapy / Rehabilitation	1
Not Available	Completed	Not Available	Anesthesia and Analgesia / Cardiac Output / Pneumonectomy; Status / Surgical Procedures, Robotic	1
Not Available	Completed	Not Available	Anesthesia Morbidity / Obesity, Morbid / Opioids Use / Pharmacological Action (PA) / Postoperative pain	1
Not Available	Completed	Not Available	Anesthesia therapy	1
Not Available	Completed	Not Available	Anesthesia therapy / Surgery	1
Not Available	Completed	Not Available	Baseline Epidemiologic Assessment	1
Not Available	Completed	Not Available	Breast Cancer	1
Not Available	Completed	Not Available	Cancer Pain / Cancer Related Pain (Breakthrough Pain) / Neuropathic Pain / Tumor	1
Not Available	Completed	Not Available	Early Labor / Pain, Labor	1
Not Available	Completed	Not Available	End-stage Liver Disease (ESLD) / Lung Cancer	1
Not Available	Completed	Not Available	Healthy Volunteers (HV)	1
Not Available	Completed	Not Available	Newborn, Infant, Disease / Pain	1
Not Available	Completed	Not Available	Orthopaedic Surgery	1
Not Available	Completed	Not Available	Pain	1
Not Available	Completed	Not Available	Spondylolisthesis, Degenerative	1
Not Available	Completed	Not Available	Trauma, Nervous System	1
Not Available	Completed	Basic Science	Cowhage / Histamine / Isotonic Saline / Morphine	1
Not Available	Completed	Basic Science	Morphine / Pruritus	1
Not Available	Completed	Basic Science	Pain	1
Not Available	Completed	Basic Science	Pain / Sleep Deprivation	1
Not Available	Completed	Basic Science	Pruritus	1
Not Available	Completed	Diagnostic	Dyspnea	1
Not Available	Completed	Health Services Research	Nerve Block	1
Not Available	Completed	Health Services Research	Postoperative Complications	1
Not Available	Completed	Other	Anesthesia therapy / Colorectal Cancer / Inflammation / Metastatic Cancer	1
Not Available	Completed	Other	Chronic Diarrhea	1
Not Available	Completed	Other	Pain, Obstetric	1
Not Available	Completed	Other	Postoperative pain	2
Not Available	Completed	Prevention	Analgesia	1
Not Available	Completed	Prevention	Analgesia / Caesarean Sections / Quadratus Lumborum Block / Spinal Anesthesia therapy	1
Not Available	Completed	Prevention	Analgesia / Delirium / Dexmedetomidine / Elderly / Postoperative Complications / Surgery	1
Not Available	Completed	Prevention	Analgesia / Spinal Anesthesia therapy / Transurethral Resection of Prostate	1
Not Available	Completed	Prevention	Anesthesia Emergence Delirium	1
Not Available	Completed	Prevention	Erector Spinae Plane Block	1
Not Available	Completed	Prevention	Erector Spinae Plane Block / Radical Cystectomy	1
Not Available	Completed	Prevention	Inflammatory Responses	1
Not Available	Completed	Prevention	Intrathecal Morphine / Intrathecal Morphine-dexmedetomidine Combination / Post-operative Pain Management / Total Knee Replacement Surgery	1
Not Available	Completed	Prevention	Pain, Labor	1
Not Available	Completed	Prevention	Pediatric Cancer / Postoperative pain	1
Not Available	Completed	Prevention	Post Operative Nausea and Vomiting (PONV)	2
Not Available	Completed	Prevention	Postoperative pain	1
Not Available	Completed	Screening	Perfusions	1
Not Available	Completed	Supportive Care	Adult Patients / Analgesic Adverse Reaction / Epidural; Analgesia / Femoral Nerve Block / Total Knee Arthroplasty (TKA)	1
Not Available	Completed	Supportive Care	Analgesia / Anesthesia therapy / Postoperative pain	1
Not Available	Completed	Supportive Care	Analgesia / Femur Fractures	1
Not Available	Completed	Supportive Care	Analgesia / Hepatectomy / Nerve Block	1
Not Available	Completed	Supportive Care	Analgesia / Hepatectomy / Paravertebral Block / Postoperative Recovery	1
Not Available	Completed	Supportive Care	Anesthesia therapy / Total Knee Arthroplasty (TKA)	1
Not Available	Completed	Supportive Care	Arthropathy of Hip / Arthropathy of Knee	1
Not Available	Completed	Supportive Care	Cesarean Sections / Intrathecal Morphine / Quality of Recovery 40	1
Not Available	Completed	Supportive Care	Cesarean Sections / Postoperative Analgesia / Spinal Anesthesia therapy	1
Not Available	Completed	Supportive Care	Efficacy of Caudal Block on Intra-operative Anal Sphincter Muscle Tone	1
Not Available	Completed	Supportive Care	Hepatectomy / Pain Management / Paravertebral Block	1
Not Available	Completed	Supportive Care	Laparoscopic Renal Surgery / Nerve Block / Pain Management	2
Not Available	Completed	Supportive Care	Lower Extremity Fractures	1
Not Available	Completed	Supportive Care	Osteoarthritis (OA) / Post-traumatic; Arthrosis	1
Not Available	Completed	Supportive Care	Pain	1
Not Available	Completed	Supportive Care	Postoperative pain	4
Not Available	Completed	Supportive Care	Postoperative Pain Treatment for Total Knee Arthroplasty	1
Not Available	Completed	Supportive Care	Postoperative pain / Undescended Testis	1
Not Available	Completed	Supportive Care	Respiratory Failure	1
Not Available	Completed	Supportive Care	Spine Diseases / Spondylolisthesis / Vertebral Subluxation	1
Not Available	Completed	Treatment	Abdominal Cancer	1
Not Available	Completed	Treatment	Abdominal Surgeries / Thoracic Surgery	1
Not Available	Completed	Treatment	Acute Myocardial Infarction (AMI)	1
Not Available	Completed	Treatment	Acute Pain	2
Not Available	Completed	Treatment	Acute Pain / Chronic Pain	1
Not Available	Completed	Treatment	Acute Pain / Post-Traumatic Headaches	1
Not Available	Completed	Treatment	Acute Renal Colic	1
Not Available	Completed	Treatment	Adverse Drug Reaction (ADR) / Bladder Cancer / Neurologic Manifestations / Neurologic Symptoms / Pain / Pathologic Processes / Postoperative Complications / Postoperative pain / Signs and Symptoms	1
Not Available	Completed	Treatment	Adverse Events / Pain Relief	1
Not Available	Completed	Treatment	Analgesia	5
Not Available	Completed	Treatment	Analgesia Post Craniotomy	1
Not Available	Completed	Treatment	Analgesia Post Fracture / Upper Extremity Fractures	1
Not Available	Completed	Treatment	Analgesia / Anesthesia therapy / Postoperative pain	1
Not Available	Completed	Treatment	Analgesia / Congenital Heart Disease (CHD) / Surgery	1
Not Available	Completed	Treatment	Analgesia / Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed Labor	1
Not Available	Completed	Treatment	Anesthesia Morbidity / Anesthesia therapy / Breast Neoplasm Female / Regional Anesthesia Morbidity / Regional Anesthesia therapy	1
Not Available	Completed	Treatment	Anesthesia therapy / Postoperative pain	1
Not Available	Completed	Treatment	Anesthesia therapy / Postoperative pain / Regional Anesthesia therapy	1
Not Available	Completed	Treatment	Anesthesia therapy / Postoperative pain / Thoracotomy	1
Not Available	Completed	Treatment	Anterior Cruciate Ligament Reconstruction	1
Not Available	Completed	Treatment	Arthritis of the Knee Joint	1
Not Available	Completed	Treatment	Arthroplasties, Replacement, Knee / Postoperative pain	1
Not Available	Completed	Treatment	Cancer / Mucositis	1
Not Available	Completed	Treatment	Catecholamines / Fetal Bradycardia / Hypertonic Uterine	1
Not Available	Completed	Treatment	Catheter Related Complications	1
Not Available	Completed	Treatment	Cesarean Delivery	1
Not Available	Completed	Treatment	Cesarean Sections	1
Not Available	Completed	Treatment	Chronic Pain	2
Not Available	Completed	Treatment	Chronic Post Cesarean Pain	1
Not Available	Completed	Treatment	Colectomy	1
Not Available	Completed	Treatment	Colon Cancer / Diverticulitis / Inflammatory Bowel Diseases (IBD)	1
Not Available	Completed	Treatment	Critically Ill Patients	1
Not Available	Completed	Treatment	Epidural Analgesia, Obstetric	1
Not Available	Completed	Treatment	Epidural; Analgesia / Labour	1
Not Available	Completed	Treatment	Flail Chest / Rib Fractures / Surgery / Trauma	1
Not Available	Completed	Treatment	Hemodynamics After Spinal Anesthesia	1
Not Available	Completed	Treatment	Hip Arthroplasty	1
Not Available	Completed	Treatment	Hispanics / Multimodal Analgesia / Opioids Use / Pain / Total Knee Arthroplasty (TKA)	1
Not Available	Completed	Treatment	Inguinal Hernias	1
Not Available	Completed	Treatment	Kidney Stones	1
Not Available	Completed	Treatment	Leak, Cerebrospinal Fluid / Postdural Puncture Headache	1
Not Available	Completed	Treatment	Living Donor Hepatectomy	1
Not Available	Completed	Treatment	Local Anaesthesia therapy	1
Not Available	Completed	Treatment	Lumbar Spine Surgeries	1
Not Available	Completed	Treatment	Musculoskeletal Injuries	1
Not Available	Completed	Treatment	Neoplasms of the Prostate	1
Not Available	Completed	Treatment	Obesity / Pain	1
Not Available	Completed	Treatment	Obstetric Surgical Procedures / Obstetrical analgesia therapy	1
Not Available	Completed	Treatment	Opioid Withdrawal (Disorder) / Physical Dependence	1
Not Available	Completed	Treatment	Osteoarthritis in the Hip Joint / Osteoarthritis of the Knee / Osteoarthritis of the Shoulder	1
Not Available	Completed	Treatment	Other Chronic Postoperative Pain	1
Not Available	Completed	Treatment	Pain	7
Not Available	Completed	Treatment	Pain Management	1
Not Available	Completed	Treatment	Pain / Post Operative Nausea and Vomiting (PONV)	1
Not Available	Completed	Treatment	Pancreatic Neoplasms	1
Not Available	Completed	Treatment	Patients Receiving Hepatectomy Under General Anesthesia	1
Not Available	Completed	Treatment	Perioperative Pain	1
Not Available	Completed	Treatment	Post Cesarean Pain Management	1
Not Available	Completed	Treatment	Post Laparotomy Pain Treatment	1
Not Available	Completed	Treatment	Post-Op Complications	1
Not Available	Completed	Treatment	Post-operative Pain Management	3
Not Available	Completed	Treatment	Postoperative Analgesia	1
Not Available	Completed	Treatment	Postoperative pain	7
Not Available	Completed	Treatment	Postoperative pain / Ultrasounds	1
Not Available	Completed	Treatment	Primary Osteoarthritis of Knee Nos	1
Not Available	Completed	Treatment	Reconstruction Breast Surgery	1
Not Available	Completed	Treatment	Renal Cell Carcinoma (RCC)	1
Not Available	Completed	Treatment	Sedation, Bronchoscopy	1
Not Available	Completed	Treatment	Sickle Cell Disease (SCD)	1
Not Available	Completed	Treatment	Spinal Bupivacaine/Morphine in Laparoscopic Surgery	1
Not Available	Completed	Treatment	Total Knee Arthroplasty (TKA)	1
Not Available	Completed	Treatment	Ultrasound Therapy; Complications	1
Not Available	Enrolling by Invitation	Not Available	Cesarean Sections / Obstetrical Anesthesia	1
Not Available	Not Yet Recruiting	Prevention	Acute Pain / Analgesia / Chronic Pain / Dexmedetomidine / Morphine / Postoperative pain	1
Not Available	Not Yet Recruiting	Prevention	Discectomy / Vertebral Fractures	1
Not Available	Not Yet Recruiting	Prevention	Inguinal Hernias	1
Not Available	Not Yet Recruiting	Prevention	Postoperative Analgesia	1
Not Available	Not Yet Recruiting	Supportive Care	Cardiac Valve Disease	1
Not Available	Not Yet Recruiting	Treatment	Analgesia	1
Not Available	Not Yet Recruiting	Treatment	Local Anaesthesia therapy / Local Infiltration / Shoulder Arthritis	1
Not Available	Not Yet Recruiting	Treatment	Pain and Cognitive Dysfunction Management in Hip Surgery	1
Not Available	Not Yet Recruiting	Treatment	Pancreatitis, Chronic	1
Not Available	Not Yet Recruiting	Treatment	Rib Fracture Multiple	1
Not Available	Recruiting	Not Available	Anesthesia therapy / Pain	1
Not Available	Recruiting	Not Available	Chronic Pain / Trauma / Trauma, Psychological	1
Not Available	Recruiting	Not Available	Effect of Drugs	1
Not Available	Recruiting	Not Available	Opioid Use, Unspecified	1
Not Available	Recruiting	Not Available	Orthostatic Hypotension / Orthostatic Intolerance	1
Not Available	Recruiting	Other	Post-Operative Confusion	1
Not Available	Recruiting	Prevention	Intrathecal Morphine / Mid-Transverse Process Block / Posterior Spinal Fusion / Scoliosis Idiopathic	1
Not Available	Recruiting	Prevention	Nausea, Postoperative / Postoperative pain / Pruritus / Vomiting, Postoperative	1
Not Available	Recruiting	Supportive Care	Advanced Malignant Neoplasm	1
Not Available	Recruiting	Treatment	Analgesia	1
Not Available	Recruiting	Treatment	Analgesia / Anesthesia therapy / Postoperative pain	1
Not Available	Recruiting	Treatment	Analgesia / Cardiac Diseases / Postoperative pain / Surgery	1
Not Available	Recruiting	Treatment	Analgesia / Postoperative Pain, Acute / Valvular Heart Diseases	1
Not Available	Recruiting	Treatment	Anesthesia therapy / Emergence Delirium / Opioid Analgesic Adverse Reaction / Pain / Post Operative Nausea and Vomiting (PONV) / Tonsillitis	1
Not Available	Recruiting	Treatment	Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction	1
Not Available	Recruiting	Treatment	Children / Dexmedetomidine / Morphine / PCA	1
Not Available	Recruiting	Treatment	Chronic Pain / Postoperative pain / Surgery, Cardiac	1
Not Available	Recruiting	Treatment	Hepatectomy / Neoplasms, Hepatic / Postoperative pain	1
Not Available	Recruiting	Treatment	Hip Fracture	2
Not Available	Recruiting	Treatment	Inguinal Surgery	1
Not Available	Recruiting	Treatment	Post-operative Pain Management	2
Not Available	Recruiting	Treatment	Postoperative pain	1
Not Available	Suspended	Not Available	Ischemia Reperfusion Injury	1
Not Available	Suspended	Treatment	Obstructive Sleep Apnea (OSA)	1
Not Available	Terminated	Not Available	Complications; Cesarean Section / Effects of; Anesthesia, Spinal and Epidural; in Pregnancy / Hemodynamics Instability / Satisfaction, Personal	1
Not Available	Terminated	Not Available	Pediatric Extremity Fracture / Pediatric Extremity Soft Tissue Injury	1
Not Available	Terminated	Other	Pain Management in Pregnant Women	1
Not Available	Terminated	Prevention	Inflammation	1
Not Available	Terminated	Supportive Care	Analgesia / Hepatectomy / Nerve Block	1
Not Available	Terminated	Supportive Care	Brain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoma / Lymphoproliferative Disorders / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndrome / Myeloproliferative/Myelodysplastic Neoplasm / Pain / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific	1
Not Available	Terminated	Supportive Care	Pain / Pancreatic Cancer	1
Not Available	Terminated	Supportive Care	Pain / Respiratory Depression	1
Not Available	Terminated	Treatment	Acute Pain	2
Not Available	Terminated	Treatment	Acute Pain / Bone Fractures	1
Not Available	Terminated	Treatment	Breast Cancer / Postoperative pain	1
Not Available	Terminated	Treatment	Hip Fracture Surgery / Post-operative Pain Management	1
Not Available	Terminated	Treatment	Pain	2
Not Available	Terminated	Treatment	Pain, Labor	1
Not Available	Terminated	Treatment	Postoperative pain	2
Not Available	Terminated	Treatment	Postoperative pain / Shoulder Pain	1
Not Available	Terminated	Treatment	Spastic Cerebral Palsy (sCP)	1
Not Available	Unknown Status	Not Available	Analgesic Response	1
Not Available	Unknown Status	Prevention	Erector Spinae Plane Block	1
Not Available	Unknown Status	Prevention	Intrathecal Morphine / Postoperative pain / Total Hip Replacements / Ultrasound Guided Supra-inguinal Fascia Iliaca Block	1
Not Available	Unknown Status	Prevention	Obesity, Abdominal	1
Not Available	Unknown Status	Prevention	Postoperative pain	1
Not Available	Unknown Status	Prevention	Postoperative pain / Preoperative sedation therapy	1
Not Available	Unknown Status	Prevention	Total Knee Replacement Surgery	1
Not Available	Unknown Status	Supportive Care	Inguinal Hernias / Postoperative pain	1
Not Available	Unknown Status	Supportive Care	Postoperative pain	1
Not Available	Unknown Status	Supportive Care	Respiratory Depression	1
Not Available	Unknown Status	Treatment	Abdominal Muscles/Ultrasonography / Adults / Anesthetics, Local/Administration & Dosage / Cesarean Sections / Humans / Nerve Block/Methods / Pain Measurement/Methods / Pain, Postoperative/Prevention & Control / Ropivacaine/Administration & Dosage / Ropivacaine/Analogs & Derivatives / Ultrasonography, Interventional	1
Not Available	Unknown Status	Treatment	Acute Pain	1
Not Available	Unknown Status	Treatment	Analgesia	1
Not Available	Unknown Status	Treatment	Analgesia / Pain / Sedation	1
Not Available	Unknown Status	Treatment	Cancer	1
Not Available	Unknown Status	Treatment	Hepatic dysfunction / Pain	1
Not Available	Unknown Status	Treatment	Interscalene Blocks / Regional Anesthesia therapy / Shouldersurgery	1
Not Available	Unknown Status	Treatment	Major Abdominal Surgeries	1
Not Available	Unknown Status	Treatment	Nerve Block / Video-assisted Thoracoscopic Surgery (VATS)	1
Not Available	Unknown Status	Treatment	Osteoarthritis (OA)	1
Not Available	Unknown Status	Treatment	Pain	1
Not Available	Unknown Status	Treatment	Post - Tonsillectomy Pain	1
Not Available	Unknown Status	Treatment	Postoperative pain	2
Not Available	Unknown Status	Treatment	Postoperative; Parotitis	1
Not Available	Unknown Status	Treatment	Sickle Cell Crisis	1
Not Available	Unknown Status	Treatment	Spinal Anesthetics Causing Adverse Effects in Therapeutic Use	1
Not Available	Withdrawn	Not Available	Analgesia / Anesthetics Agent / Pain Management	1
Not Available	Withdrawn	Not Available	Anesthesia therapy / Surgery	1
Not Available	Withdrawn	Supportive Care	Back Pain Lower Back	1
Not Available	Withdrawn	Supportive Care	Postoperative pain	1
Not Available	Withdrawn	Treatment	Abdominal Pain	1
Not Available	Withdrawn	Treatment	Analgesia	1
Not Available	Withdrawn	Treatment	Anesthesia therapy / Cesarean Sections / Postoperative pain / Quality of Recovery	1
Not Available	Withdrawn	Treatment	Anxiety / Burns / Children / Pain	1
Not Available	Withdrawn	Treatment	Caesarean Delivery	1
Not Available	Withdrawn	Treatment	Pain / Rib Fractures / Surgery / Trauma	1
Not Available	Withdrawn	Treatment	Postoperative pain	1
Not Available	Withdrawn	Treatment	Ulcers / Wounds and Injuries	1

Pharmacoeconomics

Manufacturers

King pharmaceuticals inc
Actavis elizabeth llc
Ekr therapeutics inc
App pharmaceuticals llc
Baxter healthcare corp anesthesia and critical care
Hospira inc
Mallinckrodt chemical inc
Meridian medical technologies inc
Watson laboratories inc
Roxane laboratories inc
Clonmel healthcare ltd
Endo pharmaceuticals inc
Kv pharmaceutical co
Mallinckrodt inc
Purdue pharma lp
Xanodyne pharmaceutics inc
Actavis

Packagers

Actavis Group
Alpharma Pharmaceuticals LLC
Amphastar Pharmaceuticals
Apotex Inc.
APP Pharmaceuticals
AstraZeneca Inc.
Barr Pharmaceuticals
Baxter International Inc.
Blenheim Pharmacal
Bristol-Myers Squibb Co.
Bryant Ranch Prepack
Cardinal Health
Cerovene Inc.
Cody Laboratories Inc.
D.M. Graham Laboratories Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Edenbridge Pharmaceuticals LLC
EKR Therapeutics Inc.
Elan Pharmaceuticals Inc.
Endo Pharmaceuticals Inc.
Ethex Corp.
G & W Labs
Glenmark Generics Ltd.
Hi Tech Pharmacal Co. Inc.
Hospira Inc.
Ide Interstate
King Pharmaceuticals Inc.
KV Pharmaceutical Co.
Lake Erie Medical and Surgical Supply
Lannett Co. Inc.
Lehigh Valley Technologies Inc.
Ligand Pharmaceuticals Inc.
Mallinckrodt Inc.
Marathon Pharmaceuticals
Mckesson Corp.
Meridian Medical Technologies Inc.
Novartis AG
Nucare Pharmaceuticals Inc.
P F Laboratories Inc.
Pacira Pharmaceuticals Inc.
Paddock Labs
Pharmakon
Pharmedium
Physicians Total Care Inc.
Purdue Pharma LP
Quality Care
Ranbaxy Laboratories
Roxane Labs
Stat Rx Usa
Tercica Inc.
Upsher Smith Laboratories
Watson Pharmaceuticals
Wockhardt Ltd.
Xanodyne Pharmaceuticals Inc.

Dosage Forms

Form	Route	Strength
Tablet	Oral	10.000 mg
Injection	Epidural; Intrathecal; Intravenous	0.5 mg/1mL
Injection	Epidural; Intrathecal; Intravenous	1 mg/1mL
Capsule, coated, extended release	Oral	60 mg/1
Capsule, extended release	Oral	120 mg/1
Capsule, extended release	Oral	30 mg/1
Capsule, extended release	Oral	45 mg/1
Capsule, extended release	Oral	60 mg/1
Capsule, extended release	Oral	75 mg/1
Capsule, extended release	Oral	90 mg/1
Solution	Parenteral	2.500 mg
Tablet, film coated	Oral	200 mg
Tablet, film coated	Oral	300 mg
Injection	Intramuscular; Subcutaneous	10 mg/ml
Injection	Intramuscular; Subcutaneous	15 mg/ml
Injection, lipid complex	Epidural	10 mg/1mL
Injection, lipid complex	Epidural	15 mg/1.5mL
Injection, lipid complex	Epidural	20 mg/2mL
Syrup	Oral	5 mg / mL
Capsule, extended release	Oral
Solution	Oral	0.600 g
Solution	Intravenous	250.000 mg
Tablet	Oral	30.00 mg
Injection, solution	Epidural; Intrathecal	10 mg/1mL
Injection, solution	Epidural; Intrathecal	25 mg/1mL
Capsule, extended release	Oral	10 mg/1
Capsule, extended release	Oral	100 mg/1
Capsule, extended release	Oral	130 mg/1
Capsule, extended release	Oral	150 mg/1
Capsule, extended release	Oral	20 mg/1
Capsule, extended release	Oral	200 mg/1
Capsule, extended release	Oral	40 mg/1
Capsule, extended release	Oral	50 mg
Capsule, extended release	Oral	50 mg/1
Capsule, extended release	Oral	70 mg/1
Capsule, extended release	Oral	80 mg/1
Capsule, extended release	Oral
Capsule	Oral	10 mg
Capsule	Oral	20 mg
Capsule	Oral	30 mg
Capsule	Oral	5 mg
Capsule, extended release	Oral	10 mg
Capsule, extended release	Oral	100 mg
Capsule, extended release	Oral	15 mg
Capsule, extended release	Oral	200 mg
Capsule, extended release	Oral	30 mg
Capsule, extended release	Oral	60 mg
Capsule, coated pellets		10 mg
Capsule, coated pellets		100 mg
Capsule, coated pellets		30 mg
Capsule, coated pellets		60 mg
Suppository	Rectal	10 mg
Tablet	Oral	20 mg
Tablet	Oral	40 mg
Syrup	Oral	50 mg / mL
Tablet	Oral	60 mg
Injection	Epidural; Intrathecal	200 mg/20mL
Injection	Epidural; Intrathecal	500 mg/20mL
Tablet, film coated	Oral	20 mg
Tablet	Oral	15 mg
Tablet	Oral	30 mg
Tablet, film coated	Oral	15 mg
Solution	Intramuscular; Intravenous; Subcutaneous	0.01 g/ml
Solution	Intramuscular; Intravenous; Subcutaneous	0.02 g/ml
Injection
Solution	Oral	30 mg
Solution	Oral	3000000 mg
Injection, solution	Epidural; Intramuscular; Intravenous; Subcutaneous	10 MG/ML
Injection, solution	Epidural; Intramuscular; Intravenous; Subcutaneous	100 MG/5ML
Injection, solution	Epidural; Intramuscular; Intravenous; Subcutaneous	100 MG/10ML
Injection, solution	Epidural; Intramuscular; Intravenous; Subcutaneous	20 MG/ML
Injection, solution	Epidural; Intramuscular; Intravenous; Subcutaneous	200 MG/10ML
Injection, solution	Epidural; Intramuscular; Intravenous; Subcutaneous	50 MG/5ML
Injection, solution	Parenteral	10 MG/ML
Injection, solution	Parenteral	100 MG/5ML
Injection, solution	Parenteral	100 MG/10ML
Injection, solution	Parenteral	200 MG/10ML
Injection, solution	Parenteral	50 MG/5ML
Solution	Epidural	0.01 G
Solution	Epidural	0.02 G
Injection, solution	Parenteral	20 MG/ML
Injection, solution	Intramuscular; Intravenous; Subcutaneous
Tablet, extended release	Oral	20 MG
Tablet, extended release	Oral	45 MG
Solution	Intramuscular; Intravenous; Subcutaneous	25 mg / mL
Solution	Intramuscular; Intravenous; Subcutaneous	0.01 gr
Solution	Intramuscular; Intravenous; Subcutaneous	0.02 gr
Solution	Intramuscular; Intravenous; Subcutaneous	50 mg / mL
Tablet	Oral
Solution	Epidural; Intravenous; Subcutaneous	0.5 mg / mL
Solution	Epidural; Intravenous; Subcutaneous	1 mg / mL
Injection	Intramuscular	10 mg/0.7mL
Injection	Intramuscular; Intravenous; Subcutaneous	10 mg/1mL
Injection	Intramuscular; Intravenous; Subcutaneous	15 mg/1mL
Injection	Intramuscular; Intravenous; Subcutaneous	5 mg/1mL
Injection	Intramuscular; Intravenous; Subcutaneous	8 mg/1mL
Injection	Intravenous	1 mg/30mL
Injection	Intravenous	1 mg/1mL
Injection	Intravenous	10 mg/1mL
Injection	Intravenous	4 mg/1mL
Injection	Intravenous	8 mg/1mL
Injection	Parenteral	1 mg/1mL
Injection, solution	Epidural; Intramuscular; Intrathecal; Intravenous	1 mg/1mL
Injection, solution	Epidural; Intramuscular; Intrathecal; Intravenous	2 mg/1mL
Injection, solution	Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid	0.5 mg/1mL
Injection, solution	Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid	1 mg/1mL
Injection, solution	Epidural; Intrathecal; Intravenous	0.5 mg/1mL
Injection, solution	Epidural; Intrathecal; Intravenous	1 mg/1mL
Injection, solution	Intramuscular; Intravenous	10 mg/1mL
Injection, solution	Intramuscular; Intravenous	2 mg/1mL
Injection, solution	Intramuscular; Intravenous	4 mg/1mL
Injection, solution	Intramuscular; Intravenous	5 mg/1mL
Injection, solution	Intramuscular; Intravenous	8 mg/1mL
Injection, solution	Intrathecal	40 mg/1mL
Injection, solution	Intrathecal; Intravenous	0.5 mg/1mL
Injection, solution	Intravenous	0.5 mg/1mL
Injection, solution	Intravenous	1 mg/1mL
Injection, solution	Intravenous	10 mg/1mL
Injection, solution	Intravenous	15 mg/1mL
Injection, solution	Intravenous	2 mg/1mL
Injection, solution	Intravenous	25 mg/1mL
Injection, solution	Intravenous	4 mg/1mL
Injection, solution	Intravenous	5 mg/1mL
Injection, solution	Intravenous	50 mg/1mL
Injection, solution	Intravenous	8 mg/1mL
Injection, solution	Intravenous; Subcutaneous	10 mg/10mL
Injection, solution	Intravenous; Subcutaneous	30 mg/30mL
Injection, solution, concentrate	Intravenous	25 mg/1mL
Injection, solution, concentrate	Intravenous	50 mg/1mL
Powder	Not applicable	1 g/1g
Solution	Oral	10 mg/0.5mL
Solution	Oral	10 mg/5mL
Solution	Oral	20 mg/5mL
Solution	Oral	20 mg/1mL
Solution, concentrate	Oral	100 mg/5mL
Solution, concentrate	Oral	20 mg/1mL
Suppository	Rectal	10 mg/1
Suppository	Rectal	20 mg/1
Suppository	Rectal	30 mg/1
Suppository	Rectal	5 mg/1
Tablet	Oral	15 mg/1
Tablet	Oral	30 mg/1
Tablet, extended release	Oral	100 mg/1
Tablet, extended release	Oral	15 mg/1
Tablet, extended release	Oral	200 mg/1
Tablet, extended release	Oral	30 mg/1
Tablet, extended release	Oral	60 mg/1
Tablet, film coated	Oral	100 mg/1
Tablet, film coated	Oral	15 mg/1
Tablet, film coated	Oral	200 mg/1
Tablet, film coated	Oral	30 mg/1
Tablet, film coated	Oral	60 mg/1
Tablet, film coated, extended release	Oral	100 mg/1
Tablet, film coated, extended release	Oral	15 mg/1
Tablet, film coated, extended release	Oral	200 mg/1
Tablet, film coated, extended release	Oral	30 mg/1
Tablet, film coated, extended release	Oral	60 mg/1
Tablet	Oral	200 mg/1
Liquid	Intramuscular; Intravenous; Subcutaneous	10 mg / mL
Liquid	Intramuscular; Intravenous; Subcutaneous	15 mg / mL
Solution	Intravenous; Subcutaneous	1 mg / mL
Solution	Intravenous; Subcutaneous	2 mg / mL
Solution	Intravenous; Subcutaneous	5 mg / mL
Solution	Intramuscular; Intravenous; Subcutaneous	1 mg / mL
Solution	Intramuscular; Intravenous; Subcutaneous	10 mg / mL
Solution	Intramuscular; Intravenous; Subcutaneous	15 mg / mL
Solution	Intramuscular; Intravenous; Subcutaneous	2 mg / mL
Liquid	Intramuscular; Intravenous; Subcutaneous	2 mg / mL
Solution	Intravenous	1 mg / mL
Solution	Intravenous	100 mg / 100 mL
Solution	Intravenous	5 mg / mL
Solution	Intravenous	50 mg / 50 mL
Solution	Intramuscular; Intravenous; Subcutaneous	10 mg / 1 mL
Solution	Intramuscular; Intravenous; Subcutaneous	2 mg / 1 mL
Solution	Intramuscular; Intravenous; Subcutaneous	4 mg / 1 mL
Solution	Intramuscular; Intravenous; Subcutaneous	5 mg / 1 mL
Solution	Intramuscular; Intravenous; Subcutaneous	8 mg / 1 mL
Solution	Oral	100 mg/5mL
Liquid	Intravenous; Subcutaneous	1 mg / mL
Liquid	Intramuscular; Intravenous; Subcutaneous	25 mg / mL
Liquid	Intramuscular; Intravenous; Subcutaneous	50 mg / mL
Liquid	Intravenous; Subcutaneous	2 mg / mL
Liquid	Intravenous	25 mg / mL
Liquid	Intravenous	50 mg / mL
Liquid	Intravenous	1.1 mg / mL
Injection	Intramuscular; Intravenous	15 mg/1ml
Injection	Parenteral	15 mg/1ml
Solution	Epidural	0.5 mg / mL
Solution	Epidural	1 mg / mL
Injection, solution	Epidural; Intramuscular; Intrathecal; Intravenous; Subcutaneous	10 mg
Injection	Intramuscular; Intravenous	10 MG/ML
Injection	Parenteral	10 MG/ML
Granule, for suspension	Oral	100 MG
Granule, for suspension	Oral	20 MG
Granule, for suspension	Oral	200 MG
Granule, for suspension	Oral	30 MG
Granule, for suspension	Oral	60 MG
Tablet, extended release	Oral	100 mg
Tablet, extended release	Oral	15 mg
Tablet, extended release	Oral	200 mg
Tablet, extended release	Oral	30 mg
Tablet, extended release	Oral	60 mg
Suppository, extended release	Rectal	100 mg / sup
Suppository, extended release	Rectal	200 mg / sup
Suppository, extended release	Rectal	30 mg / sup
Suppository, extended release	Rectal	60 mg / sup
Tablet, extended release	Oral	5 mg / tab
Capsule, extended release	Oral	120 mg / src
Capsule, extended release	Oral	150 mg / src
Capsule, extended release	Oral	200 mg / src
Capsule, extended release	Oral	30 mg / src
Capsule, extended release	Oral	60 mg / src
Capsule, extended release	Oral	90 mg / src
Suppository	Rectal	10 mg / sup
Suppository	Rectal	20 mg / sup
Suppository	Rectal	30 mg / sup
Tablet, multilayer, extended release	Oral	10 mg
Tablet, multilayer, extended release	Oral	20 mg
Tablet, multilayer, extended release	Oral	30 mg
Tablet, multilayer, extended release	Oral	5 mg
Granule, delayed release	Oral	100 mg
Granule, delayed release	Oral	20 mg
Granule, delayed release	Oral	30 mg
Granule, delayed release	Oral	60 mg
Tablet, extended release	Oral	10 MG
Tablet, film coated	Oral	10 mg
Tablet, film coated	Oral	100 mg
Tablet, film coated	Oral	30 mg
Tablet, film coated	Oral	60 mg
Tablet, extended release	Oral
Capsule	Oral	120 mg
Capsule	Oral	200 mg
Capsule	Oral	60 mg
Tincture	Oral	10 mg/1mL
Tincture	Oral	10 mg / mL
Solution	Oral	1 g/100mL
Solution	Oral	10 mg/1mL
Solution	Oral	10 g/1000mL
Solution	Oral	20 MG/ML
Solution	Oral	30 MG/5ML
Solution	Oral
Solution	Oral	2 mg/ml
Solution / drops	Oral	20 mg/ml
Tablet	Oral	100 mg/1
Tablet	Oral	60 mg/1
Tablet, extended release	Oral	100 mg / tab
Syrup	Oral	2 MG/ML
Liquid	Oral	2 mg/5mL
Injection	Intramuscular; Intravenous
Syrup	Oral	10 mg / mL
Syrup	Oral	20 mg / mL
Solution / drops	Oral	50 mg / mL
Solution / drops	Oral	20 mg / mL
Suppository	Rectal	20 mg
Suppository	Rectal	30 mg
Suppository	Rectal	5 mg
Syrup	Oral	1 mg/ml
Syrup	Oral	1 mg / mL
Tablet	Oral	10 mg
Tablet	Oral	5 mg
Tablet	Oral	25 mg
Tablet	Oral	50 mg
Solution	Epidural; Intramuscular; Intrathecal; Intravenous; Subcutaneous	10 mg/ml
Injection	Parenteral	100 mg
Injection	Parenteral	200 mg
Solution	Oral	5 mg/ml
Capsule, extended release	Oral	120 mg
Capsule, extended release	Oral	20 mg
Capsule, extended release	Oral	40 mg

Prices

Unit description	Cost	Unit
Depodur 15 mg/1.5 ml vial	618.18USD	ml
Roxanol 20 mg/ml Solution 120ml Bottle	95.98USD	bottle
Morphine Sulfate 20 mg/5ml Solution 500ml Bottle	65.05USD	bottle
Apokyn 30 mg/3 ml cartridge	52.48USD	ml
Morphine Sulfate 10 mg/5ml Solution 500ml Bottle	38.55USD	bottle
Kadian er 200 mg capsule	35.43USD	capsule
Kadian er 100 mg capsule	23.01USD	capsule
Roxanol 20 mg/ml Solution 30ml Bottle	22.99USD	bottle
Morphine Sulfate 10 mg/5ml Solution 100ml Bottle	21.99USD	bottle
Oramorph sr 60 mg tablet	21.76USD	tablet
Ms contin 200 mg tablet	21.5USD	tablet
Kadian er 80 mg capsule	18.66USD	capsule
Roxanol 20 mg/ml Solution 240ml Bottle	17.99USD	bottle
Avinza 90 mg capsule	17.56USD	capsule
Oramorph sr 100 mg tablet	17.16USD	tablet
Kadian 100 mg 24 Hour Capsule	16.93USD	capsule
MS Contin 200 mg 12 Hour tablet	16.32USD	tablet
Kadian 100 mg capsule sr	16.25USD	capsule
Kadian er 60 mg capsule	14.31USD	capsule
AVINza 90 mg 24 Hour Capsule	13.21USD	capsule
Kadian 80 mg capsule sr	12.96USD	capsule
Avinza 120 mg capsule	12.07USD	capsule
Kadian er 50 mg capsule	11.76USD	capsule
Ms contin 100 mg tablet	11.75USD	tablet
Avinza 60 mg capsule	11.58USD	capsule
AVINza 120 mg 24 Hour Capsule	11.33USD	capsule
Avinza 75 mg capsule	10.79USD	capsule
Morphine sulfate powder	10.61USD	g
Avinza 45 mg capsule	10.22USD	capsule
Kadian 60 mg 24 Hour Capsule	9.06USD	capsule
Morphine Sulfate CR 200 mg 12 Hour tablet	8.97USD	tablet
MS Contin 100 mg 12 Hour tablet	8.89USD	tablet
Morphine sulf 30 mg suppository	8.44USD	suppository
AVINza 60 mg 24 Hour Capsule	8.36USD	capsule
Ms contin 60 mg tablet	7.95USD	tablet
Infumorph 10 mg/ml ampul p-f	7.8USD	ml
Kadian 50 mg 24 Hour Capsule	7.71USD	capsule
Kadian er 30 mg capsule	7.13USD	capsule
Oramorph sr 30 mg tablet	6.83USD	tablet
Morphine sulf 20 mg suppository	6.71USD	suppository
Kadian er 10 mg capsule	6.35USD	capsule
Morphine sulf 10 mg suppository	6.25USD	suppository
Avinza 30 mg capsule	6.0USD	capsule
MS Contin 60 mg 12 Hour tablet	5.71USD	tablet
Kadian er 20 mg capsule	5.69USD	capsule
Ms Contin 200 mg Sustained-Release Tablet	5.62USD	tablet
Kadian 30 mg 24 Hour Capsule	4.8USD	capsule
Kadian 20 mg 24 Hour Capsule	4.76USD	capsule
AVINza 30 mg 24 Hour Capsule	4.47USD	capsule
Morphine sulf 5 mg suppository	4.45USD	suppository
Morphine Sulfate CR 100 mg 12 Hour tablet	4.33USD	tablet
M-Eslon 200 mg Extended-Release Capsule	4.3USD	capsule
Oramorph sr 15 mg tablet	4.12USD	tablet
Ms contin cr 30 mg tablet	4.09USD	tablet
Kadian 10 mg capsule sr	4.05USD	capsule
Morphine Hp 50 50 mg/ml	4.01USD	ml
Kadian 10 mg 24 Hour Capsule	4.0USD	capsule
Ms contin 15 mg tablet	3.58USD	tablet
MS Contin 30 mg 12 Hour tablet	3.26USD	tablet
Novo-Morphine Sr 200 mg Sustained-Release Tablet	3.09USD	tablet
Pms-Morphine Sulfate Sr 200 mg Sustained-Release Tablet	3.09USD	tablet
Ms Contin 100 mg Sustained-Release Tablet	3.02USD	tablet
Morphine Sulfate CR 60 mg 12 Hour tablet	3.0USD	tablet
Morphine Hp 25 25 mg/ml	2.9USD	ml
Statex 30 mg Suppository	2.55USD	suppository
Kadian 100 mg Sustained-Release Capsule	2.35USD	capsule
Statex 20 mg Suppository	2.32USD	suppository
Morphine Lp Epidural 1 mg/ml	2.24USD	ml
M-Eslon 100 mg Extended-Release Capsule	2.15USD	capsule
MS Contin 15 mg 12 Hour tablet	2.13USD	tablet
Ms Contin 60 mg Sustained-Release Tablet	1.98USD	tablet
Statex 10 mg Suppository	1.95USD	suppository
Morph sulf 5 mg/0.25 ml vial	1.83USD	vial
Statex 5 mg Suppository	1.75USD	suppository
Novo-Morphine Sr 100 mg Sustained-Release Tablet	1.66USD	tablet
Pms-Morphine Sulfate Sr 100 mg Sustained-Release Tablet	1.66USD	tablet
Morphine Sulfate CR 30 mg 12 Hour tablet	1.63USD	tablet
Morphine 8 mg/ml ampule	1.56USD	ml
Kadian 50 mg Sustained-Release Capsule	1.35USD	capsule
Duramorph 0.5 mg/ml ampul	1.31USD	ml
Astramorph-pf 1 mg/ml ampul	1.15USD	ml
Ms Contin 30 mg Sustained-Release Tablet	1.13USD	tablet
Morphine Lp Epidural 0.5 mg/ml	1.12USD	ml
Morphine Sulfate 15 mg/ml	1.03USD	ml
Morphine Sulfate 10 mg/ml	1.02USD	ml
Novo-Morphine Sr 60 mg Sustained-Release Tablet	1.01USD	tablet
Pms-Morphine Sulfate Sr 60 mg Sustained-Release Tablet	1.01USD	tablet
Ratio-Morphine Sulfate Sr 60 mg Sustained-Release Tablet	1.01USD	tablet
M-Eslon 60 mg Extended-Release Capsule	1.0USD	capsule
Statex 50 mg/ml Drops	0.99USD	ml
Morphine Sulfate CR 15 mg 12 Hour tablet	0.93USD	tablet
Duramorph 1 mg/ml ampul	0.91USD	ml
M.O.S.-Sr 60 mg Sustained-Release Tablet	0.89USD	tablet
Morphine 50 mg/25 ml-d5w syr	0.86USD	ml
Morphine-ns 10 mg/ml syringe	0.86USD	ml
Morphine-ns 5 mg/ml syringe	0.8USD	ml
Ms Contin 15 mg Sustained-Release Tablet	0.75USD	tablet
Morphine 5 mg/ml vial	0.74USD	ml
Kadian 20 mg Sustained-Release Capsule	0.73USD	capsule
Astramorph-pf 0.5 mg/ml amp	0.72USD	ml
Morphine Sulfate 15 mg tablet	0.65USD	tablet
Morphine Sulfate 30 mg tablet	0.65USD	tablet
Morphine 1 mg/ml vial p-f	0.6USD	ml
Morphine-ns 1 mg/ml syringe	0.58USD	ml
Novo-Morphine Sr 30 mg Sustained-Release Tablet	0.57USD	tablet
Pms-Morphine Sulfate Sr 30 mg Sustained-Release Tablet	0.57USD	tablet
Ratio-Morphine Sulfate Sr 30 mg Sustained-Release Tablet	0.57USD	tablet
M-Eslon 30 mg Extended-Release Capsule	0.56USD	capsule
Morphine 0.5 mg/ml vial	0.55USD	ml
Morphine sulfate 50 mg/ml vial	0.55USD	ml
Morphine sulfate ir 30 mg tablet	0.55USD	tablet
Ratio-Morphine 20 mg/ml Syrup	0.55USD	syrup
Statex 20 mg/ml Drops	0.52USD	ml
M.O.S.-Sr 30 mg Sustained-Release Tablet	0.51USD	tablet
Morphine 1 mg/ml syringe	0.48USD	ml
Morphine 10 mg/ml vial	0.48USD	ml
Ms.Ir 30 mg Tablet	0.48USD	tablet
Morphine sulfate 25 mg/ml vial	0.43USD	ml
Morphine sulf 1 mg/ml vial	0.4USD	ml
M.O.S. Sulfate 50 mg Tablet	0.39USD	tablet
Statex 50 mg Tablet	0.39USD	tablet
Kadian 10 mg Sustained-Release Capsule	0.38USD	capsule
M-Eslon 15 mg Extended-Release Capsule	0.38USD	capsule
Ms.Ir 20 mg Tablet	0.38USD	tablet
Novo-Morphine Sr 15 mg Sustained-Release Tablet	0.37USD	tablet
Pms-Morphine Sulfate Sr 15 mg Sustained-Release Tablet	0.37USD	tablet
Ratio-Morphine Sulfate Sr 15 mg Sustained-Release Tablet	0.37USD	tablet
M-Eslon 10 mg Extended-Release Capsule	0.33USD	capsule
Morphine sulfate ir 15 mg tablet	0.32USD	tablet
Morphine 15 mg/ml vial	0.3USD	ml
Morphine-ns 25 mg/25 ml syr	0.26USD	ml
M.O.S. Sulfate 25 mg Tablet	0.25USD	tablet
Statex 25 mg Tablet	0.25USD	tablet
Ms.Ir 10 mg Tablet	0.21USD	tablet
Ratio-Morphine 10 mg/ml Syrup	0.19USD	syrup
M.O.S. Sulfate 10 mg Tablet	0.19USD	tablet
Statex 10 mg Tablet	0.19USD	tablet
Morphine-ns 5 mg/ml	0.16USD	ml
Morphine-ns 55 mg/55 ml syr	0.14USD	ml
Ms.Ir 5 mg Tablet	0.14USD	tablet
M.O.S. Sulfate 5 mg Tablet	0.12USD	tablet
Statex 5 mg Tablet	0.12USD	tablet
Morphine 1 mg/ml-d5w 100 ml	0.1USD	ml
Morphine-ns 150 mg/150 ml	0.1USD	ml
Statex 5 mg/ml Syrup	0.08USD	ml
Morphine 1 mg/ml-d5w 250 ml	0.06USD	ml
Ratio-Morphine 5 mg/ml Syrup	0.05USD	syrup
Ratio-Morphine 1 mg/ml Syrup	0.02USD	syrup
Statex 1 mg/ml Syrup	0.02USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5378474	No	1995-01-03	2010-03-23
CA2065210	No	2000-08-29	2012-04-06
CA2128591	No	1999-03-23	2014-07-21
US6066339	No	2000-05-23	2017-11-25
US5931809	No	1999-08-03	2015-07-14
US5962016	No	1999-10-05	2017-01-31
US6193998	No	2001-02-27	2016-09-01
US5997899	No	1999-12-07	2016-09-01
US6241999	No	2001-06-05	2016-09-01
US5807572	No	1998-09-15	2015-09-15
US5891467	No	1999-04-06	2017-01-31
US6171613	No	2001-01-09	2016-10-01
US8685443	No	2014-04-01	2025-07-03
US8158156	No	2012-04-17	2027-06-19
US7682633	No	2010-03-23	2027-06-19
US8623418	No	2014-01-07	2029-11-07
US8685444	No	2014-04-01	2025-07-03
US8846104	No	2014-09-30	2027-06-19
US7815934	No	2010-10-19	2027-12-12
US7682634	No	2010-03-23	2027-06-19
US8877247	No	2014-11-04	2027-06-19
US9192608	No	2015-11-24	2034-03-12
US9072781	No	2015-07-07	2034-03-12
US9248229	No	2016-02-02	2034-03-12
US7955619	No	2011-06-07	2028-08-12
US9044402	No	2015-06-02	2033-07-01
US9549899	No	2017-01-24	2033-07-01
US10314788	No	2019-06-11	2028-08-12

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	255 °C	MSDS
boiling point (°C)	190ºC	Lide DR. CRC Handbook of Chemistry. 2004
water solubility	149 mg/L (at 20 °C)	MSDS
logP	0.87	Agilent Technology. LC/MS/MS Analysis of Opiates.
pKa	8.21 (at 25 °C)	Agilent Technology. LC/MS/MS Analysis of Opiates.

Predicted Properties

Property	Value	Source
Water Solubility	10.2 mg/mL	ALOGPS
logP	0.99	ALOGPS
logP	0.9	Chemaxon
logS	-1.4	ALOGPS
pKa (Strongest Acidic)	10.26	Chemaxon
pKa (Strongest Basic)	9.12	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	4	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	52.93 Å²	Chemaxon
Rotatable Bond Count	0	Chemaxon
Refractivity	80.12 m³·mol^-1	Chemaxon
Polarizability	29.94 Å³	Chemaxon
Number of Rings	5	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9971
Blood Brain Barrier	+	0.9882
Caco-2 permeable	+	0.8867
P-glycoprotein substrate	Substrate	0.8787
P-glycoprotein inhibitor I	Non-inhibitor	0.8782
P-glycoprotein inhibitor II	Non-inhibitor	0.956
Renal organic cation transporter	Inhibitor	0.6221
CYP450 2C9 substrate	Non-substrate	0.7451
CYP450 2D6 substrate	Substrate	0.8919
CYP450 3A4 substrate	Substrate	0.7375
CYP450 1A2 substrate	Non-inhibitor	0.5191
CYP450 2C9 inhibitor	Non-inhibitor	0.9046
CYP450 2D6 inhibitor	Non-inhibitor	0.647
CYP450 2C19 inhibitor	Non-inhibitor	0.8155
CYP450 3A4 inhibitor	Non-inhibitor	0.9176
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7503
Ames test	Non AMES toxic	0.9132
Carcinogenicity	Non-carcinogens	0.9634
Biodegradation	Not ready biodegradable	0.9944
Rat acute toxicity	2.8989 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8367
hERG inhibition (predictor II)	Non-inhibitor	0.874

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Download (9.42 KB)

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-00vl-1090000000-adcd23ce75ad17f72cc5
GC-MS Spectrum - EI-B	GC-MS	splash10-00li-8970000000-28acaf307ce4bc5aabf1
GC-MS Spectrum - CI-B	GC-MS	splash10-014i-0090000000-b9cf42b077ae0fa5b50d
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-000i-0090000000-98125212ed8e73f219e1
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-000i-0090000000-e9f7be236d827a716c1b
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-000i-0290000000-5066e10cd96a2c376676
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0kui-0930000000-793deeb91de6d2459cbe
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-100r-0900000000-f775c77035946f746daa
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ufr-0390000000-660ff44516f98e346016
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0090000000-22857c8ef81e65ad6bd3
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0090000000-c5194c99a9e7f30ea0c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0090000000-1980ff8ab9e654f16fe1
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0690000000-efa51d970eaf96d3b982
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0pc9-0920000000-64a693f2f51c03129c94
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-100r-0900000000-49174c3db4b1c1847080
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0090000000-3cc8784093ef460d3030
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0090000000-4bc885836f18b77696f3
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0090000000-4a16648c3e86669f2446
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-000i-0690000000-f41b2f804790e9ad8f1d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0pc9-0920000000-69393fc6563baf39d91f
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-100r-0900000000-467f39309be5edfa4c01
LC-MS/MS Spectrum - LC-ESI-ITFT , positive	LC-MS/MS	splash10-0ufr-0390000000-bd9670761ff2a7dafc55
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-b9e60f42c2a678767a82
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-0090000000-8c1871352169254d9b1b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-0090000000-6a389cf3b927867326de
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-46262bf01e645a0dc860
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00v0-0090000000-aee46827f2033b36283e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00lr-0090000000-9bda5d94f74b5d3cc982
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	169.4437406	predicted	DarkChem Lite v0.1.0
[M-H]-	169.5998406	predicted	DarkChem Lite v0.1.0
[M-H]-	171.65544	predicted	DeepCCS 1.0 (2019)
[M+H]+	168.9187406	predicted	DarkChem Lite v0.1.0
[M+H]+	169.7718406	predicted	DarkChem Lite v0.1.0
[M+H]+	174.05101	predicted	DeepCCS 1.0 (2019)
[M+Na]+	168.5961406	predicted	DarkChem Lite v0.1.0
[M+Na]+	169.4978406	predicted	DarkChem Lite v0.1.0
[M+Na]+	181.08281	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Property	Measurement	pH	Temperature (°C)	References
EC 50 (nM)	15.6	N/A	N/A	A27648 / A27649 / A27650
EC 50 (nM)	316	N/A	N/A	A27649 / A27653
IC 50 (nM)	38	N/A	N/A	A27658
IC 50 (nM)	71.6	N/A	N/A	A27659
IC 50 (nM)	70	N/A	N/A	A27660
IC 50 (nM)	4	N/A	N/A	A27631
IC 50 (nM)	77	N/A	N/A	A27661
IC 50 (nM)	58.8	N/A	N/A	A27641
IC 50 (nM)	0.57	N/A	N/A	A27643
IC 50 (nM)	4.3	N/A	N/A	A27666
Ki (nM)	3.3	N/A	N/A	A27623 / A27624 / A27627
Ki (nM)	7.71	N/A	N/A	A27659
Ki (nM)	1.8	N/A	N/A	A27628 / A27630
Ki (nM)	17	N/A	N/A	A27637 / A27641
Ki (nM)	38	N/A	N/A	A27638
Ki (nM)	6.51	N/A	N/A	A27639
Ki (nM)	0.88	N/A	N/A	A27640 / A27646 / A27647 / A27655
Ki (nM)	3.96	N/A	N/A	A27642
Ki (nM)	3	N/A	N/A	A27645
Ki (nM)	1.1	N/A	N/A	A27648 / A27649
Ki (nM)	2.55	N/A	N/A	A27662 / A27665
Ki (nM)	2.6	N/A	N/A	A27663 / A27654
Ki (nM)	1.92	N/A	N/A	A27664
Ki (nM)	4.6	N/A	N/A	A27664
Ki (nM)	2.52	N/A	N/A	A27664
Ki (nM)	0.14	N/A	N/A	A27656

Details1. Mu-type opioid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist
Regulator

General Function: Voltage-gated calcium channel activity
Specific Function: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name: OPRM1
Uniprot ID: P35372
Uniprot Name: Mu-type opioid receptor
Molecular Weight: 44778.855 Da

References

Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [Article]
Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23. [Article]
Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31. [Article]
Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8. [Article]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Raffa RB: A novel approach to the pharmacology of analgesics. Am J Med. 1996 Jul 31;101(1A):40S-46S. doi: 10.1016/s0002-9343(96)00137-4. [Article]
doi:10.1021/cn9000236 [Link]

Property	Measurement	pH	Temperature (°C)	References
EC 50 (nM)	484	N/A	N/A	A27648 / A27649 / A27650 / A27653
IC 50 (nM)	2390	N/A	N/A	A27625 / A27626
IC 50 (nM)	530	N/A	N/A	A27631
IC 50 (nM)	1.8	N/A	N/A	A27632
IC 50 (nM)	271	N/A	N/A	A27636
IC 50 (nM)	1705.1	N/A	N/A	A27643
Ki (nM)	49	N/A	N/A	A27622
Ki (nM)	33	N/A	N/A	A27622
Ki (nM)	301	N/A	N/A	A27623 / A27624
Ki (nM)	151	N/A	N/A	A27627 / A27645
Ki (nM)	86	N/A	N/A	A27628 / A27630
Ki (nM)	167	N/A	N/A	A27629
Ki (nM)	69	N/A	N/A	A27633
Ki (nM)	11.1	N/A	N/A	A27620
Ki (nM)	538	N/A	N/A	A27621
Ki (nM)	6424	N/A	N/A	A27634
Ki (nM)	330	N/A	N/A	A27635
Ki (nM)	260	N/A	N/A	A27637 / A27641
Ki (nM)	46.9	N/A	N/A	A18178 / A27648 / A27649
Ki (nM)	1870	N/A	N/A	A27638
Ki (nM)	110	N/A	N/A	A27639
Ki (nM)	24	N/A	N/A	A27640 / A27646 / A27647 / A27655
Ki (nM)	52.14	N/A	N/A	A27642
Ki (nM)	113	N/A	N/A	A27644
Ki (nM)	64	N/A	N/A	A27645
Ki (nM)	188	N/A	N/A	A15549
Ki (nM)	6.9	N/A	N/A	A27651
Ki (nM)	33.7	N/A	N/A	A27652
Ki (nM)	299	N/A	N/A	A27654
Ki (nM)	13.3	N/A	N/A	A27656
Ki (nM)	61	N/A	N/A	A27657

Details2. Kappa-type opioid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Opioid receptor activity
Specific Function: G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name: OPRK1
Uniprot ID: P41145
Uniprot Name: Kappa-type opioid receptor
Molecular Weight: 42644.665 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Leventhal L, Silva RM, Rossi GC, Pasternak GW, Bodnar RJ: Morphine-6beta-glucuronide-induced hyperphagia: characterization of opioid action by selective antagonists and antisense mapping in rats. J Pharmacol Exp Ther. 1998 Nov;287(2):538-44. [Article]
Kozak CA, Filie J, Adamson MC, Chen Y, Yu L: Murine chromosomal location of the mu and kappa opioid receptor genes. Genomics. 1994 Jun;21(3):659-61. [Article]
Teodorov E, Modena CC, Sukikara MH, Felicio LF: Preliminary study of the effects of morphine treatment on opioid receptor gene expression in brain structures of the female rat. Neuroscience. 2006 Sep 1;141(3):1225-31. Epub 2006 Jun 6. [Article]
doi:10.1021/cn9000236 [Link]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	100	N/A	N/A	A27620
Ki (nM)	1000	N/A	N/A	A27621
Ki (nM)	140	N/A	N/A	A18178

Details3. Delta-type opioid receptor

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Agonist

General Function: Opioid receptor activity
Specific Function: G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name: OPRD1
Uniprot ID: P41143
Uniprot Name: Delta-type opioid receptor
Molecular Weight: 40368.235 Da

References

Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [Article]
Dortch-Carnes J, Russell KR: Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology. 2006;77(1):17-24. Epub 2006 Mar 13. [Article]
Koch T, Wu DF, Yang LQ, Brandenburg LO, Hollt V: Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. J Neurochem. 2006 Apr;97(2):365-72. Epub 2006 Mar 15. [Article]
Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C: Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain. 2006 Aug;123(3):294-305. Epub 2006 May 2. [Article]
Asensio VJ, Miralles A, Garcia-Sevilla JA: Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56. Epub 2006 Apr 6. [Article]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol. 2002 Apr;66(5):285-306. [Article]
doi:10.1021/cn9000236 [Link]

Details4. Lymphocyte antigen 96

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Activator

General Function: Lipopolysaccharide receptor activity
Specific Function: Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response ...
Gene Name: LY96
Uniprot ID: Q9Y6Y9
Uniprot Name: Lymphocyte antigen 96
Molecular Weight: 18545.345 Da

References

Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, Somogyi AA, Yin H, Maier SF, Rice KC, Watkins LR: Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience. 2010 May 19;167(3):880-93. doi: 10.1016/j.neuroscience.2010.02.011. Epub 2010 Feb 21. [Article]

Enzymes

Details1. Cytochrome P450 2C8

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C8
Uniprot ID: P10632
Uniprot Name: Cytochrome P450 2C8
Molecular Weight: 55824.275 Da

References

Projean D, Morin PE, Tu TM, Ducharme J: Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica. 2003 Aug;33(8):841-54. doi: 10.1080/0049825031000121608 . [Article]
Daily EB, Aquilante CL: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510. doi: 10.2217/pgs.09.82. [Article]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	>50000	N/A	N/A	A15818

Details2. Cytochrome P450 3A4

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

Projean D, Morin PE, Tu TM, Ducharme J: Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica. 2003 Aug;33(8):841-54. doi: 10.1080/0049825031000121608 . [Article]
Takeda S, Ishii Y, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H: Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005 Oct;28(10):2026-7. [Article]
Daily EB, Aquilante CL: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510. doi: 10.2217/pgs.09.82. [Article]

Details3. UDP-glucuronosyltransferase 2B7

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Glucuronosyltransferase activity
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name: UGT2B7
Uniprot ID: P16662
Uniprot Name: UDP-glucuronosyltransferase 2B7
Molecular Weight: 60694.12 Da

References

Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4. [Article]
Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H: Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol. 2005 Mar;67(3):665-72. Epub 2004 Dec 20. [Article]
Yamada H, Ishii K, Ishii Y, Ieiri I, Nishio S, Morioka T, Oguri K: Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci. 2003 Dec;28(5):395-401. [Article]
Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [Article]

Details4. UDP-glucuronosyltransferase 1-1

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid binding
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name: UGT1A1
Uniprot ID: P22309
Uniprot Name: UDP-glucuronosyltransferase 1-1
Molecular Weight: 59590.91 Da

References

Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [Article]

Details5. UDP-glucuronosyltransferase 1-8

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Steroid binding
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name: UGT1A8
Uniprot ID: Q9HAW9
Uniprot Name: UDP-glucuronosyltransferase 1-8
Molecular Weight: 59741.035 Da

References

Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [Article]

Details6. UDP-glucuronosyltransferase 2B15

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Glucuronosyltransferase activity
Specific Function: UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xeno...
Gene Name: UGT2B15
Uniprot ID: P54855
Uniprot Name: UDP-glucuronosyltransferase 2B15
Molecular Weight: 61035.815 Da

References

Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [Article]

Details7. UDP-glucuronosyltransferase 2B4

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Glucuronosyltransferase activity
Specific Function: UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name: UGT2B4
Uniprot ID: P06133
Uniprot Name: UDP-glucuronosyltransferase 2B4
Molecular Weight: 60512.035 Da

References

Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [Article]

Details8. UDP-glucuronosyltransferase 1-3

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Retinoic acid binding
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name: UGT1A3
Uniprot ID: P35503
Uniprot Name: UDP-glucuronosyltransferase 1-3
Molecular Weight: 60337.835 Da

References

Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. [Article]

Carriers

Details1. Serum albumin

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Binder

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

References

Zhou R, Perez-Aguilar JM, Meng Q, Saven JG, Liu R: Opioid binding sites in human serum albumin. Anesth Analg. 2012 Jan;114(1):122-8. doi: 10.1213/ANE.0b013e318232e922. Epub 2011 Oct 24. [Article]

Transporters

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	>50000	N/A	N/A	A15818

Details1. P-glycoprotein 1

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [Article]
Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [Article]
FDA Approved Drug Products: Morphine Sulfate Oral Tablets [Link]

Drug created at June 13, 2005 13:24 / Updated at May 23, 2024 20:45

Morphine

Identification

Structure for Morphine (DB00295)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

References

References

References

Enzymes

References

References

References

References

References

References

References

References

Carriers

References

Transporters

References